,count,Outcome Measures
0,14,Safety (adverse events)
1,5,Number of cured patients|Number of patients with treatment-related adverse events
2,4,Safety|Efficacy
3,3,Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease
4,3,Number of Participants with Adverse Events as a Measure of Safety and Tolerability
5,3,Area of diabetic foot ulcers|Improvement of transcutaneous oxygen partial pressure (TcPO2)|Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)|Pain (Visual-Analog Scale)|Walking distance (treadmill) if possible
6,3,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.
7,3,Changes in American Spinal Injury Association (ASIA) Score Scale|Changes in International Association of Neural Restoration Spinal Cord Injury Functional Rating Scale (IANR-SCIRFS)|Changes in electromyogram test|Changes in residual urine
8,2,Proportion of patients with clinical improvement in EDSS score compared to baseline|Proportion of patients with a change in either gadolinium enhancing or new T2-weighted lesions on brain MRI|Proportion of patients with reduction in T2 lesion volume on brain MRI|Proportion of patients with reduction in brain volume on MRI|Proportion of patients with clinical improvement in MSIS score compared to baseline|Proportion of patients with clinical improvement in MSFC score compared to baseline|Proportion of patients with a change in mobility and leg function as measured by the 25 foot walking test|Proportion of patients with a change in upper extremity function as measured by the Nine Hole Peg Test|Proportion of patients with a change in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT)|Proportion of patients with reduced number of relapses or freedom from progression of disease
9,2,amount of regenerated bone
10,2,Unexplained local and systemic symptoms or death
11,2,Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA)
12,2,Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)
13,2,Adverse Events
14,2,number of patients cured
15,2,Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s)
16,2,Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.
17,2,Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS)
18,2,Safety and tolerability as measured by incidence of IP-related serious adverse events
19,2,Pain relief
20,2,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 6 Week
21,2,"hematopoietic recovery|infections, primary underlying disease relapse and any toxic side effects of MSCs treatment"
22,2,wound healing rate
23,2,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale
24,1,•Production of cardiomyocytes and engineered tissues from hiPSC-derived cardiomyocytes to be used in mechanistic studies of disease and testing of therapeutic interventions.
25,1,Number of participants with an adverse event as a measure of safety and tolerability|Determination of plasma concentrations of AB-16B5|Objective tumor responses in subjects with measurable disease according to RECIST|Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies
26,1,Overall Treatment Success: Bayesian Estimated Response Rate|Effectiveness Based on Number of Pain Responders|Effectiveness Based on Number of Functional Responders|Effectiveness Based on Treatment Success at 24 Months Reported as Number of Responders|Effectiveness Based on Number of Minimal Pain Responders at 24 Months|Effectiveness Based on Time to First Intervention Over 24 Months|Effectiveness Based on Number of Minimal Disability Responders at 24 Months
27,1,Maximum Tolerated Dose|Radiographic Response
28,1,clinical|radiological proof
29,1,Composite measure of severity and number of adverse events (AEs); changes in (clinical laboratory test findings (hematologic and chemistry); and physical examination. (Phase I)|clinical benefit rate (phase II)|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP) (Phase I)
30,1,Sperm detection|Hormonal profile
31,1,generation of hiPSC-EHT and in vitro phenotyping|clinical phenotyping and disease progression|genotyping
32,1,Number of adverse events as a measure of safety and tolerability
33,1,Adverse Events of Allogeneic Human Mesenchymal Stem Cells (hMSCs) Determined by CTCAE version 4|Change in Left Ventricular Ejection Fraction (LVEF)
34,1,"Phase 1b: Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03.|Phase 2, Arm 5: Objective Response Rate (ORR)|Phase 2, Arm 6: Progression Free Survival (PFS)|Objective Response Rate (ORR)|Overall survival (OS)|Progression-Free survival (PFS)|Duration of response (DOR)|Disease control rate (DCR)|Durable Response Rate (DRR)|Frequency of treatment emergent adverse events (TEAEs) as assessed by CTCAE v4.03."
35,1,Number and nature of adverse events|Incidence of major adverse coronary events (MACE)|Exercise Time and Level|Quantify myocardium perfusion measured by SPECT|Assessment of heart function by left ventricular ejection fraction|Clinical Improvement in NYHA Classification
36,1,Safety will be determined by the assessment of major adverse events.|Clinical response (CDAI points)|Endoscopic improvement is assessed by UCEIS.|Level of C-reactive protein
37,1,SDF1-α (stromal cell-derived factor alpha) Concentration|DPP-4 (Dipeptidyl peptidase-4) Activity|Monocyte State|Absolute/Differential leukocyte count|CD271+ cells
38,1,Expansion of regulatory T cell compartment of the patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Normalization of serum creatinine levels of the patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|T cell proliferation changes in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in regulatory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in memory T cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in B cells in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.|Changes in cytokine profile in patients undergoing renal transplant and infused with mesenchymal stem cells as compared to the control patients.
39,1,successful isolation of exosomes|evaluation of the liver microenvironment
40,1,Engraftment at 42 days post AD-HSC transplantation for patients with severe aplastic anemia.|To estimate the overall survival (OS) at 1 year following AD-HSC transplantation for Patients with Severe Aplastic Anemia|Relapse|Incidence of chronic graft-versus-host disease|Evaluation of the occurrence of secondary malignancies|Hematology labs|Number of participants with adverse events as a measure of safety and tolerability of intravenous AD-HSC infusion in patients with severe aplastic anemia|Transfusional requirements|To assess treatment related mortality
41,1,"Safety of MSCs infusion, number, timeframe of occurrence and severity of Adverse Events|efficacy: number of contrast-enhancing lesions (GEL) at MRI scan|Efficacy of the experimental treatment in term of combined MRI activity|Efficacy assessed by combined unique MRI activity, volume of GEL, and volume of BH|Efficacy assessed by combined unique MRI activity, volume of GEL and volume of BH|Efficacy: Number of relapses|Efficacy: Time to sustained progression of disability"
42,1,"Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)"
43,1,"Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15"
44,1,Safety Evaluation Number of patients with adverse events|Improvements in Neurophysiological Measures omatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed|Improvements in ASIA Impairment Scale|Improvements in Independence Measures and Quality of Life|Improvements in Pain assessed based on Visual analog scale (VAS)|Improvements in Urinary and Bowel Function assessed based on bladder pressure monitory before and after transplantation|Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)
45,1,Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival
46,1,Number of Temporary Weans From LVAD Support Tolerated|Number of Participants With Adverse Events|Physiologic Assessments|Histopathological Assessments of Myocardial Tissue|Overall Survival|Change in Quality of Life (QoL)|Hopkins Verbal Learning Test|Trailmaking Tests A and B|MCG Complex Figures|Digit Span|Digit Symbol Substitution Test|Controlled Oral Word Association|Length of Stay|Hospitalizations|Hospital Costs|Functional Status
47,1,Overall survival|Progression-free survival|Objective response rates defined to be a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart|Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.0|Quality of life as measured by the Functional Assessment of Cancer Therapy-Ovarian questionnaire
48,1,Baseline Visual analogue scale (VAS) Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at 1 month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months
49,1,The primary end point was safety in incidence of adverse events (AEs) within 12 months|The secondary end point was efficacy in absolute change of the global LV ejection fraction (LVEF) from baseline to 12 months by MRI
50,1,"Cell viability ratio of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Doubling time of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Percentage expression of cluster differentiation 90,105, 34, 45 surface markers of synovial membrane MSC and infrapatellar fat pad MSC from the first to the tenth cell passage|Alcian blue staining of synovial membrane MSC and infrapatellar fat pad MSC|Tyep II collagen and aggrecan gene expression of synovial membrane MSC and infrapatellar fat pad MSC"
51,1,Number of treatment related-adverse events during the study period|Improvement in clinical function as assessed by Modified Rankin Score(mRS) compared to baseline at 6 months|Improvement in clinical function as assessed by National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months|Improvement in clinical function as assessed by Barthel Index (BI) compared to baseline at 6 months|Improvement in clinical function as assessed by Brain MRI tratogram compared to baseline at 6 months
52,1,Proportion of Subjects Without a Treatment Related Severe Adverse Event
53,1,Number of participants with adverse reactions for 84 days after treatment|Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)|Hospital Re-admission between 84 days after treatment until 20 months of corrected age|Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age
54,1,Liver function|Serum creatinine|Proteinuria|Renal function|Increase in anti inflammatory factors|Increase in Treg
55,1,"C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes"
56,1,Clinically measured abnormality of laboratory tests and adverse events|Satisfaction as measured by Wexner Score
57,1,"biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses"
58,1,"Measurement of b-FGF, v-EGF MEASURED BY ELISA|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.|Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %"
59,1,"Safety will be determined by the assessment of major adverse events|Quantify pulmonary respiratory function measured by chest computerized tomography|The efficacy of UC-MSC treatment was measured by arterial blood gas analysis|The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation，IL-6|The efficacy of UC-MSC treatment was measured by biological markers,including markers of inflammation，IL-8"
60,1,Clinical horizontal bone augmentation results through direct measurement.|Volumetric measurements with CBCT
61,1,"Monitor major adverse cardiac events|Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation|Number of participants with incidence of mortality or need for transplantation after the BDCPA operation|Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation|Assessment of Co-morbidity"
62,1,Modified Rankin Scale (mRS)|Major Bleeding
63,1,"Feasibility and security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia (Number of participants with adverse events)|Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.|Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)|Incidence of BPD and PH in very low birth weight babies treated with MSC"
64,1,"A reduction in the distance in mm from the bottom of the periodontal pocket to the cementoenamel junction using a manual probe (Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) with 20-25g of pressure by a single calibrated examiner.|A reduction in the distance in mm between the gingival margin and the bottom of the defect using a manual periodontal probe (Hu-Friedy XP-23/QW) by a single calibrated examiner."
65,1,Safety will be determined by the assessment of major adverse events.|The efficacy of UC-MSC treatment was measured clinical evaluation.|The efficacy of UC-MSC treatment was measured by chest computerized tomography.|The efficacy of UC-MSC treatment was monitored by pulmonary function.|The efficacy of UC-MSC treatment was measured by lab Indicators.
66,1,Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence
67,1,maximum tolerated dose (MTD)|evidence of anti-tumor activity
68,1,Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Scar Size Percent (DEMRI)|Change From Baseline in Scar Tissue Mass (DEMRI)|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Scar Size Percent (DEMRI)-Trajectory|Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Participants With Major Adverse Cardiac Events (MACE)|Participants Experiencing Other Significant Clinical Events|Cumulative Days Alive and Out of Hospital for Heart Failure
69,1,Incidence of any treatment emergent serious adverse events (TE-SAEs)|Treatment Emergent adverse event rates|Ectopic tissue formation|48-hour ambulatory electrocardiogram (ECG) recordings.|Hematology value changes post-catheterization|Urinalysis results changes post-catheterization|Clinical chemistry values post-catheterization|Pulmonary function|Serial troponin I values|Creatine kinase-MB (CK-MB) value changes post-catheterization|Post-cardiac catheterization echocardiogram.|Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)|Echocardiographic measures of infarct scar size (ISS)|Magnetic resonance imaging (MRI) of Left Regional Ventricular Function|Echocardiographic measures of Left Regional Ventricular Function|Magnetic resonance imaging (MRI) of Global Ventricular Function|Echocardiographic measures of Global Ventricular Function|Tissue perfusion measured by MRI.|Peak oxygen consumption (Peak VO2) (by treadmill determination).|Six-minute walk test.|New York Heart Association (NYHA) functional class.|Minnesota Living with Heart Failure (MLHF) questionnaire.|Incidence of Major Adverse Cardiac Events (MACE)
70,1,LVEF (left ventricular ejection fraction)
71,1,Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure
72,1,Number of Participants with Adverse Events as a Measure of Safety|Change in whole saliva production|Subjective complaints of xerostomia|Change in volume and vascularisation - MRI of glands - composite|MRI - Change in fibrosis|histological sections - gland tissue - composite|histological sections - fibrosus|histological sections - vascularisation
73,1,Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.
74,1,Numeric Pain Rating Scale (NPRS)|Oswestry Disability Index (ODI)|SF-12 Health Survey|EQ-5D Quality Adjusted Life Years
75,1,Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)|Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment
76,1,Occurrence of study related adverse events|Anti-tumor responses to CART-133 cell infusions
77,1,Response rate of ILD|Overall Survival
78,1,Objective Response Rate|Duration of Response|Progression Free Survival|1-Year Survival Rate|Overall Survival|Number of Patients Experiencing Treatment-emergent Adverse Events|Blood Plasma Concentration of MGCD265 - AUC0-6|Blood Plasma Concentration of MGCD265 - Cmax|Blood Plasma Concentration of MGCD265 - Ctrough|Blood Plasma Concentration of MGCD265 - Accumulation Ratio AUC0-6|Blood Plasma Concentration of MGCD265 - Accumulation Ratio Cmax|Blood Plasma Concentration of MGCD265 - Peak to Trough Ratio|Blood Plasma Concentration of MGCD265 - Tmax|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Activating Mutations|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Gene Amplifications|Assess Change in Genetic Alteration Status in ctDNA With MGCD265 Treatment Over Time in the Selected Population|Blood Plasma Concentration of Soluble MET (sMET) Biomarker
79,1,"Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of Short Form 36 questionnaire (SF-36)|Clinical assessment of Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Clinical assessment of Hospital for Special Surgery (HSS) Knee Score|Clinical imaging assessment of knee X-ray|Clinical imaging assessment of MRI of the knee"
80,1,The proportion of participants with 100% healing at the end of follow-up
81,1,post operative liver injury|Total Bilirubin level|(INR) International Normalized Ratio|(ALT) Alanine Aminotransferase|(AST) Aspartate Aminotransferase
82,1,Estimated glomerular filtration rate|Incidence of slow graft function|Incidence of delayed graft function|Proportion of normal renal function recovery|Time to renal function recovery|Patient survival|Renal graft survival|Incidence of acute rejection|Severe adverse events
83,1,Estimated glomerular filtration rate (eGFR)|Patient survival rate|Graft survival rate|Donor specific antibody (DSA) level|Pathological manifestation|Severe adverse events
84,1,Estimated glomerular filtration rate|Proportion of normal renal function recovery|Time to renal function recovery (days)|acute rejection rate|patient and graft survival rate|Incidence of severe adverse events
85,1,Change from baseline in Fugl-Meyer Scale at 12 months|Change from baseline in NIH Stroke Scale at 12 months|Change from baseline in Barthel Index at 12 months|Change from baseline in SSS at 12 months|Change from baseline in mRS at 12 months|Improvement of vision measured by brain visual examination
86,1,Number of participants for whom iPSCs were created|Phenotype differences
87,1,"Ulcer size (length, mm)|Ulcer size (width, mm)|Ulcer size (depth, mm)|Pain of cutaneous wounds (Visual Analog Score for pain)"
88,1,Number of adverse events|Circulating naive and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis)|Circulating regulatory T cell count.|T-cell function in mixed lymphocyte reaction.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR
89,1,"Rate of serious and non-serious adverse events related to the procedure.|Number of new fractures|Pain, measured by Visual Analog Scale|Functionality, measured by Oswestry Disability Questionnaire|Quality of Life, measured by EuroQoL-5D test|Bone resorption, measured by biochemical index|Bone formation, measured by biochemical index|Bone metabolism, measured by biochemical index|Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)|Bone structure, measured by histomorphometric evaluation|Trabecular bone density measured by quantitative computed tomography of the radius"
90,1,Safety of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy|Efficacy of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy
91,1,Change from baseline in thickness of subcutaneous tissue|Change from base line in post operative appearance
92,1,Crohn's disease activity index|Harvey-Bradshaw index|Corticosteroid dosage
93,1,fever|Unconsciousness|The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)|FVC
94,1,Change in Functional / Clinical Score of 10 points or more|Numeric pain intensity scale (0-10)|Disease progression defined as progression to a fractural stage of osteonecrosis|Reoperation rate|Radiological progression
95,1,clinical union|Radiological healing|Pain|Quality of life|Walking distance
96,1,Evaluation of Safety and Tolerability (Adverse events)|Change in the T2 MRI signal intensity of the nucleus pulposus|Overall improvement in the Disc Height Index|improvement in Visual Analogue Scale (VAS)|improvement in Oswestry Disability Index (ODI)|improvement in Short Form-36
97,1,Change from Baseline in Clinical Diagnosis
98,1,Number of participants with Adverse Events|Number of participants with Clinical responses
99,1,Feasibility of the full procedure|Ejection Fraction|Maximal Oxygen consumption|Walking distance in 6 minutes|weaning procedure|Quality of life|Measure of heart pressures|Brain natriuretic peptide|Troponin|Major bleeding|Systemic embolism|Deaths
100,1,Change in VO2max|Left ventricular viability|NYHA/CCS class|Quality of life (Minnesota questionnaire)|VO2 max|6'walking-test|Echocardiography|Myocardial perfusion imaging|BNP blood test
101,1,Successful production of a Retinal Epithelial (RPE) layer that fulfils Regulatory Regulation for transplantation. This will be confirmed with standard laboratory characterisation of RPE and completed toxicity and safety studies on the cell layer.
102,1,Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.
103,1,Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes
104,1,Number of donors from which induced Pluripotent Stem Cells were generated|Number of stem cell lines for which the immune response was characterised|Number of immunomodulatory therapies characterised|Levels of baseline and stimulated gut hormones detected
105,1,myocardial perfusion measured in MRI.|complications of catheterization|complications of endomyocardial injection|systolic function|diastolic function|immunomodulation induced MSCs in the blood|immunomodulation induced MSCs in myocardial biopsy
106,1,SPADI(Shoulder pain and disability index)Score|Constant-Murley score|Visual Analog Scale_pain in motion|Changes in the size of rotator cuff tears determined by MRI|Changes in the size of rotator cuff tears determined by arthroscopy|Adverse event
107,1,"Ankle Brachial Pressure Index, ABPI|Collateral vessel formation on digital subtraction angiography (DSA)|Difference of Wound size|Improved transcutaneous oxygen pressure (TCPO2)|Pain on the Visual Analogue Scale(VAS)|Reduced limb amputation|Temperature change on thermography|Dose about using analgesic medicine|Change in Rutherford classification|Frequency about using analgesic medicine"
108,1,American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up|American Spinal Injury Association (ASIA) Total Score|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score|International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score|Penn Scale|Modified Ashworth Scale|Geffner Scale|Neurogenic Bowel Dysfunction (NBD) Scale|Residual Urine Volume
109,1,Number of adverse events|Sensory and motor strength|Functional Independence|Muscle strength assessment
110,1,Safety of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones by recording of adverse events.|Effectiveness by mean of radiological methods on the appearance of signs of osseous setting formation.|Comparative statistical analysis
111,1,"Degree of improvement in patients with Duchenne Muscular Dystrophy after stem cell therapy treatment administered using Northstar Ambulatory Assessment, Magnetic Resonance Imaging & Spectroscopy, muscle strength assessment equipment, and a questionnaire."
112,1,American Shoulder and Elbow Surgeons (ASES) Score|Magnetic Resonance Imaging (MRI) Scan|Functional Outcomes - Shoulder Exam|Patient Centered Outcomes - Shoulder Survey
113,1,Numbers of participants enrolled into the MSC group and control group|Incident rates of BPAR and DGF after renal transplantation with MSC prevention before operation
114,1,Change from Baseline in Psoriasis Area and Severity Index (PASI) score at 8 weeks|Change from Baseline in Dermatology Life Quality Index (DLQI) score at 8 weeks|body temperature will be monitored for any possible infusion-related toxicities.|blood pressure will be monitored for any possible infusion-related toxicities.|Psoriasis Area and Severity Index (PASI) score|Dermatology Life Quality Index (DLQI) score
115,1,Effects of autologous SVF derived MSC transplantation on reducing the dosage of immunosuppressant in living-related kidney transplant recipients.|Changes in renal function|Incidence of acute rejection|Incidence of delayed graft function|Allograft survival|Infection adverse event|Non-hematologic toxicities|Hematologic toxicities
116,1,Effects of autologous SVF derived MSC transplantation on reducing the dosage of CNI by 30% in Kidney Transplantation from Chinese Donation after Citizen Death|Changes in renal function as determined by eGFR and proteinuria|Incidence of Acute rejection|Incidence of delayed graft function (DGF)|Allograft survival|SAE (severe adverse effects)|non-hematologic toxicities
117,1,evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE|evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)
118,1,Inflammatory response as measured by laboratory measurements and functional assays of innate immunology
119,1,Adverse events|Efficacy-The Wong Baker FACES® pain rating scale|Efficacy-Transcutaneous oxygen pressure(TcPO2)|Efficacy-walking distance (TWD)|Efficacy-Ankle Brachial Pressure Index (ABPI)
120,1,"Rate of overall response (OR) in the study population at Day 28 post initiation of therapy (Day 0) with remestemcel-L (MSC)|Overall survival at Day 100 post initiation of remestemcel-L therapy|Rate of very good partial response (VGPR) at Day 28 post initiation of remestemcel-L therapy|Rate of OR at Day 100 post initiation of remestemcel-L therapy|Rate of VGPR at Day 100 post initiation of remestemcel-L therapy|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by organ involvement|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by organ involvement|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by individual subject organ involvement|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by individual subject organ involvement|Rate of OR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade|Rate of VGPR at Days 28 and 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade|Overall survival at Day 100 post initiation of remestemcel-L therapy, stratified by baseline aGVHD grade and organ involvement|Rate of aGVHD progression requiring additional aGVHD medications/therapy through Day 100 post initiation of remestemcel-L therapy|Effect of additional remestemcel-L therapy after Day 28 on rate of OR at Days 56 and 100 post initiation of remestemcel-L therapy|Effect of additional remestemcel-L therapy after Day 28 on rate of VGPR at Days 56 and 100 post initiation of remestemcel-L therapy"
121,1,To assess the safety|To assess the efficacy
122,1,Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Time of hematopoietic recovery|Neutropenic enterocolitis|Infectious complications|Transfusion needs
123,1,Cultured Cell Exosome Protein Signature Outcome Measure
124,1,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment."
125,1,Magnetic resonance imaging|Sensitivity and motor strength on the inferior limbs|Improvement in urological function|Improvements in sensorial mapping and neuropathic pain
126,1,Main outcome measures|Assessment of Clinical Parameters|Clinical Assessment|Assessment of Urinary sphin Assessment of Urinary Sphincter (Electrophysiology Study)
127,1,WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Recording of Adverse Events and Serious Adverse Events
128,1,Number of iPS cells successfully differentiated into RPE cells
129,1,"Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples"
130,1,Safety Assessment|Neurological efficacy|EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology
131,1,Mass formation|Glomerular Filtration Rate (GFR)
132,1,Adverse Events as a Measure of Safety|bone mineral density|fracture rate|growth velocity|change from baseline in degree of functionality|change from baseline in well-being
133,1,Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery
134,1,Number of Participants with serious and non-serious adverse events|Changes in pulmonary function tests
135,1,Number of patients with adverse events|Number of patients with a change in pulmonary function from baseline as measured by Forced Expiratory Volume (FEV1) following American Thoracic Society (ATS) guidelines|Number of patients with a change in pulmonary function from baseline as measured by Forced Vital Capacity (FVC) following American Thoracic Society (ATS) guidelines|Number of patients with a change in quality of life from baseline as measured by the University of Pittsburgh Medical Center (UPMC) Asthma Questionnaire
136,1,Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC)
137,1,The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines
138,1,Number of samples which successfully produced iPSCs|Number of samples with validated RB1-deficient iPSCs|Number of samples that differentiate human iPSCs toward an eye field fate
139,1,mass formation|Creatinin|GFR
140,1,Myalsia|Mass formation|Hematoma|Muscle bulk|CPK
141,1,Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Quality of life monitoring|Changes in bone tissue volume|Correlation of morphometrical analysis using cone beam CT scan with absolute value of the newly formed bone
142,1,safety assessment|Glasgow Coma Scale(GCS)|FOUR score|Functional Independence Measure(FIM)|Disability Rating Scale(DRS)|Cerebral Performance Category(CPC)scale
143,1,toxicity|survival|progression free survival|Rodnan score|Clinical response
144,1,Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group
145,1,Total daily insulin dose|Pancreatic β-cell Mass
146,1,Toxicity Profile|Quality test of CD19-CAR-T|Tumor shrinkage effect|Lymphocyte subset analysis of CD19-CAR-T|Human anti-mouse antibody (HAMA) test
147,1,Percentage of Participants achieved complete remission of CMV infection|Number of Participants with Serious and Non-Serious Adverse Events
148,1,Highest safe dose/MTD (maximum tolerated dose) or maximally planned dose if no dose-limiting toxicity observed|Time to progression assessment|The time of survival assessment|The time of biologic assessment
149,1,Improvement of Cases
150,1,The primary safety outcome will be the incidence rate of Serious Adverse Reaction (SAR).|Incidence of success|Conventional ultrasound changes from baseline|Ultrasound Tissue Characterisation (UTC) changes from baseline|Inter-observer reliability of UTC against conventional US
151,1,Complication rate|complication rate|Progression of disease to the next stage|Amount of necrotic bone in the femoral head in MRI|Pain (VAS)|serum levels of bone turnover markers
152,1,Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels
153,1,Maximum tolerated dose (MTD) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Toxicity profiles by dose level and patient (Phase I)|Proportion of patients alive at 12 months (Phase II)|Tumor response (Phase II)|Rate of progression free survival (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Maximum grade for each type of toxicity (Phase II)
154,1,"MTD after GX-051 intratumoral injection|Adverse events after GX-051 intratumoral injection|Anti-tumor response by RECIST 1.1 on computed tomography|Changes of INF-γ and IL-12 levels in blood comparing to the baseline after GX-051 intratumoral injection|Changes of immune cell distribution in tumor tissue after GX-051 intratumoral injection|Evaluation of antibody generation against IL-12 which is active ingredient of GX-051|Evaluation of long term safety examined by vital sign, physical examination, clinical laboratory tests, CT etc"
155,1,Feasibility|Difference in the median number of CTCs|Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.|Kinetics of CTCs over time during treatment with c-MET targeted therapies
156,1,Occurrence of study related adverse events|Clinical responses to CART-19 cell therapy
157,1,Percentage of Participants with Hematopoietic Recovery|Number of Participants with Serious and Non-Serious Adverse Events
158,1,Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h
159,1,Objective Response Rate (RECIST Version 1.1)|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set|Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set|Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set|Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set|Overall Survival Stratified by c-MET Status in the Safety Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.|Duration of Response|Peak Plasma Concentration of AZD6094 Following Single Dose|Time to Peak Plasma Concentration of AZD6094 After Single Dose|Apparent Volume of Distribution of AZD6094 Following Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)|Apparent Total Clearance of AZD6094 From Plasma After Single Dose|Mean Residence Time of AZD6094 After Single Dose|Elimination Half-Life of AZD6094 After Single Dose
160,1,Adverse effects at the time of infusion and infections after infusion of MSC|Mesenchymal cell efficiency in recovering cytopenia
161,1,Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.
162,1,Improvements in IIEF scores of greater than 2|Improvements in RHI (reactive hyperemic index) scores of greater than 0.3
163,1,Feasibility|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalence of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Safety
164,1,Assessment of Safety / Efficacy|Assessment of Coagulation Profile
165,1,Oxygen index at 3 days after mesenchymal stem cell infusion|Lung mechanics|Hemodynamic parameters|Mortality|Plasma cytokines|Markers for inflammation and infection|Ventilator weaning parameters|ICU and hospital stay
166,1,Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS|ALS-FRS(functional rating scale) score and EMG scale|FVC (forced vital capacity)and DWSE±QoL score
167,1,Overall Survival (OS)|Frequency of Adverse Events: Number of Participants With Treatment-Emergent Adverse Events (TEAE)|Disease Control Rate (DCR)|6-Month Disease Control Rate (6mDCR)|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Survival at 6 Months|Survival at 12 Months|Immune Response
168,1,Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.|Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.
169,1,Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at on month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months|SF-36 value at 1 month|SF 36 value at 3 months|SF 36 value at 6 months|SF 36 value at 12 months|Euroquol 5D value at 1 month|Euroquol 5D value at 3 months|Euroquol 5D value at 6 months|Euroquol 5D value at 12 months|Lequesne index at 1 month|Lequesne index at 3 months|Lequesne index at 6 months|Lequesne index at 12 months|Femorotibial distance at 6 months|Femorotibial distance at 12 months|Baseline MRI WORMS protocol|MRI WORMS protocol score at 6 months|MRI WORMS protocol score at 12 months
170,1,In-hospital mortality|Pulmonary compliance|Pulmonary tidal volume|Adverse events|All-cause mortality|Recovery of organ functions
171,1,The response and complete remission rate with different doses of Umbilical Cord Derived MSC to treat child with SAA|The relapse rate with different doses of MSC to treat child with SAA
172,1,Recommended Phase 2 Dose of LY3164530: Maximum Tolerated Dose (MTD)|Maximum Serum Concentration (Cmax) of LY3164530 Epidermal Growth Factor Receptor (EGFR) Specific ELISA Assay|Maximum Serum Concentration (Cmax) of LY3164530 Mesenchymal-Epithelial Transition Factor (MET) Specific ELISA Assay|Area Under the Serum Concentration-Time Curve (AUC[0-τ]) of LY3164530 EGFR Specific ELISA Assay|Area Under the Serum Concentration-Time Curve (AUC[0-τ]) of LY3164530 MET Specific ELISA Assay|Number of Participants With Tumor Response
173,1,"Percentage of Participants With Solicited Local Adverse Events (AEs) Post Vaccination|Percentage of Participants With Solicited Systemic Adverse Events (AEs) Post Vaccination|Percentage of Participants With Unsolicited Adverse Events Post Vaccination|Number of Participants With Serious Adverse Events (SAEs) Post Vaccination|Percentage of Responders for Envelop (Env) Clade A, B and C-specific Binding Antibody Titers at Week 28|Percentage of Responders for Clade C (C97ZA.012) Env Enzyme-linked Immunosorbent Assay (ELISA) Immunoglobulin G1 (IgG1), IgG2, IgG3 and IgG4 Gylcoprotein (gp) 140 Binding Antibody|Percentage of Responders for Env ELISA Including Consensus C and Mos1 Antigens|Percentage of Responders for Env Antibody-dependent Cellular Phagocytosis (ADCP) gp Antibody|Percentage of Responders for Human Immunodeficiency Virus Neutralizing Antibody (HIV nAb)|Percentage of Responders for Binding Antibody Multiplex Assay (BAMA) IgG1-IgG4 and IgA and IgG-t Breadth Antibody|Percentage of Responders With Interferon-gamma (IFN-gamma) T Cell Responses Enzyme-linked Immunospot Assay (ELISpot)"
174,1,Number of Serious Adverse Events|Changes in the faecal incontinence diary|Anorectal manometry|Jorge-Wexner Score|Faecal Incontinence Quality of Life
175,1,"Change of Pain During Activity From Baseline to 3 Months After Intervention|Pain During Rest|Pain During Activity|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|Disability of Arm, Shoulder and Hand (DASH) Score|University of California, Los Angeles(UCLA) Shoulder Score|Tear Size at 3 Months After Injection|Tear Size at 12 Months After Injection"
176,1,"Objective Response Rate|Adverse Events Related to Pembrolizumab Treatment in Patients With Advanced Sarcoma, by Patient|The Progression-free Survival (PFS)|Response Rate by Immune-related Response Criteria (Ir-RC)|Overall Survival (OS)"
177,1,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D|Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D|safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D
178,1,Frequency of Adverse Events|Active and inactive lesion count
179,1,cell viability|lower extremity functional score|disabilities of arm shoulder and hand
180,1,number of exosomes|number of patient with a detection test of exosomes positive measured|survival|Tumoral response
181,1,live birth rate|Reduction of intrauterine adhesion|The change of endometrial thickness|ongoing pregnant rate
182,1,"Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months."
183,1,Conduct long term safety evaluations after gene therapy
184,1,Efficacy of C3BS-CQR-1 injection based on a hierarchical composite score
185,1,Proportion of patients responding to treatment of cGvHD with MSC|Overall survival|Progression-free survival|Time without systemic immunosuppression|Cumulative incidents of non-relapse mortality|Adverse events
186,1,ventricular remodeling
187,1,Lack of serious and severe adverse events (SAEs) related to the administration of the investigational medicinal product.|Presence of new type VII collagen at the dermal-epidermal junction post treatment.|Change in general markers of inflammation|Changes in specific markers of inflammation|Change in the clinical changes in the skin assessed with clinical photographs|Differences in quality of life data|Change in BEBSS and EBDASI scores|Change in Pain scores|Change in pruritus score using the Leuven Itch Scale (LIS)|Quantification of total blister numbers over the entire body surface area|10. Increase in the skin strength measured by time to blister formation after negative pressure skin suction test|Qualitative analyses based on a series of interview questions
188,1,Incidence of adverse events by subconjunctival injection of BMMSCs|Incidence of corneal perforation rate after subconjunctival injection of BMMSCs|Time of corneal epithelialization|Visual acuity
189,1,Standard Complication Questionnaire|MS Impact Scale - MSIS-29|Modified SF-36 Cell-Based Therapy Follow Up|Physical Evaluation
190,1,The incidence of adverse events|Child-Pugh score|Serum albumin levels|Serum fibrosis markers|Improvement or disappearance of lower extremity edema|Subjective symptom scores (SF-36)
191,1,Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.|Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment|Changes in PENN score are considerate for the motor and sensory functions evaluation|Changes in VAS score are considerate for quantification of pain|Changes in BDS score are considerate for the Assessment of the functional status|Changes in GEFFNER score are considerate for the Assessment of the functional status
192,1,Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR)|Changes in Visual Acuity|Changes in Visual Field|Changes in Optical Coherence Tomography Parameters Related to Glaucoma|Changes in Retinal Ganglion Cells Function by ERG
193,1,Tissue and Hematopoietic Stem Cell Collection|Identify pharmacodynamic markers
194,1,Differential expression of Molecular pathways in tumors inducing oncogenic osteomalacia
195,1,change in cough test & urodynamic study as a measure of efficacy of treatment|Quality of life as measured by the Incontinence Quality of Life (I-QOL) Instrument Score
196,1,Severity of adverse events|Magnetic resonance imaging (MRI) of the knee|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
197,1,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation"
198,1,The incidence of ITBLs|Changes in biliary enzymology|Biliary blood supply
199,1,EDSS|Annual relapse rate|Lesion load|Retinal nerve fiber layer (RNFL)|Cognition|Immunological assessments|cerebral volume
200,1,Arterial stiffness|Biomarkers of renal disease and DNA adducts
201,1,Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test
202,1,Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %
203,1,Number of patients with adverse events|Number of subjects with a change in American Spinal Injury Association (ASIA) score from baseline|Number of subjects with a change in Frankel Scale score from baseline
204,1,Number of participants with adverse events|Number of participants with a change in joint function from baseline WOMAC assessment|Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system
205,1,"Safety and Tolerability|Improvement in erectile function, measured i IIEF-5 score"
206,1,Percentage of Participants with Hematopoietic Recovery|Incidence of graft-versus-host disease|Incidence of infections|Incidence of primary underlying disease relapse|Incidence of acute toxicity
207,1,The efficacy of treatment for steroid-resistant aGVHD|Incidence of infections|Incidence of primary underlying disease relapse|Incidence of chronic GVHD
208,1,Number of samples of primary A-T fibroblast samples that can be successfully reprogrammed to iPSCs|Number of samples of patient A-T fibroblasts that can be reprogrammed to iPSCs with and without gene correction|Quantification of the cloning efficiency of primary cells haploinsufficient for ATM relative to healthy controls
209,1,survival rate|acute GVHD|chronic GVHD|Transplant-related mortality|Rates of relapse|The implantation
210,1,Protein and mRNA levels of RING ubiquitin ligases during osteogenesis|Protein and mRNA levels of RING ubiquitin ligases in musculoskeletal tumors and its correlation to staging and grading
211,1,Incidence of adverse reactions|Incidence of opportunist diseases|Changes in CD4+ cell count and CD4+/CD8+ ratio|T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks
212,1,Number of adverse events|Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes|Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)|T-cell function in mixed lymphocyte reaction
213,1,Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation
214,1,Overall survival
215,1,unsuspected death or anaphylactic shock|Death or hydrocephalus required shunt operation
216,1,"Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content|Safety Evaluation|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in pulmonary function analysis|Clinical Indicator 3: 6-minute walk test distance|Clinical Indicator 4: change in MRC chronic dyspnea scale|Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood|Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in serum 3: concent of immunoglobulin|Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in serum 6: expression levels of IL-12, IL-10|Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood|Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in lavage fluid 3: concent of immunoglobulin|Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10|Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)|Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in serum 2: content of hydroxyproline|Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)|Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in lavage fluid 2: content of hydroxyproline|Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)"
217,1,"Safety evaluation through vital signs, the results of clinical lab tests and adverse events (AEs)|Improvement of infarct size measured by brain MRI|Modified Barthel index|National Institutes of Health stroke scale(NIHSS) score"
218,1,Duchenne muscular dystrophy gene expression
219,1,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and apoptotic marker expression in the MSC to measure effects of NF-кB dependent-proinflammation on cellular apoptosis in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.
220,1,Angiographic evaluation of angiogenesis at ischemic limb|Ankle-Brachial pressure index|Walking distance|Pain|Laser Doppler evaluation of blood perfusion at ischemic limb
221,1,"Serious Adverse Events|Efficacy measured by: The changes in the requirements of insulin, Peptide C, Resistance to the insulin, inflammatory Cytokines, pancreatic Reservation, Quantification of the degree of neovascularization (angio/arteriogenesis and vasculogenesis)"
222,1,"Rate of serious adverse events related to the procedure.|Rate of non-serious adverse events related to the procedure.|Time to Repair the injury|Local pain assessed by visual analog scale|Bone formation, measured by Computed tomography (mm)|Quality of life, measured by EuroQol-5D."
223,1,Number of treatment related-adverse events during the study period.|Comparison of National Institutes of Health stroke scale (NIHSS).|Comparison of modified Rankin scale (mRS).|Distinguish of EuroQol 5d (EQ-5D) between pre- and post-treatment 180 days.|Comparison of infarct size measured by brain MRI.
224,1,ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD)
225,1,"Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain"
226,1,The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.
227,1,Incidence of local and systemic adverse events (AEs) and serious adverse events (SAEs) in Malian adults. (All arms)|Measurement of Anti-Pfs25 and Pfs230 IgG levels
228,1,Wound size change|Granulation tissue percentage|Pigmentation change|Presence of Exudate
229,1,Improvement of liver function in form of improvement in child score|Postpone or to overcome liver transplantation complications
230,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire
231,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire|Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.
232,1,The change of integrity of nasal septum assessed by endoscopic examination|The change of nasal mucosal physiology assessed by olfactory test|The change of nasal mucosal physiology assessed by nasal mucociliary clearance time (MCT)|The change of nasal airway resistance assessed by rhinomanometry|The change of nasal obstruction assessed by acoustic rhinometry|The change of nasal obstructive symptom assessed by visual analogue scale (VAS)|The change of nasal symptom severity assessed by total nasal symptom score (TNSS)|Change from baseline in computed tomography (CT)
233,1,"Number of treatment related SAE's as assessed by CTCAE grades as defined in version 4.0|Efficacy: Post Implant Stent free period|Efficacy: Post Implant Tracheostomy free period|Efficacy: Mean Airway Diameter evaluations as captured by CT scans|Efficacy: Changes in lung function results using a combination of FEV1, FEF50 and PEFR results|Number of treatment related AEs as assessed by CTCAE grading version 4.0"
234,1,Disease free survival
235,1,Amount of dendritic cell-derived exosomes|Compositions of microRNA in the dendritic cell-derived exosomes
236,1,Number of participants with MYSTEP-score grade 3 and grade 2 (toxicity of MSC infusion)|Number of participants with occurrence of any severe adverse events (SAE)|Graft function after liver transplantation - Number of participants with abnormal liver tests|Individual need for immunosuppressive medication|Time to first biopsy-proven acute rejection (BPAR)|Immune monitoring: donor-specific antibodies (DSA)|Patient and graft survival at 1 and 2 years after liver transplantation
237,1,Knee Injury and Osteoarthritis Outcome Score|Numeric Pain Rating Scale|Patient Reported Outcome Measurement Information System Global Health Scores
238,1,closure of the fistula|complication
239,1,Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization
240,1,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of WJMSC
241,1,The change of serum creatinine elevation|The percentage of end-stage renal disease or death.
242,1,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of ATMSC
243,1,Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence
244,1,Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks
245,1,Part A (dose selection part): Dose Limiting Toxicities (DLTs)|Part B (expansion cohort): The 3-month objective response rate (ORR)|3-month objective response rate (ORR)|Best objective response rate|Disease Control Rate|Duration of response|ORR of injected and non injected lesions|Progression Free Survival (PFS)|Time To progression (TTP)|Overall Survival (OS)|Adverse Events reporting
246,1,iPSC caracterization from human fibroblast with MYT1L mutation
247,1,Comparing the number of side effects and the improvement on ASIA Impairment score between SCI patients receiving autologous AT-MSC vs BM-MSC.|Investigating the number of side effects in SCI patients receiving autologous BM-MSC.|Investigating the effectiveness of autologous BM-MSC in treating SCI patients.|Investigating the number of side effects in SCI patients receiving autologous AT-MSC.|Investigating the effectiveness of autologous AT-MSC in treating SCI patients.
248,1,"The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|Prevention of the illness caused by any influenza viral type/subtype in association with influenza like symptoms:|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause"
249,1,"Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique|Pathological findings (whether the patient has: 1.OC, organ confined; 2.EPE, extraprostatic extension; 3. SVI, seminal vesicle invasion; 4. LNI, lymph node invasion) during the radical prostectomy, confirmed by pathology section result|CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique|Prostate specific antigen (PSA) level measurement using peripheral venous blood|PSA level measurement using peripheral venous blood|Radiological evaluation including isotope bone scanning and pelvic magnetic resonance imaging (MRI) scan"
250,1,Safety of using allogenic ASC assessed by any adverse events
251,1,Vision recovery (Corrected Distance Visual Acuity)|Corneal Thickness|Topopgraphy|Anterior segment Optical Coherence Tomography|Slit Lamp Observation|refraction measurement
252,1,Death or shunt operation|ventricular dilatation|Death
253,1,Change in organ function: chronic liver failure-sequential organ failure assessment (CLIF-SOFA)|Child-Pugh score as a marker of liver function|Model for End-stage Liver Disease (MELD) score as a marker of liver function|serum bile acids as a surrogate marker of liver function|ammonia levels as a surrogate marker of liver function|Lactate levels as a surrogate marker of liver function|Hepatic portal venous gradient (HPVG)|Endothelial function measured by nitric oxide levels|Endothelial function measured by von Willebrand factor levels|Renal function measured by serum creatinine|Renal function measured by Blood urea nitrogen (BUN)|urine neutrophil gelatinase-associated lipocalin (NGAL) as a surrogate marker of renal function|Inflammatory response|Transcriptome analysis|Number of participants alive|Number of participants with treatment-related adverse events as assessed by World Health Organization (WHO) classification for acute and subacute toxicity|Change in chronic liver failure C acute on chronic liver failure score (clif C ACLF)
254,1,Phase II: Determine safety and effficacy of E7 TCR cells plus aldesleukin|Phase I: Determine a safe dose for E7 TCR cells plus aldesleukin|To assess progression-free survival
255,1,change in bone volume
256,1,Prognostic biological markers via this prospective study.
257,1,"Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28"
258,1,The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo before radiotherapy.|The match rate of PD-L1 protein expression in tumor tissue and PD-L1 mRNA expression in pExo after radiotherapy.|The best radiotherapy-division which can make PD-L1 express more.|The best timing of radiotherapy which can make PD-L1 express more.|Correlation between PD-L1 expression through radiation-induced and the ORR.|Correlation between PD-L1 expression through radiation-induced and the radiation pneumonitis.
259,1,"SOFA score|Number of living days without catecholamines|Number of living days without mechanical ventilation|Number of living days without dialysis|Duration of residence time in recovery unit|Mortality, across all causes|Administration safety (i.e. side effects)"
260,1,Incidence of Treatment Related Serious Adverse Events (TE-SAEs)|EPC-CFU levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels
261,1,The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03|The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value|The variation of SCORAD index as contrasted with baseline value|The variation of each index score of SCORAD index as contrasted with baseline value|The variation of the degrees of disease as contrasted with baseline value|The variation of investigator's global assessment (IGA) as contrasted with baseline value|The variation of eczema area and severity index (EASI) total score as contrasted with baseline value|The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value|The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value|The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value|The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value|The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value
262,1,The match rate of PD-L1 protein expression in cancer tissue and PD-L1 mRNA expression in pExo.|The match rate of PD-L1 protein expression and PD-L1 mRNA in tumor tissue.
263,1,Changes in insulin pancreatic reserve|Changes in insulin requirement
264,1,Concentration of Platelet Extracellular Vesicles/ml|Concentration of Extracellular Vesicles Exposing Fibrinogen|Concentration of Extracellular Vesicles Exposing Phosphatidylserine|Concentration of Extracellular Vesicles From Endothelial Cells|Concentration of Extracellular Vesicles From Leukocytes
265,1,Number of Adverse Events|Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score|Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score|Changes from the baseline in GDS (Global Deterioration Scale)|Changes from the baseline in CDR (Clinical Dementia Rating) Score|Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score|Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score|Change in CIBIC (Clinician Interview Based Impression of Change)-plus|Changes from the baseline in SF-36|Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)|Change in Brain MRI (Magnetic Responance imaging)|Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging|Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging|Changes of band power in qEEG (Quantitative electroencephalography)
266,1,number of nasal mesenchymental stem cells
267,1,"Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord|Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC|Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)|Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.|Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test"
268,1,Safety|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)|Change in Handheld dynamometry|Change in Electrical Impedance Myography|Change in Forced Vital Capacity (FVC)|Change in Isometric Strength|Changes in morphometric parameters of MRI of encephalon and spinal cord
269,1,"number of adverse events|safety lab tests, physical examination, ECG, vital signs|variation of Cytokine, PASI, BSA"
270,1,"Number of Participants With Vaccine Related - Grade 3 or Greater Reactogenicity and Adverse Events as a Measure of Safety and Tolerability|Number of Participants With Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) less than (<)50 copies per milliliter (copies/ml) at 24 Weeks After Antiretroviral (ARV) Analytical Treatment Interruption (ATI)|Cell-Associated HIV RNA in Total Cluster of Differentiation (CD)4+ Thymus (T) Cells|Cell-Associated HIV RNA in the Memory CD4 Subsets|Cell-Associated Human Immunodeficiency Virus Deoxyribonucleic Acid (HIV DNA) (total, integrated and 2 Long Terminal Repeats [LTR] Circles) in Total CD4+ T Cells|Cell-Associated HIV DNA (Total, Integrated and 2 LTR Circles) in the Memory CD4 Subsets|Quantification of Latent HIV in Total CD4+ T Cells Using a Viral Outgrowth Assay|Quantification of Latent HIV in Memory CD4+ T Cells Using a Viral Outgrowth Assay|Quantification of the Size of the Inducible Viral Reservoir in Total CD4+ T Cells|Quantification of the Size of the Inducible Viral Reservoir in Memory CD4+ T Cells|Single Copy HIV RNA in Samples With HIV RNA <50 copies per milliliter (copies/ml) pre and post Antiretroviral (ARV) Analytical Treatment Interruption (ATI)|Frequency of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Magnitude of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Breadth of Epitope Recognition by Enzyme-Linked Immunospot (ELISPOT)|Polyfunctionality of Thymus (T) cell Responses|Number of Binding Antibody to Envelope (Env) Regions|Breadth of antibody neutralization across different HIV-1 strains from different clades will assess immunogenicity as measured in the TZM-bl neutralization assay"
271,1,Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100
272,1,Maximum Tolerated Dose (MTD) of VSV-IFNβ-NIS Monotherapy and Combination Therapy
273,1,all kinds of adverse events which occur during the clinical sutdy|ratio of patients who is applicable to CDAI<150|ratio of patients who reduce CDAI over 70 as contrasted witd baseline(V7)
274,1,"to study the impact of protein deficits Nox2 and p22phox, in the physiopathology of neurons from inducible pluripotent bone marrow cells (iPSC)|To study the impact of protein deficits Nox2 and p22phox on cytochrome b558 synthesis process of phagocytes from inducible pluripotent bone marrow cells ( iPSC ).|To study the impact of protein deficits Nox2 and p22phox , at the physiology of fibroblasts and their transformation into myofibroblasts|Constitute cellular models of different types of CGD for future physiopathological studies and therapeutic trials"
275,1,Complete remission
276,1,Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R)
277,1,"Number of subjects with adverse events (AE), including serious adverse events (SAE).|Evaluation of the persistence of genetically modified T cells|Measurement of RCL in genetically modified T cells.|Assessment of dose limiting toxicities to determine optimally tolerated dose range|Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).|Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.|Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.|Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause.|Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause|Interval between the date of first T cell infusion and date of death due to any cause.|Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)"
278,1,Number of Participats Showing Efficacy (Functionality)|Change in Pulpal Response|Change in Apical Lesion Size|Pain to Percussion|Numbers of Participants With Adverse Event|Pulp Regeneration
279,1,Evaluation of Pain Reduction measured by VAS scaling|Evaluation of the Physical Activity measure by WOMAC scoring|Evaluation the resurfacing of articular cartilage by MRI
280,1,The supraspinatus tendon re-rupture rate|visual analogue scale|ASES score- American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form|Constant score
281,1,Return of menstrual cycle|Pregnancy|FSH levels|Follicular function|Endometrium thickness
282,1,A reduction in the marginal bone levels|Radiographic changes in the marginal bone levels|Reduction in the thickness of the buccal/lingual bone|Changes in the alveolar mucosa|Changes in the width of keratised mucosa
283,1,Changes in Motor Performance.|Motor function studies|Specific white matter tract analysis using MRI
284,1,Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio
285,1,Overall Survival（OS）|Progression - free survival（PFS）|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Quality of Life (QoL)
286,1,Occurrence of study related adverse events|Anti-tumor responses to tanCART19/20 cell infusions
287,1,Incidence of Infusion reactions|Incidence of Infections
288,1,Characterization of the ncRNAs|Overall survival|Progression-free survival
289,1,Radiographic and MRI assessment in progression|Reduction of pain using VAS|Cost analysis based on length of hospital stay
290,1,Raynaud's Condition Scale|Hand Visual Analogue Scale|Colchin Hand Function Scale|Kapandji Score (Ranging 0 to 10) - Dominant Hand|Kapandji Score (Non-dominant Hand)|Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO)|Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS)|Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ)|The Degree of Hand Edema (Right)|The Degree of Hand Edema (Left)|Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Hemorrhages)|Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array)|Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications)
291,1,"Incidence of toxicity|Dose-limiting toxicity (DLT) rates|Maximum concentration (Cmax) of autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014) cells in blood|Time to maximum concentration (Tmax), of huJCAR014 cells in blood|Area under the curve of huJCAR014 cells in blood|Presence of huJCAR014 cells in bone marrow|Complete response (CR) rate|Partial response (PR) rate|Objective response rate (ORR)|Duration of response (DOR)|Progression-free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)"
292,1,Determine the levels of circulating EVs|Determine whether these EVs contain islet-specific antigens|Mutivariate analysis will be performed with patient parameters and EV parameters
293,1,Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft versus host disease incidence in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft failure incidence in haploidentical stem cell transplantation
294,1,"Differences in the levels and mutations of circulating exosome RNA from patients with or without lung metastasis.|Differences in the classic cell signal pathway mutations of circulating exosome RNA from patients with or without lung metastasis.|Differences in the therapeutic targets mutations of circulating exosome RNA from patients with or without lung metastasis.|The correlation between circulating exosome RNA mutation levels and 3-year disease-free survival (DFS), progression-free survival (PFS), lung metastases.|The correlation between specific circulating exosome RNA mutations and 3-year disease-free survival (DFS), progression-free survival (PFS), lung metastases.|The roles of circulating exosome micro-RNA mutations on regulation of circulating exosome RNA.|The mutations of circulating exosome RNA from patients without metastasis."
295,1,Efficacy
296,1,Cytokine/Chemokine Profile|Mucositis Assessed Using WHO Classification|Objective Response Rate|Exosome Profile|Incidence of Toxicities
297,1,change of Visual Analogue Scale (VAS) score|International Knee Documentation Committee (IKDC) subjective score|Knee Injury and Osteoarthritis Outcome (KOOS) Score|Tegner Activity Level Scale
298,1,"The degree of healing of skin flap; The degree of epithelialization of burn wounds in the perforations of a skin graft|The dynamics of healing of skin flap|Dynamics of the phagocytic activity of neutrophils in the area of burn wounds, according to NBT-test.|Duration of treatment (days) to complete epithelialization of burn wounds;"
299,1,Proliferation and differentiation of intestinal MSCs in IBD patients.|Comparison of MSCs between IBD patients and control patients
300,1,Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)
301,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the MSC-PLGA engraftment|Effectiveness of using PLGA scaffolds seeded with autologous bone marrow MSCs by Radiograph
302,1,Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Change of inflammatory markers|Effect on Frailty Phenotype Score|Effect on Physical Performance through Quality of Life questionnaires|Change of Pro-inflammatory cytokines in laboratory analysis|Determine if there is an improvement in symptoms between subjects receiving umbilical cord cells versus bone marrow cells|Number of study participants experiencing safety events (difference between dose and placebo subjects)
303,1,Stage 1- Dose finding and Incidence of treatment emergent adverse events (safety and tolerability) PSC and AiH Patients|Stage 2: Incidence of treatment emergent adverse events (safety and tolerability) - Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AiH) patients|Stage 2: Activity: change in Alkaline Phosphatase (ALP) value : ( absolute % change /duration of change between baseline and day 56) - PSC|Stage 2: Activity: change in Alanine transaminase ( absolute % change /duration of change between baseline and day 56) - Autoimmune Hepatitits|Autoimmune Hepatitis secondary outcomes 1|Autoimmune Hepatitis secondary outcomes 2|AIH secondary outcomes 3|AIH secondary outcomes 4|PSC secondary outcomes 1|PSC secondary outcomes 2|PSC secondary outcomes 3
304,1,adverse events|radiographic evidence|WOMAC assessment|VAS|SF-36
305,1,MRI scan|WOMAC score|WOMAC sub-scale|Kellgren & Lawrence grade|EQ5D|ROM|KOOS (Knee Injury & Osteoarthritis Outcome Score)|PGIC(Patient Global Impression of Change)|PSQI(Pittsburgh Sleep Quality Index)|Biomarkers|Incidence of adverse reactions and characteristics associated with investigational product
306,1,"Incidence of treatment-emergent adverse events|Extent and severity of a patient's spinal cord injury|Motor electrophysiology assessment|Somatosensory electrophysiology assessment|Electrical nerve stimulation on pain perception|Mictional dysfunction|Anal sphincter integrity|Neuropathic pain|Spasticity|Functionality|Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)|Urinary disorder|Size injury|Presence of allogeneic cells|Immunology"
307,1,"Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI"
308,1,Visual Acuity|Visual Fields|Optical Coherence Tomography (OCT)
309,1,Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages
310,1,Number of Subjects with any Adverse Events that are related to study drug|Number of Subjects with healing in response to the study drug treatment
311,1,"Incidence of adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Appearance of target antigen/major histocompatibility complex loss variants upon disease recurrence|Clinical response rates|Duration of response|Immunological parameters associated with T cell persistence, bioactivity and functionality|Overall survival|Progression free survival"
312,1,Incidence of adverse events of grade 3 or higher|Clinical response|Progression-free survival|Overall survival
313,1,"Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib|Maximum Plasma Concentration Observed (Cmax) of Tepotinib|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib|Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Maximum Plasma Concentration Observed (Cmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Time to Reach the Maximum Plasma Concentration (Tmax) of Tepotinib Metabolites (MSC2571109A and MSC2571107A)|Apparent Terminal Half-Life (t1/2) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Apparent Terminal Rate Constant (λz) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A) in Plasma|Total Body Clearance of Drug From Plasma (CL/f) for Tepotinib|Apparent Volume of Distribution (Vz/f) for Tepotinib|Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity (%AUCextra) of Tepotinib and Metabolites (MSC2571109A and MSC2571107A)|Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Metabolite (MSC2571109A or MSC2571107A) to AUC0-inf of Tepotinib|Ratio of Maximum Plasma Concentration Observed (Cmax) of Metabolite (MSC2571109A or MSC2571107A) to Cmax of Tepotinib|Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation|Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Parameters"
314,1,Phenotype-genotype gene expression correlations|Incidence of gene mutations
315,1,"To establish the safety, tolerability and the maximum tolerated dose (MTD) of LMP744 (NSC 706744)|Characterize the pharmacokinetic (PK) profile of LMP744"
316,1,Incidence of any treatment-emergent serious adverse event (TE-SAE)|Change in Symptoms for pulmonary function test|Change in Symptoms 6-minute walk test|Change in Symptoms of body mass index|Change in Rate of pulmonary exacerbations|Change in Local and Systemic Inflammation in inflammatory markers|Change in Local and Systemic Inflammation for sputum inflammatory markers|Change in Local and Systemic Inflammation related to quality of life|Change in Local and Systemic Inflammation via the short form-36|Change in Local and Systemic Inflammation via the PHQ-9 Questionnaire|Change in Local and Systemic Inflammation via the CFQ-R Questionnaire|Change in Local and Systemic Inflammation via the GAD-7 Questionnaire
317,1,Step 1: sensitivity of CTC detection with 3 methods in cell spiking experiments|Step 2: diagnostic accuracy of the best CTC detection method and onco-exosome quantification for pancreatic adenocarcinoma diagnosis.|Step 1: reproducibility of CTC detection with the 3 methods|Step 2: correlation between CTCs presence and numbers or onco-exosome concentration with clinical and biological parameters and with patient clinical outcome
318,1,Number of mature follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Number of antral follicle development|Ovarian volume|Pregnancy rate
319,1,Plasma concentration of Ang peptides|Urinary concentration of exosomal Na channel proteins|24h urinary Na excretion|Plasma renin concentration|Plasma aldosterone concentration|Repeatability of Ang peptide and urinary exosomal Na channel concentrations under spontaneous vs. standardized laboratory conditions.
320,1,Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality
321,1,Therapy Success|Major amputation|Minor amputation|Mortality|Ulcer healing|Changes in pain|Pain-free walking distance|Ankle-brachial index (ABI)|Toe-brachial index (TBI)|Quality of life based on EuroQol 5D (EQ5D) questionnaire scores|Quality of life based on Short Form 36 (SF36) questionnaire scores|Clinical status according to Fontaine classification|Clinical status according to Rutherford classification
322,1,Insertion torque values at the time of placement of dental implant|Implant stability quotient (ISQ) using Resonance frequency analysis (RFA).
323,1,Changes in left ventricular ejection fraction from baseline to 12 months'
324,1,change of tumor size
325,1,Hemoglobin levels in peripheral blood|The number of red blood cell in peripheral blood|The number of granulocyte in peripheral blood|The number of white blood cell in peripheral blood|The evaluation of bone marrow megakaryocytic series|adverse reaction
326,1,Relief of the rest pain|Reduction of ulcer area in the target limb|Total walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Quality of life (QOL) by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)
327,1,Changes in action potential of muscles on ElectroMyoGram (EMG) test|Changes in Motility on Modified Barthel Index Score
328,1,WOMAC scores|VAS scores|SF-36 scores|Outbridge scoring|CRP|Cartilage defect size|Cartilage volume
329,1,Neonatal Behavioral Neurological Assessment|number of adverse events|Bayley score|Peabody development measure scale|Number of death|Number of participants with treatment-related central nervous tumor as assessed by Magnetic Resonance Imaging or CT
330,1,"Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)|Imaging indicator: Quantitative analysis of CT density histograms|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in MRC chronic dyspnea scale|Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|self-evaluation"
331,1,Severity of adverse events|RA Serology|Disease Activity Score (DAS 28) Index
332,1,Safety and Tolerability assessed by Adverse Events|Number of Antral follicle development|Estradiol (E2) serum level|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Pregnancy rate
333,1,SGOT|SGPT|Respiration rate|6 min walk test|rates of panic attacks|CRP concentration
334,1,Pain|Bone density|Quality of life evaluated by Visual Analogue Score (VAS)|Infection: Presence of any sign or symptoms of infection|Cyst formation: Presence of any cyst or mass formation
335,1,"Safety and Tolerability assessed by Adverse Events|IIEF-5 (International Index of Erectile Function)|Mean scores of the Sexual Encounter Profile (SEP) Question 2, 3|Penile cavernosal artery peak systolic velocity (PSV)|Nocturnal penile tumescence (NPT)|The change of results of Nerve electrophysiological examination|Maximum Flow Rate (Qmax)"
336,1,Change in cytokine levels (picograms per mL) in patients with DME who were previously non-responders to ranibizumab (non-responders) between baseline aflibercept injection.|Relation of baseline aqueous cytokine levels in patients with DME who were previously non-responders to ranibizumab (non-responders) to baseline Snellen BCVA in response to aflibercept
337,1,Severity of adverse events|Hepatic function|Liver fibrosis index
338,1,WOMAC score|WOMAC 3 subscale|KOOS (Knee Injury & Osteoarthritis Outcome Score)|SF(Short Form)-36 Score|Global assessment of disease activity|Overall satisfaction|X-ray|MRI scan|Arthroscopy evaluation|Histological evaluation|VAS|IKDC|ROM|Quadriceps power|effusion|Crepitus|Ligament laxity|Medial joint line tenderness|Pes tenderness
339,1,Maximally Tolerated Dose|Number of Patients Who Experienced a Dose-limiting Toxicity (DLT)
340,1,Change in global left ventricular ejection fraction (LVEF)measured by echocardiography.|Change in infarct size and myocardial viability within the infarcted region measured by emission computed tomography (ECT).|Pump failure Killip classification|New York Heart Association(NYHA) classification|Occurrence of major adverse event
341,1,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 12 Week
342,1,Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies.|General improvements of testicular morphology will be assessed with histological studies.|Improvement in sexual function will be assessed using a questionnaire
343,1,"The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint|The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration|LV end diastolic volume|LV end systolic volume|Infarct size measured by MRI, with contrast|Global Left Ventricular Ejection Fraction"
344,1,"Incidence of adverse events that are related to study treatment and associated with the grafting site|Percentage of wound closure as determined|Scar outcome assessment|Incidence of contracture release or revision surgeries|Incidence of increased temperature sensitivity|Incidence of paresthesias, pain, dulling of sensation assessed|Incidence and severity of infections at grafting sites|Incidence of all adverse events|Percentage area of re-grafting as determined"
345,1,Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Clinician's Interview-Based Impression of Change (CIBIC-plus) Score|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score|Change in Neuropsychiatric Inventory (NPI) Score|Changes in AD Biomarkers
346,1,"Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group|Change From Baseline on Visual Analog Scale (VAS) in JointStem Group|MRI Improvement Evaluation in JointStem Group|Change From Baseline on WOMAC Between JointStem and Positive Control Groups|Change From Baseline on VAS Between JointStem and Positive Control Groups|Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups|Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups|Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups|Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups|Change From Baseline on WOMAC in JointStem Group|Change From Baseline on VAS in JointStem Group|Comparison of MRI Improvement Evaluation in JointStem Group|Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12|Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group"
347,1,Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Reduction of Inflammation
348,1,"Evaluation of treatment emergent adverse events from the bone marrow-derived allogeneic mesenchymal stem cells implant|Clinically: to assess changes in the Crohn's Disease Activity Index (CDAI), the Perianal Disease Activity Index (PDAI).|Endoscopic assessment of rectum using a limited simplified endoscopic activity score for Crohn's disease (SES-CD) to evaluate extent and severity of ulcers.|Radiologic assessment using MRI|Evaluate symptomatic patients.|Evaluate the effect of local treatment with allogeneic bmMSCs using the short Inflammatory Bowel Disease Questionnaire (sIBDQ)|Evaluate the effect of local treatment with allogeneic bmMSCs using the Short Form (SF)-36 score|C-reactive protein (CRP)|Major Adverse Events"
349,1,Effects of treatment on the mesenchymal gene expression profile|Extent of targeted inhibition of PDGFR and KIT phosphorylation in cancer cells|Correlation between plasma imatinib trough levels on day 14 and intratumoural concentration of imatinib in the resection specimen|Correlation between the extent of PDGFR and cKIT inhibition and systemic and intratumoural imatinib and CGP74588 concentration|Change in plasma CEA-concentrations|Change in plasma levels of circulating tumor DNA|Effects of imatinib on the ability of cancer cells to form in vitro 3D cell cultures (organoids)|Number of participants with treatment-related adverse events as assessed by CTCAEv4.02
350,1,"Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation."
351,1,Safety measured by incidence of serious adverse events|Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment
352,1,Patient Continuous Clinical Response (pCCR)|Total Mayo Score|Partial Mayo Score|Modified Partial Mayo Score|Week 14 Clinical Response|Clinical Remission|Clinical Flare|Corticosteroid Free Remission|Mucosal healing
353,1,"Safety, recording of Adverse Events and Serious Adverse Events|WOMAC Score|VAS Score|SF-36|The volume of articular cartilage|WORMS Score"
354,1,Incidence of treatment-emergent adverse events|Myocardial blood flow|Left ventricle ejection fraction (LVEF)|Infarct size|New York Heart Association (NYHA) Functional Classification|Canadian Cardiovascular Society (CCS) Angina Grading Scale
355,1,"The mean change in the number of MSCs present in the knee pre- and post- microfracture/microfracture plus arthroscopic synovial brushing.|Number of patients whose clinical effusion scores improve at 3, 6 and 12 months|Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months|Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)|Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Visual Analogue Scale (VAS)"
356,1,Endothelial function: Changes in endothelial function as assessed by the following:|Difference in rate of change in the metabolic syndrome as defined by the following:
357,1,"Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging spinal cord injury|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain"
358,1,Improvements in IIEF scores|Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection|Safety and Tolerability assessed by Adverse Events
359,1,Area of re-epithelization|Percentage of a target wound's re-epithelialization|Time taken to re-epithelization|Safety assessed by clinically measured abnormality of laboratory tests and adverse events
360,1,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days|change in p38 pathway from baseline to 14 days|change in phosoho-p38 from baseline to 14 days|Show oxidative DNA damage associated with p38 activation|change in VEGF from baseline to 14 days|change in APE-1 from baseline to 14 days|change in NPM1 from baseline to 14 days|change in phospho-NPM1 from baseline to 14 days
361,1,∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.
362,1,Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI
363,1,Occurrence of Study related adverse events|Anti-tumor responses to CART-meso cell infusions
364,1,International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis
365,1,Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism
366,1,"Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy"
367,1,clotting time|clot formation|clot stability|clot lysis|CD62P
368,1,Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:
369,1,Safety: Number of serious adverse events|DLCO changes from baseline|FVC changes from baseline|exercise capacity changes
370,1,To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.
371,1,ovary mass|ovary abcess|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Number of antral follicle|Antral follicle volume|Menstruation recurrence rate|Pregnancy rate
372,1,Part 1: Number of Participants With Dose Limiting Toxicity (DLT)|Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs|Part 2: Overall Response Rate (ORR)|Part 2: Duration of Response (DOR)|Part 2: Percentage of Participants With Clinical Benefit|Trough Serum Concentration (Ctrough) of Amivantamab|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Amivantamab|Maximum Serum Concentration (Cmax) of Amivantamab|Time to Reach Maximum Observed Serum Concentration (Tmax) of Amivantamab|Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of Amivantamab|Maximum Serum Concentration (Cmax) of Lzertinib|Time to Reach Maximum Observed Serum Concentration (Tmax) of Lazertinib|Trough Serum Concentration (Ctrough) of Lazertinib|Accumulation ratio (R) of Amivantamab|Number of Participants With Anti-Drug Antibodies (ADA)|Progression-Free Survival (PFS)|Time to Treatment Failure (TTF)|Overall Survival (OS)
373,1,Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS)
374,1,"Safety of Treatment - Determined by changes in vital signs, electrocardiographic, biochemical, hematological, and urinalysis measures, and reported adverse events|Change in Leg Ulcer|Numeric pain intensity scale (0-10)|Ulcer Healing|Quality of Life"
375,1,Time of re-epithelialization|Safety (laboratory tests and adverse events)|Burn Scar Index|healing status of the wound evidenced by photography
376,1,Proportion of re-epithelialization|Time to re-epithelialization|Number of Participants with Adverse Events as a Measure of Safety and Tolerability
377,1,Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause
378,1,"safety of XCEL-MT-OSTEO-BETA in proximal femur fractures by Adverse events, physical exam, laboratory tests.|efficacy through CT scan|efficacy through xRay|efficacy by clinical assessment|efficacy by quality of life questionnaire"
379,1,Improvements in ASIA (American Spinal Injury Association) Impairment Scale|Improvements in Somatosensory Evoked Potentials (SSEP)|Improvements in Motor Evoked Potentials (MEP)|Improvements in Independence Measures|Changes at the transplantation site in spinal cord by Magnetic Resonance Imaging (MRI)|Improvements in Urinary and Bowel Function|Safety and Tolerability assessed by Adverse Events
380,1,Proportion of patients with non-serious and serious adverse events|Wrinkle Severity Rating Scale (WSRS) Evaluation|Global Aesthetic Improvement Scale (GAIS) Evaluation
381,1,House-Brackmann facial nerve grading scale
382,1,Generation of Marfan Syndrome and Fontan Cardiovascular Models using Patient-specific Induced Pluripotent Stem Cells
383,1,Severity of adverse events|Immunological Indicator in serum|The level of ceruloplasmin in serum|The level of type Ⅲ procollagen peptide in serum|Lung function as assessed by spirometry|Chest high kilovolt X-ray examination
384,1,"Morphological characterization of the extracellular vesicles|Size distribution profiles characterization of the extracellular vesicles|Characterization of extracellular vesicles populations by specific markers|Qualitative (names) and quantitative (expression levels) information about the different biomolecules that could be present in the samples: DNA, RNA, proteins, lipids and other small metabolites."
385,1,Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):
386,1,Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)
387,1,Number of subjects experiencing adverse events.
388,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure
389,1,Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow
390,1,The Assessment of Spondyloarthritis International Society (ASAS)20 response|BASDAI score comparing to baseline|BASFI score comparing to baseline|Imageology|C-reactive protein (CRP)|Erythrocyte sedimentation rate (ESR)|Tumor necrosis factor alpha (TNF-α)|Interleukin 6 (IL-6)|Interleukin 17 (IL-17)
391,1,"The incidence of adverse reactions after umbilical cord blood derived mesenchymal stem cells (UC-MSC) infusions.|The survival time of patients after UC-MSC infusions.|The influence on levels of ALT (U/L) and AST (U/L) after UC-MSC infusions|The influence on levels of ALB(g/L) after UC-MSC infusions|The influence on levels of TBil (umol/L) after UC-MSC infusions|The influence on levels of INR after UC-MSC infusions|The influence on levels of MELD score, SOFA score and CTP score after UC-MSC infusions|The incidence of fatal complications after UC-MSC infusions.|Comparison of levels of NKG2A among the groups after UC-MSC infusions|Comparison of levels of NKG2D among the groups after UC-MSC infusions|Comparison of levels of NKP46 among the groups after UC-MSC infusions|Comparison of levels of KIR2DL1 among the groups after UC-MSC infusions|Comparison of levels of KIR2DL3 among the groups after UC-MSC infusions|Comparison of levels of KIR3DL1 among the groups after UC-MSC infusions|Comparison of levels of perforin among the groups after UC-MSC infusions|Comparison of levels of FasL among the groups after UC-MSC infusions|Comparison of levels of gramzymeB among the groups after UC-MSC infusions"
392,1,"Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea"
393,1,Radiological progression of bone fusion|Comparison of the rate of complications between the 2 groups|Incidence of increased temperature sensitivity by questionnaire|Incidence and severity of infections at grafting sites by questionnaire
394,1,Improvement of liver function measured by change in the model for end-stage liver disease (MELD) score|Improvement of liver function measured by change in Child-Pugh score|Change in clinical laboratory parameters of liver function|30-Day Survival|Change in the size of liver and spleen and inner diameter of spleen portal venous
395,1,Changes in epithelial sodium channel (ENaC) appearance in urinary exosomes|Plasma aldosterone|Renin
396,1,Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody
397,1,Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]|Acute GVHD-restaging [Efficacy]|Chronic GVHD-restaging [Efficacy]|Survival analysis at six months after MSC infusion|Incidence free survival at six months after MSC infusion
398,1,Changes in the amount of mesenchymal stromal cells after allogeneic hematopoietic stem cell transplantation
399,1,Safety of aMBMC administration|Efficacy of aMBMC administration
400,1,Cell count
401,1,Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI)
402,1,Incidence of treatment related adverse events at 12 months post MSC administration as evidenced by the Investigator|Changes in circulating inflammatory cell phenotypes as measured by 18-FDG PET/CT
403,1,Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function
404,1,Between-group difference of NIHSS (stroke severity score)
405,1,Muscle regenerative capacities|Satellite cell dysfunction after sepsis|Regenerative capacities of Human satellite cells in presence of mesenchymal stem cells
406,1,Knee Function Change and Improvement|Severity of adverse events
407,1,"Best response using the World Health Organization response criteria|Incidence of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose defined as the highest safely tolerated dose level where at most 1 out of 6 patients experience dose-limiting toxicity (DLT) with the next higher dose having at least 2 patients out of a maximum of 6 patients experience DLT|Absolute percentage change in quality of life measured using the Brief Pain Inventory (short form) and Brief Fatigue Inventory|Change in biodistribution of virally infected cells at various time points after infection with MV-NIS using single photon emission computed tomography/computed tomography|Growth-rate between treated and untreated lesions|Humoral and cellular immune response to the injected virus|Incidence of measles virus shedding/persistence following intratumoral administration|Incidence of viral replication following intratumoral administration|Incidence of viremia following intratumoral administration|Progression-free survival by radiographic response of the treated lesion using World Health Organization response criteria guidelines|Time to progression|Time until hematologic nadirs (absolute neutrophil count, platelets, hemoglobin)|Viral gene expression|Virus elimination as monitored by single photon emission computed tomography/computed tomography imaging"
408,1,"Reversal of brain death as noted in clinical examination or EEG|Cerebrospinal fluid (CSF) analysis of color consistency, cell counts, and microbial evaluation|MRI analysis to analyze any changes in meninges|Pulse|O2 saturation|Blood Pressure|Respiration changes"
409,1,Correlate an exosome gene expression signature with the presence or absence of high grade prostate cancer in the prostate needle biopsy.
410,1,All cause mortality
411,1,Basal blood glucose value before starting TPN|Periodical blood glucose|Variation of average blood glucose compared with total dose of insulin|Number of hypoglycaemia|Number of severe hypoglycaemia|Hypoglycemia blood glucose values|Hypoglycemia symptoms|Standard deviation of blood glucose|Blood glucose coefficient of variation (CV)
412,1,Efficacy: one year graft survival rate|the rate of acute rejection|the rate of ischemic-type biliary lesions|safety: rate of (serious) adverse events in the study population
413,1,Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days
414,1,iPSC derivation and characterization
415,1,"Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms|Preliminary efficacy of Cellavita HD by UHDRS improvement and global clinical response (CIBIS)|Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers|Immunological Response of Cellavita HD|Preliminary efficacy of Cellavita HD by comparison of the CNS assessment|Risk of suicidal ideation by Hamilton Depression Rating Scale (HDRS)"
416,1,Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events|Area under the plasma concentration-time curve from zero to infinity [AUC(0-inf)] of oral TP-0903|Area under the plasma concentration-time curve from zero to last measured time point [AUC(0-last)] of oral TP-0903|Peak plasma concentration (Cmax) of oral TP-0903|Activity of TP-0903 on predictive biomarkers|Objective response rate using RECIST v1.1 and iRECIST
417,1,Determination of Implant Stability with RFA
418,1,Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Percentage of wound epithelialization|Formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Quality of life (QoL) assessment using the SF-36 questionnaire|Dermatologic quality of life assessment using the DLQI questionnaire|Physical examination and vital parameters
419,1,Safety and Tolerability assessed by Adverse Events|Improvement in IIEF-5 (International Index of Erectile Function)|Improvement in penile colour Doppler ultrasonography
420,1,derive iPSs from skin fibroblasts
421,1,In Vivo TCA cycle flux in skeletal muscle and splanchnic tissue|Changes in the protein and metabolite contents within circulating exosomes derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue|Changes in the metabolome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue|Changes in the proteome derived from the arterial-venous blood supply of the skeletal muscle and splanchnic tissue in response to hormonal manipulation.|Oxygen consumption in skeletal muscle and splanchnic tissue in response to hormonal manipulation|Mitochondrial respiration in skeletal muscle tissue|Reactive oxygen species emissions in skeletal muscle tissue
422,1,pulmonary function testing (PFT)|St. George's Respiratory Questionnaire (SGRQ)|6 minute walk test (6MWT)
423,1,Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
424,1,Bone formation on interface between bone tunnel and graft|Arthroscopic grading of graft|Telos stress X-ray|KT-2000|clinical knee scoring|Instability assessing with physical examination|Tunnel enlargement after anterior cruciate ligament reconstruction
425,1,"Change of bone quality|Number of patients with infection ( increase of local temperature, tenderness, leukocyte count >10,000/ µL, confirmed by Gram stain and blood culture).|Number of patients with bleeding after surgery (Persistent bleeding, ineffectiveness stopping bleeding using dressings)|Number of patients with surgical wound dehiscence (subcutaneous tissue , bone or osteosynthesis material exposed and seen through opened skin )"
426,1,Incidence of Treatment-emergent Adverse Events [Safety and Tolerability] (Phase 1b)|Determine Progression-free Survival following Treatment (Phase 2)|Tumor Marker Cancer Antigen-125 (CA-125) (Phase 2)|Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)|Evaluation of Tumor Response to Treatment (Phase 1b)|Evaluation of Immune-related Tumor Response|CA-125 Response (Phase 1b)|Determine Progression-free Survival following Treatment (Phase 1b)|Overall Survival|Clinical Benefit Rate
427,1,Changes from baseline exogenous insulin dose at different time points post treatment|C-peptide level|HbA1c level|titres of islet antigen antibodies
428,1,Number of adverse events and participants with those adverse events|Change in functional outcomes as measured by National Institutes of Health stroke scale (NIHSS) score|Change in motor recovery evaluated by Brunnstrom stage|Change in self-care ability as measured by Barthel Index (BI)|Change in pain intensity as measured by Visual Analogue Scale (VAS)|Change in electrical brain activity as measured by Electroencephalography (EEG)|Changes in brain electrophysiology as measured by Somatosensory evoked potential (SSEP)|Change in brain pathology diagnosed by Head CT scan
429,1,Complete response: disappearance of all symptoms|Partial response: with a decrease at least of one degree of GVHD|VGPR: decrease to the stage I of GVHD|Stable disease: when there is a stability of the disease (by Clinical evaluation)|Number of infection (by Clinical and laboratory evaluation)|Type of infection (by Clinical and laboratory evaluation)
430,1,Change of Vancouver Scar Scale (VSS)|Wound healing status|Erythema measured by reflectance|Pigmentation measured by reflectance|Scar Thickness and Uniformity|Change of scar area|Immunoglobulin concentrations in breast milk|Subject's satisfaction|Adverse events occurrence
431,1,"Fibrosis by quantitative Sirius Red scoring of MSC treated and untreated groups|Renal function and proteinuria|Number of participants with CMV and BK infection an other opportunistic infections between groups|Number of participants with adverse events|composite end point efficacy failure (biopsy proven acute rejection, graft loss or death)|Presence of donor specific antibodies and immunologic monitoring|Progression of subclinical cardiovascular disease in the different treatment groups bij assessing echocardiographic parameters"
432,1,"Progression-free survival (PFS). Cohort A|Progression-free survival (PFS). Cohort B|Progression-free survival (PFS). Cohort C|Progression-free survival (PFS). Cohort D|Progression-free survival (PFS). Cohort E|The incidence of reported CTCAE (Common Terminology Criteria for Adverse Events) version 4.03 adverse events. All cohorts.|Overall response rate (ORR). All cohorts.|Progression-free survival (PFS), Cohorts A and B, after crossover.|Response rate (RR), Cohorts A and B, after crossover.|Time to tumor progression (TTP), Cohorts A and B, after crossover.|overall survival (OS). Cohorts A and B, after crossover.|Disease Specific Survival (DSS). Cohorts A and B, after crossover."
433,1,collection of blood samples for production of iPSCs or iPSV-derived therapy products
434,1,The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.
435,1,"The levels of serum Total Protein and Albumin|The levels of serum Total Bilirubin and Direct Bilirubin|The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)|The level of alpha-fetoprotein (AFP)|The content of ascites|Survival rate and time|Body temperature, tetter and allergy|The levels of Prothrombin Activity (PA) and Prothrombin Time (PT)|The score for Model for End-Stage Liver Disease"
436,1,"echocardiography|24h HOLTER|The level of serum BNP,TNI,HGF、LIF and G/M-CSF|The expression level of c-kit,CD31,CD133 on peripheral blood mononuclear cells"
437,1,C peptide release test|Exogenous insulin dose|blood glucose|glycosylated Hemoglobin A1c|Number of severe and documented hypoglycemic events|Immunologic reconstitution parameters
438,1,survival time|incidence of HCC events|The levels of serum albumin|The levels of serum total bilirubin|The levels of serum prothrombin activity|the levels of serum cholinesterase|complications
439,1,"the result of enteroscopy and pathological report|the clinical symptom (including stomachache,abdominal distention,bloody purulent stool)"
440,1,Liver Function|Immune function
441,1,"Number of adverse events|Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment|Overall survival and disease-free survival.|Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups."
442,1,Liver Function|Immunity
443,1,"The result of liver function and liver histological improvement.|The disappearance or reduction of abdominal dropsy|The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs )"
444,1,Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Efficacy by imaging procedures.|Clinical outcomes.
445,1,"To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study|To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales"
446,1,The level of serum alanine aminotransferase (ALT）|The level of serum total bilirubin (TB)|The level of serum prothrombin time (PT)|The level of serum prealbumin(PA)|The level of serum albumin (ALB)|Overall survival|liver biopsy
447,1,Disease remission|Disease Improvement|Improvement in Quality of Life (IBDQ)|Number of Adverse events as a measure of safety|Infusional toxicity as a measure of safety and tolerability
448,1,Maximum Tolerated Dose (MTD)|Response (Complete Response (CR) + Partial Response (PR)) to Therapy|Number of Participants With Adverse Events
449,1,"Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)|Major adverse event (death, target limb amputation)|Ankle Brachial Index|University of Texas Classification at target limb"
450,1,Percentage surface area of wound healing|Investigator's assessment of graft|duration of type VII collagen production
451,1,Total Atheroma Volume|MACE (Major Adverse Cardiovascular Events)-Free Survival|Per Cent of Fibro-fatty Component|Event Free Survival|Restenosis Rate|Late Definite Thrombosis|Coronary Vasomotion - Mean Lumen Diameter After Infusion of Acetylcholine 10-6 M|Per Cent Atheroma Volume|Target Lesion Revascularization|Per Cent of Fibrous Component|Per Cent of Necrotic Core|Per Cent of Calcium|Minimal Lumen Diameter|MACE|Cardiac Death|TLR (Target Lesion Revascularization)|TVR (Target Vessel Revascularization)|Mean Number of Membrane Defects on Membrane of Red Blood Cells
452,1,safety evaluation
453,1,Serum creatinine concentration.|Neutrophil gelatinase-associated lipocalin (NGAL)|N-acetyl-p- D glucosaminidase enzyme (NAG)
454,1,"To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.|To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS)."
455,1,"Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography.|Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE)."
456,1,"Concentration of curcumin in normal and cancerous tissue|safety and tolerability of curcumin alone as determined by adverse events|effects of curcumin on normal and cancerous colon cells by measuring the biomarkers using histochemical staining|the immune system response to curcumin, measured by serum cytokine levels|immune response in ex vivo cell cultures of colon cancer cells treated with curcumin and Exo-cur, to be evaluated by using histochemical staining|measurement of curcumin alone on metabolic characteristics of normal colon mucosa and colon tumors|safety and tolerability of curcumin with plant exosomes as determined by adverse events|measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors"
457,1,Number of participant with adverse reaction|Incidence of BPD at 36 Week's postmenstrual age
458,1,"Angiographic evaluation of angiogenesis at ischemic limb|Pain|Ankle-Brachial pressure index|Wound healing (wound size, wound stage)|Walking distance|Rate and extent of amputations"
459,1,the total CD4 T cell counts compared with CD4 T cell counts at baseline|the CD38 expression on CD8 T cells|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|plasma RNA copies/mL|the ratio of CD4 and CD8 T cells|the HLA-DR expression on CD8 T cells|Quality of live|the occurring rate of tumor|occurring rate of opportunistic infections
460,1,effect of mesenchymal cell transplantation to decrease limb inequal|improve life quality
461,1,Disease Diagnosis|Understanding disease pathophysiolgy|Potential genetic counseling
462,1,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months"
463,1,"To determine the overall safety of MSB-CAR001 plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the overall efficacy with MSB-CAR001 plus Hyaluronan compared to Hyaluronan alone using MRI scans and x-ray of the involved knee joint and access the change in outcomes (KOOS, SF-36) and pain (VAS)"
464,1,Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy|Incidence of infusional toxicity|Induction of remission|Improved quality of life|Endoscopic improvement.
465,1,"The type of AE(s), number of AE(s) and proportion of patients with AE(s).|Improvement of neurological recovery as assessed by NIH Stroke Scale (NIHSS).|Improvement of the Functional recovery - assessed by Barthel's Index for activities of daily living.|Improvement of Global outcome as assessed by the Modified Rankin Scale|MRI Parameters - Change in infarct size T2 - weighted images and blood flow in infarct area as evaluated by Diffusion Weighted Index"
466,1,treatment-related mortality|Hematopoietic recovery
467,1,Peritoneal membrane function|Oxydative stress status|Mesothelial cell transformation (Epithelial to Mesenchymal Transition)|Residual renal function
468,1,MDS clinical symptoms (mainly anemia symptoms)|A routine blood test|Bone borrow cytomorphologic examination|Percentage of T regulatory cell population in peripheral blood
469,1,ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;|Serious adverse event frequency and severity
470,1,Safety|Neurologic disability score
471,1,Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.|Serious adverse event frequency and severity
472,1,Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety
473,1,The relations between the cytokine concentrations in the BAL fluid and PAP.|The severity score of BPD ranging from 0 to 6 on the serial chest radiographs
474,1,C peptide release test
475,1,Security and tolerance|therapeutic effect
476,1,Progression free survival
477,1,"IKS, International Knee Score|KOOS, Knee Injury and Osteoarthritis Outcome Score"
478,1,Safety
479,1,To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.|To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC|To document survival post MSC infusion
480,1,SAA clinical symptoms|The number of blood cells|Bone borrow hemocytology|Percentage of systemic T regulatory cell population and T lymphocyte subsets
481,1,Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee.|Indication of Efficacy
482,1,Radiological progression of bone fusion|Reduction of pain using VAS|Cost analysis based on length of hospital stay
483,1,fulfill bone cyst defect|effect of mesenchymal cell transplantation
484,1,Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose
485,1,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.|Level of cytopenias|Transfusional requirements|Incidence of infections and febrile neutropenia
486,1,Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population|Interstitial Fibrosis/Tabular Atrophy (IF/TA)|Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade|Risk Factors of IF/TA Progression|Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification|Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification|Number of Participants With Epithelial-mesenchymal Transition (EMT) Status|Number of Participants With Epithelial-mesenchymal Transition (EMT) Score|Change in EMT Score|Incidence (Number) of Subclinical Rejections and Borderline Lesions|Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)|Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model|Change in Urine Protein/Creatinine Ratio (Without Imputation)|Treatment Failures|Type of Biopsy Proven Acute Rejection (BPAR)|Severity of BPAR|Incidence (Number) of BPAR|Incidence (Number) of Participants With Graft Losses
487,1,The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage|Neurological conditions
488,1,Absolute changes in global LVEF by SPECT|Changes in left ventricular end-diastolic volume (LVEDV)|Changes in left ventricular end-systolic volume (LVESV)|Changes in regional wall motion score index (WMSI) by Echocardiography|Major adverse cardiac event (MACE)
489,1,Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire
490,1,Electromyogram and Electroneurophysiologic test
491,1,Reduction in left ventricle systolic volume on 15% mesured by MRI|All-cause death|number of patients with thromboembolic events|number of heart failure hospitalizations|Distance during 6-minute walking test|number of patients with life-threatening arrhythmias|BNP level|SPECT and Echo data
492,1,Hyaline cartilage production for chondral knee lesions repair|Efficacy: Clinical evolution|Efficacy: Functional evolution|Efficacy: Histological evaluation|Efficacy: Radiological evaluation|Safety: Adverse events|Safety: Acute inflammatory events
493,1,Osteogenic Potential of Mesenchymal Stem Cells
494,1,To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus|To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus
495,1,Fusion Rate (%)(as determined by CT assessment)|Radiographic outcome assessments|Functional outcome measurements
496,1,The Assessment of Spondyloarthritis International Society (ASAS)20 response|erythrocyte sedimentation rate (ESR)|imageology|C-reactive protein (CRP)|Percentage of systemic T regulatory cell population|Side effects
497,1,"Safety of Mesenchymal Stem Cells injection in nonunion fractures.|Proportion of patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 6 and 12 months, compared to patients receiving placebo.|Proportion of patients receiving Mensechymal Stem Cells that develop a partial or complete callus at 2, 3, 4, 8 and 10 months, compared to patients receiving placebo|Timing of development of a partial or complete callus in the 2 groups.|Patient evaluation of pain and global satisfaction.|Proportion of patients achieving different degrees of functional success.|Incidence of adverse events and severe adverse events in the 2 groups.|Evaluation of early homing of Mesenchymal Stem Cells.|Value of [18F]-NaF PET scans for early prediction of the onset of the bone healing process."
498,1,"Infusional toxicity|Incidence of infections (bacterial, viral, fungal, parasitic) and cancers|Patient and graft survivals|Effects of MSC on graft function|Biopsy-proven (Banff classification) rejection rates|Feasibility and safety of weaning or decreasing immunosuppression|Recipient's immune function|Anti-MSC donor HLA antibodies."
499,1,clinical and radiological bony union at 3 months and 6 months.
500,1,safety|pain|physical function|defect
501,1,"Total atheroma volume|Composite end-point of any MACE (major acute cardiovascular events), all-cause death, any revascularization|Composition of plaque|Major and minor bleeding|Restenosis rate|Stent thrombosis rate|Coronary flow-mediated vasodilatation|Coronary intima-media thickness|Minimum diameter stenosis|Minimum lumen diameter"
502,1,serum level of alkaline phosphatase|histological changes in liver biopsies|Serum levels of TNF-alpha|changes in fatigue|The occurrence of cirrhosis and its complications|Serum levels of Interleukin|changes in pruritus severity
503,1,"Overall safety profile of combined PF 02341066 plus PF 00299804 including adverse events (AE), as defined and graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], and first cycle Dose Limiting Tox...|Plasma concentrations and pharmacokinetic (PK) parameters of PF 02341066 and PF 00299804 including AUCtau, Cmax, Ctrough, Tmax, and CLss/F|Clinical activity of combined PF 02341066 plus PF 00299804 including objective response (OR) and stable disease (SD) as defined by RECIST version 1.1, duration of response (DR) and progression free survival (PFS).|Biomarkers in tumor and blood that are potentially predictive for drug activity: for example, KRAS mutations, EGFR mutations (eg, T790M), EGFR and HER2 amplifications, c Met amplification and mutations, ALK, PTEN and PIK3A status in tumor biopsi...|Pharmacodynamic biomarkers in tumor biopsies (e.g., phospho c Met, c Met, EGFR, phospho EGFR) and in blood (e.g., HGF and s Met) that are modulated following drug exposure."
504,1,Intervention Related Adverse Events|Functional Status and Ventricular Function
505,1,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)|Dose Level and Dose Schedule|Detection of Anti-tumor Activity"
506,1,The ratio of wound contraction and re-epithelialisation|Complete healing time for investigated burn area|Vancouver Scar Scale|Incidence of infections and bleedings in burn wounds|Engraftment assessment: Vitality of the graft|McGill pain Questionnaire|Incidence of Adverse Events and Serious Adverse Events
507,1,Number of participants with adverse events|Effect assessment
508,1,Number of participants with adverse events|Electromyogram and Electroneurophysiologic test|Muscle strength assessment|Motor and sensory assessment
509,1,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline
510,1,Exercise test|Clinical evaluation
511,1,To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts|Indication of efficacy
512,1,Number of Participants Who Demonstrated Acute Adverse Events Following Infusion|Percentage Change in Lung Function as Assessed by FVC Compared to Baseline|Percentage Change in 6 Minute Walk Distance Compared to Baseline|Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline
513,1,differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies
514,1,Feasibility and safety of bone marrow stem cell transplantation in patients with spinal cord injury|Functional improvement in muscle strength|Improvement of sphincters control.
515,1,Safety evaluation|WOMAC(Western Ontario and McMaster Universities) Index|Magnetic Resonance Imaging|KSCRS(Knee Society Clinical rating System)|VAS(11-point box visual analogue scale)|Histological evaluates
516,1,"Treadmill Walking Distance|VAS(Visual Analog Scale)|Toe-Brachial Pressure Index, TBPI|Transcutaneous oxygen pressure, TcPO2|Arterial Brachial Pressure Index, ABPI|Pain Free Walking Distance, PFWD|Angiography|Laser Doppler|dose and frequency in use of a analgesic medicine|Safety Evaluation"
517,1,"Number of participants with adverse events|Hematologic response|Relapse|Clonal evolution to PNH, myelodysplasia or acute leukemia|Survival"
518,1,The volume change of fatty layer|Clinical lab tests|Fat absorption rate
519,1,Number of patients with complete closure of fistula (week 8)|Grade of investigator's satisfaction|Number of patients with closed fistula|Photo of target fistula|Number of patients with adverse events
520,1,Number of Participants With Dose Limiting Toxicities (DLTs)|Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE) Detection Above Background|Number of Days of Quantifiable CD19 CAR Post T-cell Infusion|Failure to Engraft|Progression-free Survival at 1 Year
521,1,To evaluate number of paticipants with adverse events|GVHD clinical response
522,1,AUC C-peptide levels during mixed meal tolerance test|Safety|Daily insulin use|Hemoglobin A1C|Anti-GAD titres|Immunologic reconstitution parameters
523,1,Liver Function|Immune state
524,1,Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration
525,1,Toxicity of gene transfer|Hematological and non-hematological organ toxicity|Development of insertional mutagenesis or hematologic malignancy|Development of replication competent lentivirus|Efficacy of G-CSF and plerixafor mobilization in Fanconi anemia (FA) patients|Efficacy of lineage depletion of bone marrow or mobilized cell product|Transduction efficiency|Detectable levels of transduced cells in blood and marrow|Improved blood counts|Demonstrable functional expression by growth of recipient cells in mitomycin C
526,1,MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC|quality of life|RAO Test|intravenous cell transplantation
527,1,"Overall Survival (OS)|Liver function improvement|The size of liver and the width of portal venous|Incidence of hepatocellular carcinoma within 1 year|Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)|The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )"
528,1,Objective Response Rate (ORR)|Duration of Overall Response|Progression Free Survival|Best Overall Response|Overall Survival|Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)|Number of Participants With Worst Post-Baseline Grade Results for Hematology Parameters|Number of Participants With Worst Post-Baseline Grade Results for Clinical Chemistry Parameters|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-infused (NY-ESO-1 Genetically Engineered T) Cell Antibody Result|Concentration of Cytokines in Cytokine Release Syndrome (CRS) by CRS Status: Cohort 1: High NY-ESO-1 Expression Treated With Regimen A|Concentration of Cytokines in CRS by CRS Status: Cohort 2: Low NY-ESO-1 Expression Treated With Regimen A|Concentration of Cytokines in CRS by CRS Status: Cohort 3: High NY-ESO-1 Expression Treated With Regimen B|Concentration of Cytokines in CRS by CRS Status: Cohort 4: High NY-ESO-1 Expression Treated With Regimen C|Time to Maximum Persistence of NY-ESO-1 Genetically Engineered T Cells
529,1,Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event
530,1,To characterize protein surface markers and RNA profiles in tumor derived exosomes from breast cancer patients undergoing neoadjuvant chemotherapy
531,1,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR
532,1,Collection of adverse events|Safety laboratory values|ECG findings|Analysis of inflammation markers|Comparison of course of haemodynamic and vascular processes
533,1,scores of International Cooperative Ataxia Rating Scale （ICARS） scale and Berg Scale|the volume of Cerebellum of Brain Magnetic Resonance Imaging （MRI） Scan|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Serious Adverse Events as a Measure of Safety and Tolerability
534,1,Score of Expanded Disability Status Scale (EDSS)|Visual Evoked Potential (VEP)|Brainstem Auditory Evoked Potential (BAEP)|Somatosensory Evoked Potential(SEP)|Brain Magnetic Resonance Imaging （MRI） Scan
535,1,Can Stem Cells Predict Orthopaedic Outcomes?
536,1,c-peptide area under the curve during OGTT|The incidence and severity of adverse events related to the stem cell infusion procedure|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The reduction in exogenous insulin requirements|Decrease in HbA1c|insulin area under the curve during OGTT
537,1,To assess the safety of allogeneic anti-CD19 CAR|To measure the persistence of anti-CD19-CAR- transduced T cells in the blood of patients after infusion|To determine if administering anti-CD19-CAR-transduced T cells from the original transplant donor can cause regression of B-cell malignancies that are relapsed or persistent after alloHSCT
538,1,"Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction|Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function"
539,1,Change in disease activity according to National Institutes of Health criteria for oral graft-versus-host disease|Change in self-assessed disease activity and quality of life|Safety
540,1,"The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.|The secondary objectives are to explore functional efficacy for subsequent study design."
541,1,Day-100 incidence of non-relapse mortality|1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution
542,1,Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture.|Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union.|Comparison of the rate of complications between the 2 groups.|Economic impact study.
543,1,Serum cholesterol and LDL levels|Tracking the infused cells
544,1,"Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing"
545,1,Duration of clinical benefit (Crohn's disease activity index)|Re-induction of clinical benefit (Crohn's disease activity index)|Improvement in quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ] instrument)
546,1,"Evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI.|Explore efficacy for subsequent study design and dose related tolerance: •Effect related to cardiac function.•Change from baseline in SF-36, KCCQ, SAQ, and the NYHA Classification.•Follow-up safety through Day 360 • Dose selection for future stu"
547,1,Evaluate osseous setting at 3-months follow-up and compare our results with past studies|Feasibility and tolerance of this therapeutic strategy
548,1,Percentage of Participants with Treatment Success|Percentage of Participants with Overall Response|Percentage of Participants with Induction of a 2-grade decrease in (Graft Versus Host Disease) GVHD by Study Day 28 with maintenance of a 2-grade decrease in GVHD through Study Day 56|Percentage of Participants with Induction of CR lasting for greater than or equal to 14 Days|Percentage of Participants with Induction of a CR after Study Day 28 and clinically managed with steroids with second line/escalation therapy through Study Day 56|Percentage of Participants with Induction of PR during the first 28 days|Time to achieve CR|Number of CR per organ|Total corticosteroid dose administered|Number of corticosteroid-related complications|Number of Infectious complications|Number of Days of Hospitalization|Average Daily Corticosteroid Dose
549,1,Number of Patients With Serious Adverse Events|Change in Infarct Scar Size (ISS) Over 18 Month Period|Left Ventricular Function (LVF) in Region of MSC Injection|Regional Left Ventricular Wall Thickening|Left Ventricular End Diastolic Wall Thickness|Change in Left Ventricular End Diastolic and Systolic Volume|Change in Left Ventricular Ejection Fraction|Change in Peak Volume Oxygen|Change in Six Minute Walk Test|Change in NYHA Functional Class|Minnesota Living With Heart Failure Questionnaire Scores|Incidence of Major Adverse Cardiac Events (MACE)|Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings|Change in Pulmonary Function|Serial Troponin Values (ng/mL)|Creatinine Kinase - Muscle/Brain (MB) (ng/mL)|Number of Clinically Significant Laboratory Values|Rate of Treatment Emergent Adverse Events|Number of Abnormal Echocardiogram Readings 2 Days Post CABG.
550,1,Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.|Arm 2. Efficacy of MSC infusion as treatment for poor graft function|Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT|Toxicity of MSC infusion
551,1,Classification of sarcomas
552,1,"Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion|Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays|Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood"
553,1,Improvement of left ventricular function|Functional status
554,1,Improvements in left ventricular function|Clinical improvements
555,1,Exogenous insulin requirement|Hemoglobin A1c|Glucose and C-peptide levels|liver function|kidney function|Portal vein Ultrasound|autoantibodies|Complete Blood Count
556,1,Incidence rate of biopsy-proven acute rejection and early renal function recovery|Patient and graft survival and prevalence of adverse events
557,1,"the proportion of participants who achieve and maintain remission|Patient survival|Creatinine and proteinuria.|SLE disease activity index|Serology (ANA, dsDNA)|ComplementC3 and C4"
558,1,Creatinine and creatinine clearance rate|Patient and graft survival [ Time Frame: At 1 years post-transplant ].|The proportion of renal biopsy after 12 months|The incidence of infectious complications|Incidence of adverse events associated with MSC and immunosuppression
559,1,Number of Participants with Adverse Events (AEs)|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume to Forced Vital Capacity Ratio (FEV1/FVC) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) %predicted at Year 1 and Year 2|Change from Baseline in Alveolar Volume (VA) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide to Alveolar Volume ratio (DLCO/VA)at Year 1 and Year 2|Change from Baseline in Functional residual capacity (FRC) at Month 6|Change from Baseline in Total Lung Capacity (TLC) at Month 6|Change from Baseline in Residual Volume (RV) at Month 6|Change from Baseline in Airway Resistance (RAW) at Month 6|Change from Baseline in 6-Minute Walk Test at Year 1 and Year 2|Change from Baseline in Borg Dyspnea Scale at Year 2|Change from Baseline in Health-related quality of life: St George's Respiratory Questionnaire (SGRQ) at Year 1 and Year 2|Change from Baseline in Physician Global Assessment Scale at Year 1 and Year 2|Time to COPD Exacerbation|Number of COPD Exacerbations|Change from Baseline in Pulmonary Hypertension at Month 6|Change from Baseline in Systemic Inflammation at Year 1 and Year 2
560,1,C-peptide area under the concentration curve (AUC) response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies
561,1,"Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)|Lupus serology (ANA, dsDNA, C3, C4)|Renal function (GFR, BUN, urinalysis)|Percentage of systemic T regulatory population"
562,1,Comparison of treatment adverse event rates|Concomitant Medications|Visual Analog Scale
563,1,To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI)
564,1,Engraftment and Time to Engraftment
565,1,Disease remission (CDAI at or below 150)|Disease improvement (Reduction by at least 100 points in CDAI)|Improvement in quality of life (IBDQ)|Reduction in number of draining fistulas
566,1,"MELD score, quality of life, liver volume, histological improvement (In a subset of patients with evidences of clinical and biochemical improvement, follow up liver biopsy will be performed at the end of follow up).|All cause mortality, tracking the infused cells in the patients' bodies."
567,1,Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status
568,1,"Safety, tolerability, and feasibility|Clinical response|Time to progression|Survival|Correlation of clinical response with immunological response"
569,1,"Evaluate TP-38 at a 100 nanograms/mL concentration for sufficient activity|Efficacy parameters including time to progression, safety, and survival"
570,1,"Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups."
571,1,"Protocol 260 - Response by Day 28, also called Overall Response. Overall response. includes complete response (CR) and partial response (PR)|Protocol 261- Patients were followed for 2 years for safety. The incidence rate of different adverse events among subjects treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90"
572,1,Adverse events|Radiographic response|Performance scale|Overall survival|Immune response|Presence of G207 in blood and saliva
573,1,To evaluate the safety of the stromal cell infusion
574,1,To find out the effects (good and bad) of bone marrow cell infusions using donor bone marrow that has had CD3+ cells removed|To find out if there is any effect on the growth rate of children with osteogenesis imperfecta who receive donor bone marrow which has had CD3+ cells removed|To find out if there is any effect on the total bone mineral content of children with OI|who receive donor bone marrow which has had CD3+ cells removed|To find out the effect of the CD3 washed-out marrow cell therapy on the growth rate of the children
575,1,Alveolar bone defect|Tooth mobility
576,1,Meniscal Volume|Quality of Life Questionnaire|Visual Analog Scale (VAS)|Lysholm Knee Scale|Safety Assessment Adverse Event|Safety Assessment Immunological|Safety Assessment Laboratory|Safety Assessment Physical Exam|Safety Assessment Magnetic Resonance Imaging (MRI)
577,1,Safety|Number of patients reaching clinical union of fracture
578,1,Response by Day 28|Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at day 1|Best stage of each involved organ by Day 28|Time to improvement or resolution of GVHD in one or more organs|Adverse events|Infusional toxicity|Overall relapse of underlying disease|Overall survival|Formation of ectopic tissue foci|Incidence of infection
579,1,"Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I)|Maximum Tolerated Dose (MTD) (Phase I)|Proportion of Confirmed Response, Defined as a Partial Response (PR) or Better (Phase II)|Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase I)|Number of Patients With Clinical Responses (Phase I)|Overall Survival (Phase II)|Time to Progression (TTP) (Phase II)|Progression-free Survival (Phase II)|Failure-free Survival (Phase II)|Overall Toxicity Rate, Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) (Phase II)"
580,1,Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points|Number of Participants with Reduction in CDAI of at Least 70 points|Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)|Time to Improvement in IBDQ|Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression|Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150|Time to Reduction in CDAI of at Least 100 Points|Time to Reduction in CDAI of at Least 70 Points|Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.|Number of Participants with Adverse Events
581,1,During Screening Phase: Incidence of Alloantibody Development|During Screening Phase: Timing of Alloantibody Development|Number of Participants With 50 Percent (%) Decrease in Circulating Anti-Human Leukocyte Antigen (HLA) Antibodies|Number of Deaths 12 Months Post Treatment Initiation|Number of Participants Experiencing Graft Loss 12 Months Post Treatment Initiation|Number of Participants Experiencing Biopsy-proven Post-Transplant Lymphoproliferative Disease (PTLD)|Number of Participants Experiencing Loss of Peritubular Capillary (PTC) C4d Staining on Kidney Biopsy|Number of Participants With Viral Replication of Cytomegalovirus (CMV)|Number of Participants With Evidence of Viral Replication of Epstein-Barr Virus (EBV)|Number of Participants With Viral Replication of Polyomavirus (BKV)
582,1,Control of GVHD|Infusional toxicity|Risk of relapse
583,1,"Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD"
584,1,Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration|Overall Survival at 180 days Post First Infusion
585,1,Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score
586,1,"Dose Limiting Toxicity|Number of Responses (Complete and Partial, Stable and Progressive Disease)|Change in CA-125 Levels From Baseline to Last Recorded Value (up to 18 Months)|Time to Progression"
587,1,"Does a bone marrow transplantation therapy increase the ejection fraction of the heart measured with MRI, when compared with placebo treatment?|Does a bone marrow transplantation therapy increase any cardiac function parameter measured by a an echocardiography, MRI or PET ischemia area, when compared with no treatment group?|Does a bone marrow transplantation therapy improve BNP-value?|Does a bone marrow transplantation therapy decrease hospitalization or the days stayed in hospital?|Does pericardial fluid growth factor concentrations correlate to left ventricular function improvement?|Does autologous cardiac stem cell quality correlate to left ventricular function improvement?"
588,1,Liver function test|MELD score|Cirrhosis mortality after 6 months
589,1,Determine the safety/efficacy of expanded in-vitro allogenic mesenchymal stem cell infusion in patients developing a GVHD refractory to the usual therapeutic measures after undergoing an allogeneic hematopoietic stem cell transplant.|Efficacy will be evaluated in terms of GVHD response.|Safety will be evaluated in terms of incidence of adverse events and toxicities related to the administration of MSC.|Evaluation of infectious complications after MSC infusion.|Analyse the influence of MSC infusion on the posttransplant relapse risk of the base disease.|Study the influence of MSC infusion on DFS and OS.|Determine MSC grafted into the bone marrow (or in other organs).
590,1,"Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes|inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality"
591,1,"Primary 1 Safety: rate of (serious) adverse events in the study population 2 Feasibility: determination of the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses|Secondary endpoints: 1 Presence of late acute rejection (in the 6 month biopsy compared with the 4 week biopsy). 2 Sirius red staining for renal cortical matrix accumulation. 3 Immunologic response before and after MSC infusion."
592,1,Tissue Collection
593,1,"GVHD re-staging and/or GVHD mortality ,side effects"
594,1,Incidence of Infectious Myocarditis|Incidence of Myocardial Rupture|Incidence of Neoplasm|Incidence of Hypersensitivity Reaction|Incidence of Immune Sensitization|Assessment of LVAD Wean|Incidence of Study Intervention-related Adverse Events|Incidence of All Serious Adverse Events|Number of Patients Who Experienced Donor-specific HLA Sensitization|Incidence of Myocardial Neovascularization at Time of Explant|Incidence of Cardiomyocyte Regeneration at Explant|Incidence of Cell Engraftment and Fate at Explant|Incidence of Survival to Cardiac Transplantation
595,1,"the intrauterine transmission rate;vertical transmission rate (intrauterine and delivery)|liver function normalization rate; HBV DNA and HBeAg reduction and negative conversion rate;|drug adverse reaction in pregnant women; complications during pregnancy and delivery, gestational age at delivery, the method of delivery, peripartum hemorrhage, the newborn growth and development milestones, Apgar score, newborn deformity prevalence"
596,1,"Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence|Immunological reaction"
597,1,"Sjögren's syndrome disease activity index|pSS Serology (ANA, dsDNA, SS-A, SS-B)|Improvement of salivary gland function (measured as stimulated saliva flow rate)"
598,1,Magnetic resonance angiography
599,1,Short-term therapeutic effects of transplantation.|Long-term outcomes of transplantation.
600,1,Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT
601,1,"mRSS score,HRQOL score, SF-36 score for SSc patients|Remission for organ function, VC, DLCO, PAP, serum albumin, serum creatitin, weight loss, 24h proteinuria|SSc Serology(ATA,ACA,ANA,anti-ssDNA,anti-dsDNA,IgM,IgG,and IgA,complement C3 and C4|Change of peripheral blood B and T cells"
602,1,The total Response rate defined as patients with complete and partial response.|Overall Survival|Events Free Survival|The percentage of patients who can taper or discontinue the immunosuppressive agents|Serum cytokine levels and lymphocyte subsets in patients with chronic GVHD
603,1,"The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB)"
604,1,Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.
605,1,"Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2)."
606,1,"The levels of serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), precollagenⅢ(PCⅢ), collagenⅣ(Ⅳ-C), laminin(LN), hyaluronidase(HN), liver histological improvement."
607,1,Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Quality of Life|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Number of participants experiencing Acute GVHD
608,1,"Adverse events, vital signs, cardiac and ECG parameters and clinical laboratory safety assessments.|Plasma concentrations of GSK1070806 and derived pharmacokinetic parameters thereof.|Serum levels of Interleukin-18 (IL-18).|Endpoints of immune function and derived pharmacodynamic parameters thereof.|Serum levels of anti-GSK1070806 binding antibodies."
609,1,"Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors|Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation"
610,1,ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores
611,1,One-year overall survival in the 2 arms.|Incidence of grade II-IV and grade III-IV acute GVDH|Number of absolute donor T cells after HCT in each arm|Cumulative incidence of non-relapse mortality|Incidence of extensive chronic GVHD in each arm|Incidence of graft rejection in each arm.|Quality and timing of immunologic reconstitution in each arm.|Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC|Proportion of patients with measurable disease at HCT who achieve a complete response in each arm.|Cumulative incidence of relapse|Incidence of progression-free survival|Incidence of infections
612,1,"Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death"
613,1,"To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells|To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales."
614,1,"To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.|To determine if MSCs elicit an immune response after repeated infusions.|To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy."
615,1,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred|Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion"
616,1,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells
617,1,"Adverse events, Safety laboratory values and ECG findings|Immunological reaction|Tumorigenesis"
618,1,Scores on unified MSA rating scale
619,1,death|myocardial infarction|pulmonary embolism|ischemic stroke|deep venous thrombosis|other arterial or venous thrombosis|Infection requiring IV antibiotics
620,1,"Anticancer activity in terms of progression-free survival time (PFS)|Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0)|Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria|Overall survival|Correlation of tumor marker CA-125 with imaging methods"
621,1,"Assessing the percentage of inhibition of memory T cell response and/or naive T cell response, the induction of donor-reactive T cell anergy and the appearance in the peripheral blood of regulatory T cells.|Safety parameters related to MSC infusion, graft function, graft rejection"
622,1,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT."
623,1,Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS
624,1,Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease
625,1,"Safety as measured by laboratory assessments, ecg and temperature.|Efficacy as measured by SPECT scan, MUGA scan and 2D Echogradiogram"
626,1,"Determine the safety and tolerability of GL-ONC1, administered intravenously to patients with advanced solid tumors.|Detection of virus delivery to primary and/or metastatic tumors by PCR and immunohistochemistry.|Evaluation of anti-vaccinia virus immune response (antibody responses)|Evaluation of viral delivery by fluorescence imaging|Determine recommended dose and schedule for future investigation.|Evaluation of anti-tumor activity|Determine possible predictive value of Circulating Tumor Cell counts and Beta-glucuronidase levels relative to patient survival outcomes.|Assess correlation of CTC number with radiological (imaging) as early pharmacodynamic and response rate indicators for GL-ONC1 treatment."
627,1,Change in left ventricular ejection fraction|6-min walking distance|Quality of Life|All cause mortality|Cardiovascular events
628,1,The femoral head blood-supply artery angiographies and the areas of femoral head necrosis|Coxa joint paining|Walking distance|Joint functions|Life
629,1,"To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months"
630,1,"wound measurements, healing of wounds, pictures of wounds"
631,1,- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate|- AGVHD grade
632,1,Improvement in Clinical Scores and Radiological images
633,1,number of adverse events after infusion of MSC (hPPL)|Number of severe infections after MSC infusion|Response of acute GVHD|Determination of incidence of chronic GVHD|Survival
634,1,Presence of small genetic alteration in mesenchymal stem cells
635,1,Knee cartilage defects|pain
636,1,Time to fill bony defect|Adverse reaction from bone graft
637,1,feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study
638,1,Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3|Left Ventricular End Systolic Volume|Infarct Size|Left Ventricular Ejection Fraction|Left Ventricular End Diastolic Volume|Number of Participants with Ventricular Arrhythmias|Duke Activity Status Index (DASI) Assessment|New York Heart Association (NYHA) Congestive Heart Failure Classification Status|Maximal Symptom-limited Exercise Test (Treadmill)|Number of Participants with Major Adverse Cardiac Events (MACE)|Overall Survival|Number of Participants with Adverse Events
639,1,"Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.|To examine re-expression or a reduction in promoter methylation in genes involved in tumor suppressor pathways known to be important in colorectal cancer (CRC) or involved in EGFR signaling pathway.|Evaluate overall response (OR = CR +PR) according to RECIST criteria at 2, 4, and 6 cycles. Progression free survival, measured as the first evidence of tumor growth from the start of treatment will also be assessed.|Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression."
640,1,AE and ECG parameters|Regional myocardial perfusion and infarct size
641,1,AE and symptomatic relief|Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler
642,1,Lysholm score|Radiographics
643,1,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline
644,1,ALT|AST|Serum Albumin|Liver Fibrosis|Progression of fibrosis
645,1,Change in angiogenesis|Change in ulcer size|Visual Analog Score|Exercise Treadmill Test|Improvement in vascularity and blood supply
646,1,"Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infection|Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)|Number of admissions to Emergency Room|Survival|Growth measured by Z-score|Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy|Deafness or Blindness|Number of adverse events|Significant changes in vital signs|Significant changes in physical exam"
647,1,mortality|Evaluation of MSC therapy effects on organ dysfunction|Evaluation of MSC therapy effects on systemic inflammatory parameters|Evaluation of MSC therapy effects on septic shock reversal
648,1,Number of Adverse Events
649,1,Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion|Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA|Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA
650,1,"change in immune function,liver function in blood"
651,1,Safety|efficacy|Efficacy
652,1,Change from baseline in Visual analog scale (VAS) at 6 and 12 weeks
653,1,Biomarkers|LRRK2 expression and/or phosphorylation
654,1,Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire)
655,1,gingival cervicular fluid BMP-2 level|intrabony components (defect bony filling)
656,1,Feasibility
657,1,Occurrence of study related adverse events|Anti-tumor responses to CART-19 cell infusions
658,1,Derivation of iPS cells|Differentiation of iPS cells to cardiomyocytes|Electrophysiology on iPS-derived cardiomyocytes
659,1,Absence of lung deficits during the procedure and/or in the 4 months follow-up|Quality of Life|Pulmonary function|Inflammation
660,1,Assessment of changes in International Standards for Neurological Classification of Spinal Cord Injury according to American Spine Injury Association|Assessment of changes in score of pain index using Short-form McGill Pain Questionnaire|Assessment of changes in score of activity of daily living|Assessment of changes in sensory evoked potentials and motor evoked potentials
661,1,pain|physical activity|walking distance|Imaging
662,1,fistula closure|CDAI
663,1,"Clinical Benefit Rate (CBR) in Cohort A|Clinical Benefit Rate (CBR) in Cohort B|Progression-free Survival (PFS)|Percentage of Participants With Objective Response Rate (ORR)|Overall Survival (OS)|Number of Participants With Physical Examination|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Sign Measurements|Number of Participants With Worst Shift From Baseline Values to Post-baseline Values in Laboratory Parameters|Number of Participants With TEAEs Related to Electrocardiogram (ECG) Findings|Number of Participants With TEAEs Related to Echocardiography Parameter|Number of Participants Reporting One or More TEAEs and Serious Adverse Event (SAE)|Cmax, SS: Maximum Observed Plasma Concentration at Steady State for Ponatinib"
664,1,"Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)|Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)|MELD Score|Child-Pugh grade|Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)|Visual Inspection (Liver volume, Fibroscan)"
665,1,Improvement in Liver function tests|Changes in liver function according to Child-Pugh|Changes in liver function according to MELD Score|Improvement in QUALITY OF LIFE SCALE (QOL)
666,1,Increased expression of chondrogenic markers|Increasing secretion of anti-inflammatory molecules in vitro
667,1,Adverse Events Related to Study Treatment|Evaluate the Direct Anti-tumor Activity of NY-ESO-1ᶜ²⁵⁹T|Peak Persistence of Modified T-cells in the Peripheral Blood
668,1,Reduction of the total necrotic area by Magnetic Resonance Imaging (MRI)|Pain reduction by measurement of the Visual Analog Scale (VAS)|Functional status evaluated by Harris Hip Score (HHS) and Western Ontario McMaster Universities Arthritis Index (WOMAC)|maintenance of structural integrity of the joint by Radiography (RX)
669,1,Change in WOMAC (Western Ontario and McMaster Universities)score|Change from baseline in cartilage thickness at 6 months by MRI|Knee pain relief (WOMAC and Lequesne scores)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)
670,1,"Safety compared with placebo|Change from baseline in the lung tissue density measured by CT-densitometry at6, 12, 24 months|DLCO change from baseline at 6, 12, 24 months|Change from baseline in the functional parameters (FEV1, TLC, RV, FEV1/FVC) at 6,12,18,24 months|Dynamics of the physical capacity (by the 6-min test results)|Dynamics of the blood gas composition (PaO2, PaCO2)|Dynamics of serum level IL-6, TNF-α, Leptin|Quality of life indices by the questionnaire (SF-36)|Number and frequency of exacerbations|Body mass index"
671,1,"MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0|Number of toxicity incidents defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment|Number of responses using Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1|Time to tumor progression"
672,1,Adverse effects after intravenous infusions|Clinical outcome
673,1,Incidence of treatment-emergent AEs (frequency and severity at each dose level)|Incidence of SAEs|Change in Six Minute Walk distance|Change in Dyspnea Score|Change in WHO Functional Classification|Change in Plasma NT-pro-BNP levels|Change from Baseline in echocardiography parameters|Change in cardiopulmonary hemodynamics
674,1,"The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint.|The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available:|• LV end diastolic volume|• LV end systolic volume|• Infarct size measured by MRI, with and without contrast (only for patients eligible for MRI)|• Global Left Ventricular Ejection Fraction (measured by echocardiography)|• SF-36 Health Assessment|• Incidence of Ventricular Arrhythmias requiring intervention at 1 and 3 months post-administration"
675,1,Fever|Unconscious|Vomiting|ALS-FRS|FVC
676,1,MSC Safety and Tolerability|MSC Efficacy
677,1,Volume Maintenance|Immunophenotyping
678,1,Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge
679,1,Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters
680,1,"• Characterization of the molecular profile in tumor derived exosomes from advanced gastric cancer patients undergoing first-line chemotherapy|• Correlation of plasma level and kinetics of gastric cancer derived exosomes (at baseline and monthly during therapy until tumor progression or death) and time-to-event end-points: Overall survival, Progression-free survival and Overall response rate."
681,1,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
682,1,Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.|The evaluation of other emerging potential cardiovascular risk factors
683,1,"clinical and radiological union at 1 month to 6 months|•Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects.|Incidence of adverse events in patients (e.g infection , malignancy , ...) Adverse events will be continuously monitored"
684,1,Safety/efficacy
685,1,survival rate|Liver function|Marker of liver cancer|The degree of hepatic necrosis|The improvement of symptoms|The score for Model for End-Stage Liver Disease|The improvement of immune function|complications|The incidence of hepatocellular carcinoma
686,1,Evaluate the feasability and security of the autologous ASC for the feminine stress urinary incontinence|Quality of life assessment using the SF-12 Questionnaire|Adverse events
687,1,Phenotypic cellular differences (fibroblasts and/or ps-iPSC-ECs) between cases and controls
688,1,Recording of Adverse Events and Serious Adverse Events|Electrocardiogram|Vital signs|Physical examination|WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Laboratory tests|SF-36|NRS-11|The volume of articular cartilage
689,1,"Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events"
690,1,Safety of inject mesenchymal stem cells in MMII|Quality of life of patients after treatment
691,1,incidence of adverse events|changes in brain images
692,1,Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA|Intubation duration|Incidence of BPD|Survival rate|Duration of ventilator dependence|Duration of CPAP treatment|Postnatal steroid use (%) for the purpose of ventilator weaning|Cumulative duration of oxygen use|Incidence of Retinopathy of Prematurity (ROP) of Grade III or more|Retinopathy of Prematurity (ROP) that require treatment with avastin or laser|Growth velocity (Z-score)|Length of stay prior to the first discharge from the hospital|Incidence of adverse events|Clinically significant laboratory findings|Incidence of pneumothorax that require intubation|Incidence of moderate to severe pulmonary hemorrhage|Incidence of intraventricular hemorrhage of grade 3 or more
693,1,Renal blood flow and function in the treated kidneys.|Level of kidney function.
694,1,Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers
695,1,The primary objective of the study is to assess the safety and tolerability of MPC therapy|Exploratory assessment of the efficacy of MPC therapy
696,1,The number of patients with any relevant side effects observed|Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.
697,1,Compare the adverse events between mesenchymal stem cell treatment and placebo groups|Hospital indices by treatment group
698,1,Change from baseline in cartilage thickness at 12 months by MRI|Visual Analog Score|IKDC Subjective Knee Evaluation Form (2000)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)
699,1,Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)
700,1,"Number of Participants with Adverse Events, Ratio of patients who is applicable to CDAI<150|the ratio of patients who reduce CDAI over 70 as contrasted with baseline value|a variation of CRP value as contrasted with baseline|a variation of MR enterographic score as contrasted with baseline|a variation of fecal calprotectin as contrasted with baseline|a variation of IBDQ score as contrasted with baseline|a variation of SF-36 score as contrasted with baseline|reduction of the number of draining fistula|all kinds of adverse effects which occur during the clinical study"
701,1,Number of participants with adverse events|Number of participants with a change in joint function from baseline WOMAC assessment at 12 months|Number of participants with a change in radiogrpahic evidence of knee OA from baseline Kellegren-Lawrence grading system at 12 months
702,1,"Phase 1: Safety and Tolerability|Phase 2: 1-year Disease-Free Survival|Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months|Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months|Disease-free Survival at 3, 6, 18, and 24 Months|Overall Disease-free Survival|Overall Survival, Expressed as the Number of Participants Alive|Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months|Proportion of Patients Undergoing Cystectomy by 12 and 24 Months|Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.|Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated|Total PBMC Counts by Flow Cytometry|Tumor Antigen Expression|Tumor Infiltrating Lymphocytes (TILs)|T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment|Safety of the Combination of the HS-410 and BCG|Safety of the High Dose HS-410 Monotherapy"
703,1,Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.
704,1,Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB)
705,1,To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF).|- To explore effects of allo hMSCs on lung function: forced vital capacity (FVC).|To explore effects of allogenic human mesenchymal stem cells on symptom related quality of life.|Difference in frequency of acute exacerbations of Idiopathic Pulmonary Fibrosis (IPF)|Death from any cause.|To explore effects of allogenic human mesenchymal stem cells on lung function: Diffusing Capacity (DLCO)
706,1,Number of Participants With a Clinical Activity-radiographic Response|Count of Participants With Serious and Non-serious Adverse Events|Percentage of Participants Overall Survival|Progression Free-Survival|Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
707,1,number of subjects with adverse events|Assessment of visual function changes from the base line
708,1,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation
709,1,Change in Non-detection rate of CTC's in men with CRPC|Median number of CTC's detected by each capture method|Change in median number of CTC's for each method|Correlation of CTC enumeration with presenting clinical stage|Correlation of CTC enumeration with sites of metastatic disease|Correlation of CTC enumeration with Gleason sum|Correlation of CTC enumeration with PSA kinetics|Correlation of CTC enumeration with therapies|Correlation of CTC enumeration with overall survival|Correlation of CTC enumeration with progression-free survival|Correlation of CTC enumeration with response to therapy
710,1,Number of subjects with adverse drug reactions|Respiratory outcomes|Survival|Z-score|Potential neurological development test outcomes
711,1,All Cases Improvement|All Cases Fertility Improvement
712,1,"Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects, comparing the non-detection rate over time.|Comparison of the proportion of patients with no detectable CTCs between capture methods over time|Changes in CTCs (using each method) over time during systemic therapy|Change in correlation of CTC enumeration using each method with baseline clinical and pathologic disease characteristics (for example, clinical stage, site of metastatic disease, Gleason sum for CRPC, PSA for CRPC, previous therapies)|Median number of CTCs detected by each method over time"
713,1,"Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by left ventricular ejection fraction (LVEF [radionuclide ventriculography {RVG} or echocardiogram])|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - European Quality of Life (EuroQoL) 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBCs, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic blood pressure [BP], diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QT interval with Fridericia's correction (QTcF), heart rate-corrected QT interval (QTcB), QT, Q wave, R wave and S wave (QRS) complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data"
714,1,vital parameters|assessed of acute graft versus host disease (GvHD)
715,1,VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires
716,1,Number of participants with adverse events|Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)|Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale|Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT)|Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test|Number of participants with a change in mobility and leg function as measured by the 25 foot walking test|Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire|Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)|Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI)
717,1,Adverse Events Analysis|Efficacy Analysis
718,1,Change from baseline in safety|Change from baseline in effectiveness by MRI|Feasibility|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect
719,1,"Safety: Adverse Events|Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score"
720,1,Safety of the procedure|Analyze the efficacy of the procedure
721,1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with reduced symptoms or stabilized conditions after treatment
722,1,Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers
723,1,"proportion of lymphocytes, myeloid and mesenchymal populations in the samples"
724,1,Pain relief|Functional Outcome
725,1,Number of participants with adverse events|Number of participants with a change in disease activity index as measured by 28-DAS Score|Number of participants with a change in current disease activity as measured by EULAR Response Criteria|Change from baseline quality of life measure (based on Stanford HAQ)|Change from baseline C-reactive protein|Change from baseline erythrocyte sedimentation rate (ESR)|Change from baseline anti-citrulline antibody measure|Change from baseline rheumatoid factor (RF)
726,1,Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy
727,1,Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.|Change in quality of life|Changes in exercise capacity|Changes in plasma inflammatory markers
728,1,"Safety|Efficacy: Change from Baseline in Modified Truelove-Witts score|Efficacy: Change from Baseline in Quality of Life index, Inflammatory Bowel Disease Questionnaire (IBDQ-32)|Efficacy: Change from baseline in Mayo endoscopic index.|Change from Baseline in C Reactive Protein|Change from Baseline in fecal calprotectin"
729,1,To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC
730,1,Number of participants with adverse side effects.|Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF
731,1,Visual acuity|Visual fields
732,1,maximum tolerated dose (MTD) of IV MSCs|Improved functional outcome
733,1,The interplay between Twist1 and other EMT regulators throigh microRNA-29 family
734,1,Gross Motor Function Measure Score|Routine Blood Test and Biochemical Test
735,1,Treatment of hypertensive leg ulcer by adipose tissue grafting|treatment of angiodermatitis necrotitis by lipofilling
736,1,Amount of New Bone Mass Formed|Quality of Bone Regeneration
737,1,GVHD|Overall survival|Relapse-free survival|Infection rate
738,1,Clinical outcome|Radiological outcome
739,1,"Cellular gene expression, cellular protein expression, and site directed mutagenesis of induced pluripotent stem cells in response to antihypertensive drugs."
740,1,The examination of heart function|all-cause mortality|all-cause morbidity|major adverse cardiac and cerebrovascular events
741,1,HbA1C|Fasting Blood Glucose
742,1,Adverse effects|efficacy
743,1,"Major adverse cardiac adverse events. SAEs and AEs.|NYHA functional class.|Incidence of complications with the use of NOGA XPTM catheters.|Laboratory parameters including C-reactive protein an brain natriuretic peptide|NYHA Functional Class|Max.oxygen consumption(MVO2),functional capacity.|Quality of life questionnaires|Extension. of perfusion defects(MRI/SPECT).|LVEF, ventricular vol.,wall motion score index(echocard./MRI/SPECT|LVEF(left ventriculogram, electromech. mapping parameters(NOGA XPTM))"
744,1,"clinical and radiological union at 1 month to 6 months|Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects(infection,malignancy,local or systemic allergic reaction)"
745,1,National Institutes of Health Stroke Scale (NIHSS) scores.|The Barthel Index|The Mini-Mental State Examination (MMSE)|The Montreal Cognitive Assessment(MoCA)|Unified Parkinson's Disease Rating Scale (UPDRS)|adverse reaction
746,1,C-peptide derived from the Mixed Meal Tolerance Test (MMTT)
747,1,Improved healing of scarred vocal folds
748,1,Amount of systemically infused (MSC) DNA relative to recipient DNA at sites of prostate cancer in men with localized adenocarcinoma of the prostate that are scheduled to undergo a prostatectomy|Feasibility of infusing MSCs into men with localized prostate cancer who plan to undergo a prostatectomy.|Determine the proportion of MSC to recipient DNA in the peripheral blood|Determine the proportion of MSC to recipient DNA within the seminal vesicle.|Changes in the Sexual Health Inventory for Men (SHIM) survey post-prostatectomy.|Change in urinary function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in bowel habits as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in sexual function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in hormonal function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in overall satisfaction as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Safety as assessed by number of participants experiencing adverse events|Safety as assessed by number of participants experiencing serious adverse events|Safety as assessed by number of participants experiencing treatment-related adverse events
749,1,ASIA (American Spinal Injury Association) scale|Magnetic Resonance Imaging|MEP/SSEP|ADL (activities of daily living)|SF-36|ODI (Oswestry Disability Questionnaire)|Frequency of Adverse Events
750,1,Efficacy between groups post-index procedure|Efficacy and safety between groups post-index procedure
751,1,The efficacy of treatment for refractory cGVHD|acute and late toxic side effects of MSCs treatment
752,1,The efficacy of treatment for refractory aGVHD|acute and late toxic side effects of MSCs treatment
753,1,"Safety of UCB-MSC in SR-GVHD|Complete, Partial Response Rate at 28 and 180 Days in participants with SR-GVHD treated with UCB-MSC"
754,1,"safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)"
755,1,Viability and safety of mesenchymal stem cell transplant|Absence of complications in pre and peri surgical implantation|Improvement of 2 lines in Best Corrected Visual Acuity
756,1,survival time|Serum markers regarding liver and kidney function|Serum markers regarding lipid and sugar profile|Serum markers regarding cytokine profile|Serum levels of Hepatitis B and C|tolerance and the adverse events|Changes of any clinical symptoms
757,1,Primary objective of the study is to assess the safety and tolerability of MPC therapy
758,1,"Safety and Tolerability as measured by the number of patients with Adverse Events, as well as type of AE and frequency|Presence of Virus in Tumor|Determine Initial Susceptibility of tumor to viral infection|Anti-Tumor Activity (Early Efficacy)"
759,1,Recording of Serious Adverse Events|Functional status of the knee|Quality of life
760,1,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)"
761,1,Find dose of autologous T cell receptor
762,1,"Survival at one year after onset of graft versus host disease|Response at 14 days after commencement of treatment for acute graft versus host disease|Response at 28 days after commencement of treatment of acute graft versus host disease|Incidence of severe infection|Disease free survival at one year|Time to treatment failure, requiring salvage therapy"
763,1,"Safety|Liver function tests.|CT scan of abdomen.|Change in MELD score|Improvement in quality of life as assessed by SF 36 questionnaire|Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA|Change in Child-Pugh score"
764,1,Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.|All-Cause Mortality or Dialysis (composite endpoint).
765,1,The improvement of the fusion of the posterolateral fusion measured on X-rays|The improvement of the fusion of the posterolateral fusion measured on X-rays and CT scans.
766,1,Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC)
767,1,"Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0|Total number of GELs at weeks 4, 12 and 24 after MSC therapy|contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.|Comparison of contrast enhancing lesions between treatment periods|Combined unique MRI activity|Relapses|Progression of disability|Disease free patients|MSFC score|peripheral immune responses|Type 4 hypersensitivity reaction"
768,1,Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF)
769,1,Activities of Daily Living(ADL)scale|Incidences of Adverse Event and Serious Adverse Event|Change from baseline in CK|Change from baseline in LDH|Change from baseline in ALT|Change from baseline in AST|Change from baseline to manual muscle test(MMT)|Change from baseline in electromyography(EMG)
770,1,Number of patients with Sustained efficacy of complete closure of fistula|Number of patients with sustained efficacy of closure of fistula|Evaluation of Fecal Incontinence Score|Grade of Investigator's satisfaction|Number of patients with adverse events as a measure of systemic tolerance and physical examinations
771,1,Safety|Engraftment
772,1,Significant MRI Change before and after intervention|Significant neurologic funtion Change before and after intervention|Significant Electrophysiological Change before and after intervention|Adverse event
773,1,healing of fracture|VAS
774,1,Degree of improvement in knee assessments compared to the active control (microfracture)|Number of subjects with adverse events
775,1,Treatment Emergent Adverse Events|Immunogenicity|Assessment of the Effect of PA401 on Induced Sputum Total Neutrophils|Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)|Pharmacokinetic Parameters: Time of Occurrence of the Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetic Parameters: Terminal Half-life (t1/2)|Pharmacokinetic Parameters: Area Under the Plasma Concentration-time Curve From Zero to Infinity|Assessment of the Effect of PA401 on Induced Sputum Percentage Neutrophils
776,1,Safety of treatment of treated recto-vaginal fistulae. Percentage of treated enterocutaneous fistulae and percentage of subjects with closed fistulae|Quality of life assessment using the SF-12 Questionnaire|Adverse events
777,1,Number of participants with adverse event|Changes from the baseline in Alzheimer' s Disease Assessment Scale-cognitive subscale(ADAS-Cog) at 10 weeks post-dose
778,1,Safety of MSC treatment.|RA Serology|Disease Activity Score (DAS 28) Index Mean Change From Baseline|Patient's assessment of pain.
779,1,physical function improvement|change in pain density|joint swelling|joint erythema|deterioration of joint function|Allergic reactions
780,1,Change in NIH Stroke Scale|Change in Barthel Index|Change in modified Rankin Scale|Change in size of infarct based on brain MRI stroke sequences|Change in Stroke Specific Quality of Life Scale|Change in Stroke Impact Scale
781,1,Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).
782,1,PIB PET scan|Neuro-psychological tests|FDG PET Scan
783,1,Overall Survival|Liver function improvement|Complications|The improvement of ascites after 12-week treatment|Child-Pugh score|MELD score|SF36-quality of life
784,1,"Relief of the rest pain|Healing of ulcerations or reduction of ulcer area in the target limb|Pain free walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Increase in transcutaneous partial oxygen pressure (TcPO2)|Quality of life by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)|The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).|Assessment of clinical laboratory parameters|Physical examination findings and assessment of vital signs|Assessment of electrocardiogram (ECG) parameters"
785,1,blood test|Nerve functional evaluation|Urinal test|Electrophysiology examination
786,1,Nerve functional evaluation|Forced vital capacity|Blood test|Urinal test|Electrophysiology examination
787,1,Glycosylated hemoglobin (HbA1c)|The acute reaction and severity of adverse events related to the stem cell infusion procedure|Number of severe and documented hypoglycemic events|C-peptide release test|The reduction in fasting blood glucose (FBG)|The increase in basal C-peptide|The postprandial blood glucose|The random glucose level
788,1,swelling of hip joint|deterioration of joint function|skin allergic reaction|Respiratory reaction|Quantitative changes in pain intensity|physical function improvement|subchondral bone edema|cartilage thickness
789,1,clinical improvement|liver regeneration
790,1,Changes in Systolic Blood Pressure (BP)
791,1,reduction of total prosthesis|Pain reduction|functional status
792,1,iPSC development
793,1,"Change in disease activity according to National Institute of Health criteria|Change in disease activity as measured by histological examination|Change in self-assessed disease activity and quality of life|Safety (Adverse events, infections and relapse)|Freedom from steroids at 1 year after MSC treatment"
794,1,Number and location of lesions detected by 68GA-DOTATATE PET/CT compared to 99mTc-HYNIC-TOC SPECT/CT and/or 18F-FDG PET/CT|Number of participants and kinds of adverse events as a measure of safety
795,1,The total Response rate defined as patients with complete and partial response|one-year survival rate|disease relapse|quality of life
796,1,Change from baseline in laser flare and cell measurements|Change from baseline in visual function tests
797,1,"Development of secondary dislocation within 12 months postoperative|Functional outcome 6 weeks, 6 and 12 months after fixation|Safety|bone mineral density|Histology|Dose-response"
798,1,"Derive and characterize patient-specific, induced pluripotent stem (iPS) cells that carry monoamine transporter polymorphisms and differentiate them into dopaminergic neurons."
799,1,Efficacy and Safety
800,1,Clinical Response Rate|Clinical Response|Remission|Crohn's Disease Activity Index Level|C-reactive Protein levels|Fecal calprotectin levels|Immune modulation investigation|Incidence of infections
801,1,Combine remission of perianal fistulising Crohn's|Efficacy Assessment by week 24|Efficacy Assessment by week 52|Efficacy Assessment by week 104|Safety analysis throughout the study:
802,1,"Number of subjects with Adverse Drug Reaction|Neurological development test outcome from the subjects who were treated with Pneumostem®, compared with the patients who suffered from the same conditions but not treated with Pneumostem®|Growth"
803,1,Magnetic Resonance Imaging|SPECT/CT|Hip X-ray|HHS (Harris Hip Score)|WOMAC (Western Ontario and McMaster Universities) Index|UCLA (University of California Los Angeles) hip questionnaire|Safety evaluation
804,1,Magnetic Resonance Imaging|Changes of Neurological Functions|Safety evaluation
805,1,Number of adverse events and serious adverse events|Evolution of chronic critical ischemia
806,1,To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.|To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).
807,1,IKDC Score|VAS|Lysholm Score|KOOS Score
808,1,Production of cardiomyocytes modele from skin fibroblast of arrhythmic patient|Production of valve interstitial cells modele from skin fibroblast of patient with a valvulopathy
809,1,Occurrence of study related adverse events|Anti-tumor responses to CART-20 cell infusions
810,1,"Change from Baseline in Visual Analogue Scale (VAS)|Change from Baseline of Quality of life scores|Change from Baseline of Reduction in analgesics|Number of adverse events reported|Change from Baseline in x-ray, sonogram, or MRI imaging of affected joint compared to baseline."
811,1,• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP)
812,1,"The improvement of Liver Histologic grade|The evaluation of hepatic dendritic cells activity by immunohistochemistry|Liver fibrosis quantitative analysis using Hydroxyproline contents in liver tissue|Real-Time Polymerase Chain Reaction for relative mRNA expression of TGF-beta, collagen, procollagen, MMP2 or 9|Hepatic venous pressure gradient(HVPG)|Hepatic vein arrival time using microbubble contrast enhanced ultrasonography|Liver stiffness measurement with transient elastography|Child-Pugh score|MELD score"
813,1,"British Isles Lupus Assessment Group score (BILAG)|Lupus serology (Alb, ANA, dsDNA, C3, C4)|Renal function (GFR, Blood Urea Nitrogen, urinalysis)"
814,1,Failure of cranioplasty implant|Quantitative bone density of the tissue engineered construct and adjacent bone from CT scan at 12 months.|Assessment of cosmesis by photography
815,1,Serum Level of follicle-stimulating hormone|Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow|Modified Kupperman Score|Incidence of Adverse Events and Serious Adverse Events
816,1,Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image|Differences the results obtained in the two groups of patients due to determined parameters.
817,1,RADIOGRAPHIC UNION SCALE (RUST Score) as a measure of bone union|Visual analog scale as the measure of clinical union
818,1,Wound closure|Overall rate of wound healing reduction
819,1,iMP-related adverse events|Hypersensitivity|Scar reduction|LVEF|Change in quality of life
820,1,Safety of UC-MSC in patients with acute graft-versus-host disease|Efficacy of UC-MSC in patients with acute graft-versus-host disease
821,1,Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas|Percentage of Participants With 6 Month Progression Free Survival (PFS)|Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)|Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)|Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)|Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)
822,1,"forced vital capacity( FVC), forced expiratory volume(FEV1), FEV1/FVC|six minute walk test"
823,1,Improvement in myocardial perfusion/viability|Morbidity|Change in left ventricular function
824,1,fever|unconsciousness|brain hematoma|vomiting|ALS-FRS|EMG-NCV
825,1,Fever|Unconsciousness|vomiting|ALS-FRS|FVC|EMG-NCV
826,1,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function
827,1,Any toxic effect reported during MSCs infusion or in the subsequent 10 days by clinical monitoring|Feasibility as the possibility of producing adequate lots of patient dedicated MSCs for any patients presenting with steroid resistant GVHD|Number of patients with GvHD resolution|Determination of recurrence of GvHD|Relapse of haematological disease|Survival
828,1,one year survival rate|MELD score|Child Pugh Score|alpha fetoprotein|renal function
829,1,"Survival rate and time|Improve biochemical indexes [alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]|The clinical symptom improvement [including appetite, debilitation, abdominal distension, edema of lower limbs, et al]|Liver function evaluation using Child-Pugh score and MELD score|Immune function improvement [including Th1/Th2]|The occurrence of complications [including body temperature, tetter and allergy]|Incidence of hepatocellular carcinoma"
830,1,Rate of patients experiencing dose limiting toxicities of engineered T cells #1138.|Definition of maximum tolerated dose (MTD) of engineered T cells #1138.|Preliminary evidence of response to treatment
831,1,Pain caused by oral mucositis|Level of immune biomarkers in blood|Level of immune biomarkers in mucosal tissue
832,1,Accuracy of black spots in diagnosis of gastric intestinal metaplasia
833,1,Safety evaluation|Alterations in SARA score|Positron emission tomography|Magnetic resonance spectroscopy|Assessment of language and swallowing functions|Evaluation of syncope|Balance test
834,1,Safety evaluation|Positron emission tomography|Magnetic Resonance Imaging|Electroencephalogram|Neuropsychological assessment|Electrodiagnostic Testing|Assessment of language and swallowing functions|Measure of the severity of disability|Assessment of spasticity and strength|Assessment of brain motor control
835,1,LVEF amount of change|Infarct size amount of change|Left ventricle end systolic size change|Left ventricular end-diastolic size change|Incidence of critical heart events|Heart rate variability change amount|Left ventricular local wall movement disorder index change|N-terminal pro-brain natriuretic peptide (NT-proBNP) change
836,1,Number of adverse events|Crohn's disease activity Index (CDAI)
837,1,Liver Histology change|Serum alanine aminotransferase (ALT)|Serum AST|Serum Tbil|Serum immunoglobulin G (IgG)|Serum γ-globulin|MELD score|Number of participants with treatment side effects|Number of participants with improvement of clinical symptoms
838,1,Serum alkaline phosphatase (ALP)|Histological changes in liver biopsies|Serum Bilirubin|Serum AST|Mayo risk score|Number of patients with Portal Hypertension after 12 weeks treatment|MELD score|Number of participants with improvement of clinical symptoms
839,1,"Number of Adverse Events and Severe Adverse Events|Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)"
840,1,Major Adverse Events Analysis (MAEs)|Ankle-Brachial Index (ABI)|Digital subtraction angiography (DSA)|Thermography|Wong-Baker FACES Pain Rating Score|Treadmill test
841,1,Intrinsic variability of MSCs measured by time to third passage of confluent MSC|2-3 IDO production measured as ug/mL of passage 3 MSCs|Percent specific inhibition of CD4 and CD8 T cell proliferation toward donor target cells in one way mixed-lymphocyte reactions
842,1,"Compared change of Motor Score of the American Spinal Injury Association (ASIA) scale|Sensory score of the American Spinal Injury Association (ASIA) scale|Electrophysiological change (Motor Evoked Potentials-MEP, Somatosensory Evoked Potentials-SSEP)|MRI and Diffusion Tensor Imaging of spinal cord"
843,1,"Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation|Changes in functional status|Improvement in other LV parameters as assessed by echocardiogram and cardiovascular magnetic resonance(CMR).|Resolution of scar tissue volume/area on cardiac MRI|Change in serum N Terminal-pro B type natriuretic peptide(NT-proBNP)level|Freedom from major adverse cardiac events as defined by myocardial infarction, hospitalization for angina, myocardial infarction or heart failure, or death (all cause of mortality)."
844,1,"Number of participants with Adverse events, complications.|Efficacy"
845,1,Frequency of Adverse Events
846,1,Constant Shoulder Score|Nuclear Magnetic Resonance (RMN)
847,1,"Incidence rate of acute rejection and early liver function recovery|Patient and graft survival, and prevalence of adverse events"
848,1,Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients|Functional improvement in muscle strength|Functional Improvement in sphincters control|Functional improvement in spasticity control
849,1,Overall Survival|PFS|TTP|ORR|DCR|TTR|Safety|Immunogenicity
850,1,the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria|BASDAI score comparing to baseline|BASFI score comparing to baseline
851,1,Change from baseline in NIH Stroke Scale at 12 months|Improvement of infarct size measured by brain MRI
852,1,Categorical shift in modified Rankin scale (mRS)|Change of National Institutes of Health stroke scale (NIHSS)|Early improvement of National Institutes of Health stroke scale (NIHSS)|Dichotomized modified Rankin scale (mRS)|Change of modified Rankin scale (mRS)|Dichotomized modified Barthel index (mBI)|Change of modified Barthel index (mBI)|Change of gross motor function|Change of Fine motor function|Change of Mobility|Change of mini-mental status exam (MMSE)|Change of quality of life|Safety outcome
853,1,HbA1c|exogenous insulin requirements|fasting hemoglucose|fasting c-peptide|The incidence and severity of adverse events related to the stem cell infusion procedure
854,1,"Maximum tolerated dose of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib phosphate)|Incidence of adverse events|Number of clinical responses|Viral replication and shedding in blood, throat washings, urine, and buccal swabs assessed via quantitative reverse transcriptase polymerase chain reaction|Biodistribution and kinetics of virus spread and NIS gene expression in vivo|Time until treatment related grade 3+ toxicity|Time until hematologic nadirs (white blood cells, absolute neutrophil count, platelets)"
855,1,Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Phase-II portion: Anti-tumor effect (CR+CRi rate)
856,1,Number of patients who didn't require the repeated surgical interventions|Tracheostomy decannulation
857,1,PD-L1 expression profiles of exosomes|miRNA expression profiles of exosomes
858,1,"Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Repetitive Behavior Scale Revised - parent/guardian questionnaire|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version"
859,1,Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size|Change in salivary gland stiffness measured by shear wave velocity|Participant Drop out Rate
860,1,Percent of participants with treatment related Serious Adverse Events (SAE)|Change in inflammatory marker levels|Change in systemic inflammatory marker levels|COVID-19 Viral Load|Change in SOFA score|Change in electrolytes levels|Change in LDH levels|Number of subjects discharged from the ICU|Percentage of participants with less requirement for vasoactive agents|Rate of Mortality|Percentage of participants with changes in immune marker expression|Percentage of participants with changes in radiologic findings|Percentage of participants with less pneumonia symptoms
861,1,Number of Participants With Non-serious and Serious Adverse Events During Trial|Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure|Time to Clinical Recovery (TTCR)|SpO2 Concentration|C-reactive Protein|Lactic Acid Dehydrogenase (LDH)
862,1,survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications
863,1,7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality
864,1,Vertebral bony fusion
865,1,"Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline"
866,1,Safety assessment(evaluation)|Efficacy assessment(evaluation)
867,1,Proportions of subjects who achieved complete wound closure.|Time to initial complete wound closure between the 2 groups.|Changes in wound size compared to baseline between the 2 groups.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.|Durability of complete wound closure for the additional 24 weeks.
868,1,Improvement of Low Back Pain|Tissue Improvement
869,1,ORR|PFS
870,1,miR-1 abundance
871,1,Decreasing total daily dose of insulin (>= 30%)|Increasing of C-peptide level|Decreasing of insulin resistance level|Immunology/inflammatory markers|Adverse events|HbA1c
872,1,Bone Mass Density (BMD)|Visual Analog Scale (VAS)
873,1,"Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale|Safety and tolerability as measured by serious adverse reactions.|Safety and tolerability as measured by immunologic responses.|Motor function as measured by the Timed-Up-and-Go (TUG) scale|Global measurement of disability as measured by the change in the screening ""Off"" modified Hoehn and Yahr (H&Y)|Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)|Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)|Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)|Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).|Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)|Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)|Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)|Measurement of putative paracrine mechanism of MSCs using neuroimaging|Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors|Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid"
874,1,"Number of Participants Experiencing Dose Limiting Toxicities (DLTs) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events (AEs) Version 5.0|Number of Participants with Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) Assessed by Investigators|Overall Survival (OS) Assessed by Investigators|Number of Participants with Adverse Events (AEs) and Treatment Related Adverse Events (TRAEs)|Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings|Number of Participants With Anti-Drug Antibodies (ADAs) for Cetuximab"
875,1,Treatment related adverse events|Complete clinical healing
876,1,Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell|Change in type VII collagen and anchoring fibril expression at dermoepidermal junction|Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)|Change in Global severity score|Change in total body surface area affected by RDEB|Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire|Change in blister count|Change in pruritus visual analogue scale (VAS)|Change in pain visual analogue scale (VAS)
877,1,•Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|change in Neurogenic Bladder Symptom Score (NBSS)|change in Neurogenic Bowel Symptom Score|Incidence of abnormal CSF composition|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Correlation of adverse events to study drug
878,1,VAS score|WOMAC score|IKDC score|KOOS score|PROMIS29 score|Kellegren-Lawrence grading|Interleukins
879,1,Incidence of adverse events|Incidence of abnormal results of Physical examination|Percentage of abnormal Vital signs|Percentage of abnormal results of Laboratory tests|SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)|BILAG 2004 (British Isles Lupus Assessment Group 2004)|SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index|Disease activity assessed by PGA (Physician Global Assessment)
880,1,The change of PELD scores during study|The change of albumin (Liver function)|The change of total bilirubin (Liver function)|The change of prothrombin time|The change of liver biopsy|The number of Adverse Events (AE) and Serious Adverse Events (SAE)
881,1,ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change)|Treatment related Adverse Events
882,1,Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs
883,1,Whole blood sample collection|iPSC disease modeling
884,1,Incidence of infusion-related adverse events|Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)|Selection of an appropriate dose of BX-U001 for the following Phase 2 study|All-cause mortality|Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.|Duration of ICU stay|Duration of hospital stay|Changes in blood cytokine levels
885,1,"Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up."
886,1,Clinical deterioration or death
887,1,Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council
888,1,"SAE incidences over the study period|SUSAR incidences over the study period|TEAE incidences over the study period|Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.|Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits|Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits|Change and ratios of MRI image from baseline to subsequent scheduled visits|Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits"
889,1,"Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months"
890,1,The changes in HbA1C level|Reduction of insulin requirement|The changes in blood glucose level
891,1,Overall survival|Clinical improvement|Time of COVID19 PCR negativity|Radiological improvement (day 15 and day 30 assessment)|days required to discharge from hospital
892,1,To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)
893,1,The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test
894,1,"the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.|Any organ damage or safety concerns determined by SMAC 20 blood test.|Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|changes in joint images (X-ray or MRI) from the baseline"
895,1,Safety as measured by adverse events|Adverse Events|Levels of exosomes|Tumor response|Survival
896,1,Overall survival|Changes on inflammatory C-reactive protein|Hospital stay|Oxygenation index (PaO2/FiO2)|Improvement in Liao's score (2020)|Radiological improvement|Time of COVID19 PCR negativity
897,1,"Number of participants with adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Physical function improvement measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC).|Radiographic evidence. Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Quality of Life (QOL) assessment|The Visual Analog Scale (VAS) assessment"
898,1,Oxygen saturation|Oxygen pressure in inspiration|ground-glass opacity|Pneumonia infiltration|Lactate dehydrogenase|C-reactive protein|D-dimer|Ferritine
899,1,"Clinical characteristics|Duration of treatment with InO|Number of cycles of InO|Interrupted cycles of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).|Doses of InO prescribed|Modification of doses of InO, including reasons (liver toxicity TRAEs, other AEs, tolerance, treatment failure, and course complete).|Azole antifungal therapy concomitant to InO treatment|CR, CRi and CR/CRi response rates by the end of InO treatment, overall and according to the number of salvage therapies in the pre-index observation period (0, 1, ≥2);|Median time to CR/CRi (95% CI)|Number and proportion of patients achieving MRD negativity overall and by the number of completed cycles of InO (after 1, 2, ≥3 cycles of InO) in patients evaluated by flow-cytometry/ molecular assessment / both.|The number and proportion of patients surviving at 3, 6 and 12 months after InO initiation|Cause of death|Median OS (95% CI)|The number and proportion of patients who are relapse-free at 3, 6 and 12 months after InO initiation; Median RFS (95% CI) In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT|Median RFS (95% CI)|In patients undergoing follow-up HSCT; Median NRM (95% CI) from the date of follow-up HSCT|Document and report the number of patients who have received post-InO treatment including: new chemotherapy (blinatumomab, other), HSCT, CAR T cell therapy.|In those who received post InO treatment recorded response to treatment and survival|Incidence of grade 3/4 treatment-related adverse events (lung/cardiac/kidney) following InO initiation in all patients|Incidence of liver dysfunction following InO initiation in all patients"
900,1,Number of patients with tropic ulcers cured|Number of patients with treatment-related adverse events
901,1,Clinical improvement: Presence of dyspnea|Clinical improvement: presence of sputum|Clinical improvement: fever|Clinical improvement: ventilation status|Clinical improvement: blood pressure|Clinical improvement: heart rate|Clinical improvement: respiratory rate|Clinical improvement: oxygen saturation|General laboratory outcome from leukocyte level|General laboratory outcome from lymphocytes level|General laboratory outcome from blood pH|General laboratory outcome from blood level of CO2|General laboratory outcome from blood base excess level|General laboratory outcome from blood oxygen partial pressure|General laboratory outcome from blood level of HCO3|General laboratory outcome from blood level of O2 saturation|General laboratory outcome from level of CRP|General laboratory outcome from level of SGOT/SGPT (AST/ALT)|General laboratory outcome from the level of ureum/creatinine level|General laboratory outcome from the level of eGFR|General laboratory outcome from the level of sodium|General laboratory outcome from the level of potassium|General laboratory outcome from the level of chloride|Changes in procalcitonin level|General laboratory outcome from albumin level|General laboratory outcome from total bilirubin level|Changes in D-Dimer level|Changes in fibrinogen level|Cardiac changes from troponin level|Cardiac changes from NT proBNP level|Changes in Leukemia Inhibiting Factor|Changes in level of IL-6|Changes in level of IL-10|Changes in level of vascular endothelial growth factor (VEGF)|Changes in level of ferritin|Changes in level of CXCR3|Changes in level of CD4|Changes in level of CD8|Changes in level of CD56|Radiologic Improvement from Chest X-Ray/CT Scan
902,1,miRNA cointained in exosomes
903,1,"Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.|Changes in length of hospital stay|Changes in mortality rate|Changes of С-reactive protein (CRP, mg/L)|Evaluation of Pneumonia Improvement|Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.)|Peripheral blood count recovery time"
904,1,Rate of adverse event|Rate of serious adverse event|Rate of cure rate
905,1,Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations
906,1,Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen
907,1,Safety: Adverse Event
908,1,Prognostic role of exosomes and their contents on the survival of colorectal cancer patients|Association between the number and size of exosomes and their content on cancer stage and progression
909,1,To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.
910,1,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)|Number of fractures [ Time Frame: From baseline to 16 months follow-up ]|Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.|Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)|Growth (cm). [ Time Frame: From baseline to16 months follow up]|Weight (kg). [ Time Frame: From baseline to 16 months follow up]|Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]|Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)|Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples."
911,1,The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline
912,1,Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU
913,1,Number of participants with non-serious and serious adverse events during trial|Number of participants with non-serious and serious adverse during inhalation procedure|Time to clinical recovery (TTCR)|SpO2 concentration changes|Chest Imaging Changes|Blood biochemistry (CRP)|Procalcitonin concentration|Ferritin concentration|Creatinine concentration|Urea concentration
914,1,Assay Evaluation
915,1,Incidence of Treatment-Emergent Adverse Events (TEAEs)|Incidence of Treatment-Emergent Adverse Events|Changes of pain after stem cell injection|Changes of PUF (Pelvic Pain and Urgency/Frequency) scores after stem cell injection|Changes of ICQ (O'Leary-Sant interstitial cystitis symptom index/problem index) scores after stem cell injection|Changes of voiding profiles after stem cell injection|Changes of Hunner lesion after stem cell injection
916,1,"Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE."
917,1,Proportion of subjects who are completely blocked fistula|Proportion of subjects who are more than 50% blocked fistula|Score of evaluation about Investigator satisfaction using questionnaire|Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test|Visual improvement effect of perianal fistula wound through photography of it
918,1,Number of ventilator-free days|All-cause mortality|Duration of mechanical ventilation
919,1,"Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest."
920,1,Ocular Surface Disease Index (OSDI)|Non-invasive keratography tear break-up time (NIKBUT)|Tear meniscus height (TMH)|Schirmer's I test|Tear osmolarity|Oxford scale|HLA anti-bodies
921,1,Number of all-cause mortality cases|Efficacy of CAP-1002 on Cytokine|Efficacy of CAP-1002 on Laboratory Biomarker
922,1,Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.|Modified Rankin Scale|National Institute of Health stroke scale|Mini-mental State Examination|Barthel Index|Geriatric Depression Scale
923,1,"PaO2 / FiO2 ratio|respiratory function evolution|respiratory assistance|organ failures 1|organ failures 2|organ failures 3|duration of intensive care|Cause of death|respiratory morbidity (TDM, functional respiratory measures)|viral load|Anti-HLA antibody rate|immediate hypersensitivity reactions|thromboembolic adverse events 1|thromboembolic adverse events 2|infectious adverse events"
924,1,Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness
925,1,Describe the range of exosomal expression of P4HA1 in participants being clinically assessed for a suspected lung cancer diagnosis and compare the range of expression between the cancer and non-cancer participant population.|Describe the range of expression of precursor microRNA in exosomes derived from participants being clinically assessed for suspected lung cancer and compare the range of expression between the cancer and non-cancer participant population.|Develop a combined risk score combining multi-dimensional parameters to discriminate between cancer cases and non-cancer cases.
926,1,Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography
927,1,Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score
928,1,Number of participants experiencing Dose Limiting Toxicity (DLT) events|Number of participants experiencing adverse events|Number of participants experiencing progression free survival|Number of participants experiencing overall survival
929,1,senstivity|specificity|survival time
930,1,Number of circulating tumor cells
931,1,Incidence of treatment-related unexpected grade 3 or higher adverse events|Best overall response|Peripheral blood concentration of infused transgenic T cells over time|Concentration of transgenic T cells in tumor tissue|Progression-free survival|Overall survival|Objective response rates
932,1,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
933,1,Wound Healing|Wound Pain|Measured Quality of Life|Systemic Infection|Survival State
934,1,"Platelet reactivity|Concentration of extracellular vesicles from platelets, leukocytes and endothelial cells|Platelet-rich thrombus formation parameters"
935,1,Intrahospital mortality|Length of stay in the ICU and Hospital|Days without mechanical ventilation in 28 days|PaO2 / FiO2 ratio|Incidence of secondary infections|Incidence of adverse events|Quantification of inflammatory response markers
936,1,Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.
937,1,"Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 / FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test"
938,1,Evaluation of the distinction between healthy controls and lung cancer patients through deep-learning analysis of exosomes|Evaluating the possibility of distinguishing between normal and lung cancer patients through the analysis of lung cancer-specific exosomal protein|Evaluation of the possibility of distinguishing the early pathological stages in lung cancer patients through deep-learning analysis of exosomes|Evaluation of the possibility of distinguishing the early pathological stages in lung cancer patients through quantitative analysis of lung cancer specific exosomal proteins
939,1,Correlation between urinary biomarkers and NL|Description of clinical features of patients|Description of immunological characteristics of patients with NL
940,1,Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change
941,1,Wound healing evaluation
942,1,Treatment
943,1,Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination
944,1,Wound healing time and healing rate
945,1,Fold changes of ncRNA expression between eosinophils subtypes|ncRNA levels in rEOS- and iEOS-derived exosomes|Fold changes of ncRNA profiles of distinct eosinophil subtypes|The fold changes of rEOS and iEOS surface integrins expression|The fold changes of rEOS and iEOS eosinophilopoietins receptors expression|The efficiency of iEOS and rEOS adhesion|iEOS and rEOS survival differences|Quantity of iEOS and rEOS synthesized reactive oxygen species|Apoptotic iEOS and rEOS number|Concentrations of iEOS and rEOS produced proteins in investigated subjects' body fluids.|iEOS and rEOS effect on airway smooth muscle cells or pulmonary fibroblasts proliferation|iEOS and rEOS effect on apoptotic ASM cells and pulmonary fibroblasts number|iEOS and rEOS effect on migration of ASM cells.|iEOS and rEOS effect on migration of pulmonary fibroblasts|iEOS and rEOS effect on ASM cells contractility|iEOS and rEOS effect on pulmonary fibroblasts contractility|iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins expression;|iEOS and rEOS effect on fold changes of ASM cells and pulmonary fibroblasts proteins gene expression;
946,1,Treatment related adverse events|Clinical and endoscopic remission|Clinical and endoscopic response|Partial clinical and endoscopic response|Lack of response|Mayo clinic score
947,1,Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal
948,1,MTD of M28z1XXPD1DNR|overall response rate (ORR)
949,1,Treatment related adverse events|Complete clinical healing|Clinical response|Partial clinical response|Lack of response|Crohn's disease activity index|Inflammatory bowel disease questionnaire|EuroQol 5 Dimensions survey|Inflammatory bowel disease patient reported treatment impact survey|Short Form 36 health survey
950,1,"Safety of the Investigational Product, hCT-MSCs, infusion reactions|Safety of the Investigational Product, hCT-MSCs, related adverse events|Safety of the Investigational Product, hCT-MSCs, anti-HLA antibodies|Survival|Inotrope support|Hospital Discharge|Duration of ICU stay|cardiac abnormalities"
951,1,Any composite of major adverse cardiovascular events|Checking patient LVEF|Checking patient infarct size|checking patient perfusion defect.|Coronary disease|Coronary congestive heart failure|Coronary changes in hsCRP
952,1,"The primary end point was checking incidence of adverse events (AEs) within 12 months,|The secondary end point was measuring low attenuation plaque volume LAPV|The secondary end point was efficacy 2"
953,1,vancouver scale
954,1,Engraftment|Overall and event free survival|Graft vs host disease|Graft rejection|Viral reactivation|Immune reconstitution
955,1,Adverse Events|Kidney function|SF-36 (The MOS item short from health survey)|Change in HbA1c
956,1,"Incidence of composite serious adverse events (Phase I)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Overall survival rate (Phase I)|Survival rate in patients who present intubated on ventilator support (Phase I)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Clinical parameters (Phase I)|Oxygenation parameters (Phase I)|Respiratory parameters (Phase I)|Laboratory markers (Phase I)|Hospitalization stay (Phase I)|Intensive care unit stay (Phase I)|Incidence of infusion-related adverse events (Phase I)"
957,1,Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure|Proportions of subjects who achieved complete wound closure at every visit|Change rates in wound size and depth compared to baseline groups
958,1,Survival Rates|Contraction Rates
959,1,Adverse Events|Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|WOMAC 3 subscale score|SF-36|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan
960,1,Maximum tolerated dose (MTD)|Preliminary efficacy of tumor reactive autologous lymphocytes with knockout of CISH gene in patients with refractory metastatic gastrointestinal epithelial cancers: changes in diameter|Safety of tumor reactive autologous lymphocytes with knockout of the CISH gene - Incidence of Adverse Events|Progression-Free Survival (PFS)|Overall Survival (OS)|Toxicity profiles resulting from treatment using these engineered tumor-infiltrating lymphocytes
961,1,"The number of (S)AESI [(Serious) Adverse Event of Special Interest]|Disease progression|Pulmonary function decline|Muscle strength decline|Upper motor neuron function|Cognitive function|Quality of life changes|The change of defined cytokines, chemokines, growth factors, cystatin C and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)|The change of defined cytokines, chemokines and cystatin C level in blood|The change of creatinine and p75ECD level in urine|Muscle function changes|The change of the brain visualization|SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI|Survival period to disease progression|Mortality rate"
962,1,Neurocognitive testing|Core clock gene and kidney clock control gene detection|Blood samples and Apolipoprotein E genotyping
963,1,ICRS-Cartilage Repair Assessment Total Score|ICRS-Cartilage Repair Assessment Overall Grade|Improvement degree of Cartilage Repair by MRI|Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)|Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)|Degree of Functional improvement in Tegner activity score|Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)|Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)
964,1,Number of participants with treatment-related adverse events|Number of participants with mucosal healing|Number of participants with clinical symptom response|Number of participants with improved healing on pathology
965,1,Clinical outcome|CT Scan|RT-PCR results
966,1,Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)
967,1,Safety of HUC-MSCs infusion|Difference in rate of decline of Frailty|Difference in subject quality of life assessments|Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts|Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts
968,1,Visual Analog Scale (VAS)|Western Ontario and McMaster Universities Osteoarthritis Index|Laboratory Asessment|Magnetic Resonance Imaging (MRI) T2 mapping
969,1,Gross Motor Function|Cognitive Function|Chemical Marker
970,1,Visual Acuity Test|Visual Field Test|Funduscopy|Electrorectinography|Optical Coherence Tomography (OCT)|Angiography
971,1,"Obtaining biological samples, and correspondent clinical and imaging data to use, as fresh blood tissues or frozen stored tissues from lung cancer patients and controls obtained from the Division of Thoracic Surgery and LDCT lung-cancer screening program|Tumor antigens identified by RPPA in lung cancer circulating exosome|Investigate the potential role of CTCs as diagnostic and prognostic tool in a screening content|Development and validation of a panel of mutations on circulating DNA as diagnostic test for lung cancer.|Investigate a radiomic signature to discriminate malignant lung nodule Background"
972,1,"Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;"
973,1,Incidence of Adverse Events|Changes in 24h urine protein quantification before and after treatment；|Changes in eGFR before and after treatment;|Changes in SLEDAI score before and after treatment；
974,1,Assessments of diagnosis of CRC by EMT-TF mRNA levels in blood|Prediction of prognosis of CRC by EMT-TF mRNA levels in blood
975,1,Assessments of diagnosis of PC by EMT-TF mRNA levels in blood|Prediction of prognosis of PC by EMT-TF mRNA levels in blood
976,1,change in the contractile function of the heart|change in the size of the heart|change in the volumes of the heart|change in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status|change in the markers of myocardial dysfunction|change in the in the 6-minute walk test|change in the functional status|change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey|change in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire|change in the quality of life evaluated by the Minnesota Living with Heart Failure Questionnaire
977,1,Alfa SMA-1|Collagen type 1|Core Biopsy/Histopathology|Ultrasonography
978,1,Knee Society Score|Knee Society Function Score|Magnetic resonance image (MRI) and X-ray assessment|Health related quality of life score (HRQoL) - SF36|Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Visual Analogic Scale (VAS) pain evaluation
979,1,Dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of a single dose (10 mL) of PEP at escalating concentrations of extracellular vesicles delivered at a single time point (during PCI for AMI) for the treatment of downstream sequela of AMI.|Infarction scar size|Ejection fraction|Abdominal abnormalities|Alloimmune Response
980,1,Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation
981,1,"Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage"
982,1,TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)
983,1,"Change of total score in WOMAC (Western Ontario and McMaster University)|Change of score in WOMAC three subscales (Pain, stiffness, physical function)|Change of score in 100 mm VAS (Visual Analogue Scale)|Change of score in IKDC(International Knee Documentation Committee)|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)|Change in K&L(Kellgren-Lawrence) grade|Change in joint space width|Change in mechanical axis, anatomical axis|Rate of surgery to treat application site after treatment of SMUP-IA-01|Changes in biomarker"
984,1,"The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time"
985,1,Visual acuity change|Summary of adverse events|Retinal Structure (optical coherence tomography)|Retinal sensitivity and fixation (microperimetry)|Multifocal electroretinography responses|Retinal Structure (color and autofluorescence imaging)|Retinal structure (fluorescein angiography)
986,1,"Change of the Constant-Murley score|Change of the VAS pain score|Change of range of motion (ROM)|clinical change based on the DASH scale (disability of the arm, shoulder and Hand)|clinical change based on the , American Shoulder and Elbow Surgeons (ASES) score|evaluation of shoulder MRI results|evaluation of shoulder X-ray (XR) results"
987,1,"Overall tumour Response Rate, according to RECIST v 1.|Choi criteria response rate|Overall Survival|Progression Free Survival (PFS)|Clinical Benefit Rate|Duration of response|Adverse events related to the treatment"
988,1,Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen
989,1,Safety of administration of adipose tissue-derived mesenchymal stem cells measured as reported adverse events|Safety of administration of adipose tissue-derived mesenchymal stem cells measured as neurological o systemic complications|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the Modified Rankin Scale|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the NIHSS|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measuring blood brain repair biomarkers
990,1,Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase
991,1,Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video
992,1,Genomic profiling of MBC patients
993,1,"Incidence of adverse events|Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)|Mortality|Overall survival|Duration of continuous respiratory support|Duration of continuous use of vasopressors or pulmonary vasodilators|The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition|The developmental quotient in Kyoto Scale of Psychological Development 2001|Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words|Presence of spasticity|Presence of epilepsy|MRI score|Gross Motor Function Classification System (GMFCS) score"
994,1,Oxygenation index|28 day mortality|Hospital stay|2019-nCoV antibody test|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)|C-reactive protein(CRP)|CD4+ T-Lymphocytopenia|CD8+ T-Lymphocytopenia|natural killer cell(NK)
995,1,change in gingival inflammation|change in pocket depth|change in attachment level|change in Bone level
996,1,"Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio"
997,1,Change in Numerical Rating Scale|Patient Global Impression of Change|Knee Injury and Osteoarthritis Outcome Score|PROMIS-Physical Functioning Short Form
998,1,PASI score improvement rate|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI(Dermatology Life Quality Index)
999,1,Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality
1000,1,Gut microbiome composition|Infectious complications after transplantation|Organ or tissue rejection
1001,1,"Change on Extracellular vesicles number by ultracentrifugation with sucrose cushion|Change on anxiety, depression and stress (Depression Anxiety Stress Scales, DASS21)|Change on Cancer antigen (CA 15-3)|Change on Prostate-specific antigen (PSA)|Change on Carcinoembryonic Antigen assays (CEA)|Change on Adrenocorticotropic Hormone (ACTH)|Transcript inflammatory response genes (IL-1, IL-6, IL-8, IL-10, IFNγ and TNF)|Change on Analytic biomarkers (Erythrocytes number)|Change on Analytic biomarkers (PCR number)|Change on Analytic biomarkers (telomerase activity)|Change on Analytic biomarkers (hemoglobin glycosylated (HPLC))|Change on Global distress (Clinical Outcome Routine Evaluation - Outcome Measure, CORE-OM)|Change on quality of life (Functional Assessment of Cancer Therapy, FACT)|Change on quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale, FACIT-SP)|Change on fear of cancer recurrence (Fear of Cancer Recurrence, FCR-7)|Change on satisfaction perceived social support (ESSS)|Change on emotional regulation processes (Emotion Regulation Questionnaire, ERQ, emotion suppression subscale)|Change on impact of events (Impact of Event Scale - Revised, IES-R)|Change on Mindfulness Attention and Awareness (Mindfulness Attention and Awareness Scale, MAAS)|Change on self-compassion skills (Self-Compassion Scale - Short Form, SHORT FORM)|Change Interview (Elliot, 1999)|Change on smoking dependency (Fagestrom Test)|Change on physical activity (IPAQ,The International Physical Activity Questionnaire)"
1002,1,Change in Inflammation Surface Area.|Change in Chronic Otitis Media Questionnaire 12 Score|Bacterial Presence
1003,1,mortality|average length of stay|Changes of inflammatory index - the number of leukocyte or lymphocyte|Changes of inflammatory index - the percentage of lymphocytes|Changes of inflammatory index - cytokines|Changes of oxygenation index|Throat swab/blood viral load|Chest imaging outcome
1004,1,"Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) × voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality"
1005,1,Compare HER2-HER3 dimer expression as detected by FLIM-FRET (% positive for HER2-HER3 dimer expression with FRET efficiency ≥8.56%) to HER2 over-expression (% positive for HER2 over-expression by IHC ± FISH) in patient-derived tumour samples.|Describe the range of FRET efficiency determined by measuring tumoural HER2-HER3 dimerisation as a continuous variable.|Compare the HER2-HER3 dimer expression level in tumour samples to matched blood samples (exosomal expression) as detected by FLIM-FRET.|Compare HER2 expression in blood samples (exosomes) by protein detection assays e.g. dot blots to HER2 status in matched tumour tissue as determined by IHC ± FISH.|Determine the range of measurable exosomal FRET efficiency determined by measuring exosomal HER2-HER3 dimer expression.|Determine if patient derived tumour and blood samples (exosomes) demonstrate a change in HER2-HER3 dimer expression in response to systemic HER2-directed therapy (% positive for change in HER2-HER3 dimer expression).|Determine the statistical association of FRET efficiency (at baseline and any subsequent changes) determined by measuring tumoural HER2-HER3 dimer expression with radiological and pathological responses to systemic treatment.|Determine the statistical association of FRET efficiency (at baseline and any subsequent changes) determined by measuring exosomal HER2-HER3 dimer expression with radiological and pathological responses to systemic treatment|Determine the statistical association of the levels of expression of immune cell markers (at baseline and any subsequent changes) with radiological and pathological responses to systemic treatment. (OPTIONAL CONSENT-Guy's hospital site only).|Determine feasibility of using exosomal expression testing in a National Health Service (NHS) practice.
1006,1,SCI evaluation and patients follow up|SCI evaluation and MSCs transplantation
1007,1,"Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection|Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040|Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040|Mechanical ventilation-free days 28 days after the administration of HCR040|Percent mortality 28 days after the administration of HCR040|Daily pulmonary mechanics values (Ppl, DP, CRS)|Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040|Vasopressor-free days 28 days after the administration of HCR040|ICU-free days 28 days after the administration of HCR040"
1008,1,Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing
1009,1,"Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes"
1010,1,Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG
1011,1,Change in bone width|Pain postoperatively in the two different treatments|Radiological examination of bone volume
1012,1,Union|Short Form 12 Physical Component Summary scale.
1013,1,Major adverse cardiac events (MACE) endpoints of mortality|Re-infarction|Target vessel revascularization (TVR)|Heart failure hospitalization|Cardiac MRI|Echocardiography|Electrocardiography (ECG)|Wellness Parameter|Laboratory Assessment
1014,1,Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization
1015,1,Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test
1016,1,RNA-sequencing|quantitative real-time polymerase chain reaction|fertilization and pregnancy rate
1017,1,Incidence of any infusion associated adverse events|Incidence of Severe Adverse Events|All Cause Mortality|Survival Rate|Cytokine Levels|D-dimer Levels|C-reactive protein Levels|Quantification of the COVID-19|Improved Organ Failure|Chest Imaging Changes
1018,1,Incidence of Serious Adverse Events and Adverse Events
1019,1,Serious Adverse Events (SAEs)
1020,1,Number of participants with treatment-related abnormal laboratory values of Liver or kidney function|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Cognitive function|Quality of life evaluation|MRI Neuroimaging|PET-CT Neuroimaging
1021,1,Adverse reaction (AE) and severe AE (SAE)|Efficacy Assessment|The Rate of Recovery Without Mechanical Ventilator
1022,1,Number of ventilator free days|All-cause mortality|Duration of mechanical ventilation
1023,1,"All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin"
1024,1,"Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups."
1025,1,Number of participants with treatment-related adverse events
1026,1,"Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on macromolecules|Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on integrins|Diagnostic performances of markers derived from circulating tumor exosomes in the context of colorectal cancer, focusing on metallo proteases"
1027,1,GCSF Response on Bile flow (KBA)|GCSF Response on transplant-free survival (NoK)|GCSF response on liver function and outcome (KBA)|GCSF response on liver function (NoK)
1028,1,Target heart wall thickness|Heart wall thickening fraction
1029,1,"Determine feasibility of recruiting healthy volunteers in a clinically useful timeframe.|Manufacture a cell-based product suitable for clinical use|Establishment of a robust process of production|Production of stability data to be used in the MHRA dossier for the COMET clinical trial.|Production of cell-based products to be administered to COVID-19 patients with severe pneumonitis.|Analysis of cells for understanding production, manufacture and related research."
1030,1,Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs
1031,1,Safety of the Investigational Product- Infusion Reactions|Safety of the Investigational Product- delayed reactions|Safety of the Investigational Product- formation of anti-HLA antibodies|Time to recovery|Increase in PaO2/FiO2 ratio|Days to hospital discharge to home|The number of ventilator free days|Number of days requiring oxygen support|Percent of screened patients who are enrolled and randomized
1032,1,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28
1033,1,The data of multimodal image recognition system|Molecular subsets in in diffuse gliomas|Overall survival
1034,1,"Clinical assessment of nature, incidence, and severity of adverse events (AEs)|Self-reported assessment of nature, incidence, and severity of AEs|Study personnel assessment of nature, incidence, and severity of AEs|Global Health Scale (GHS)|Visual Analog Scale (VAS) - back and leg pain|Oswestry Disability Index (ODI)|Patient Health Questionnaire-4 (PHQ-4)|Narcotic Use Questionnaire|Work Status Questionnaire|PROMIS-CAT|Changes from Baseline evaluated by MRI|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide"
1035,1,"Lumbar disc signaling values from magnetic resonance imaging|Visual Analogue Scale (VAS) (0-10 scores, the higher scores mean a worse outcome)|Oswestry Disability Index(ODI) (0-50 scores, the higher scores mean a worse outcome)|The Short Form (36) Health survey (SF36) (0-100 scores, the higher scores mean a better outcome)|Disc Height Index (DHI) from X ray|Size of herniated nucleus pulposus from magnetic resonance imaging|Number of participants with treatment-related adverse events by CTCAE v4.0"
1036,1,Functional Respiratory changes: PaO2 / FiO2 ratio|Clinical cardiac changes: Heart rate per minute|Clinical Respiratory Changes: Respiratory rate per minute|Changes in body temperature|General biochemical changes in Leukocytes|General biochemical changes on lymphocytes|General biochemical changes on platelets|General biochemical changes on fibrinogen|General biochemical changes on pocalcitonin|General biochemical changes on ferritin|General biochemical changes on D-dimer|Changes on inflammatory C-reactive protein|Cahnges on Inflammatory cytokine TNFa|Changes on Inflammatory cytokine IL10|Changes on Inflammatory cytokine IL1|Changes on Inflammatory cytokine IL6|Changes on Inflammatory cytokine IL 17|Changes on VEGF|Radiological Changes|Immunological changes on T cell|Immunological changes on Dendritic cells|Immunological changes on CD4+ T|Immunological changes on CD8+ T|Immunological changes on NK cell|Adverse events|RNA detection by SARS-Cov2 PCR
1037,1,changes in myocardial metabolic activity|Changes in left ventricular ejection fraction (LVEF)|incidence of cardiovascular events|overall mortality|adverse events at 12 months after transplantation of autologous BM-MSCs
1038,1,lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9)
1039,1,"Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin"
1040,1,"Incidence of adverse events|Clinical remission (proteinuria, hematuria)|Proteinuria|Hematuria|Estimated glomerular filtration rate (eGFR)"
1041,1,Measure of safety one month after first infusion (adverse events)|Measure of safety one month after second infusion (adverse events)|Change in modified Rodnan skin score (mRss) between Month 0 and Month 12
1042,1,Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14
1043,1,"Changes of oxygenation index (PaO2/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein"
1044,1,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in mortality status|Ventilator Free Days (VFD)|Change in Oxygenation Index (OI)|Change in Lung Injury Score (LIS)|Change in positive end-expiratory pressure (PEEP)|Change in Lung Static Compliance|Change in acute physiology and chronic health evaluation score (APACHE II)
1045,1,Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9
1046,1,Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate
1047,1,Percentage of Dose-Limiting Toxicities (DLTs)|Percentage of Adverse Events (AEs)|Percentage of Serious Adverse Events (SAEs)|Maximum Tolerated Dose (MTD) of ONCR-177|Recommended Phase 2 Dose (RP2D) of ONCR-177|Percentage of Objective Response Rate (ORR)|Durable Response Rate (DRR)|Progression Free Survival (PFS)|Overall Survival (OS)|Incidence and rate of detection of ONCR-177|Changes in the level of HSV-1 antibodies compared to baseline
1048,1,Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9
1049,1,knee pain assessed by Visual Analogue Scale.|knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.|Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix
1050,1,Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate
1051,1,"Number of Participants With Pre-Specified Infusion Associated Adverse Events|Number of Subjects With Serious Adverse Events by 31 Days After First Infusion|Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity|Subjects With Adverse Events and Serious Adverse Events by Severity|Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment|Subjects With Adverse Events by Relatedness to Treatment|Survival at 31 Days Post First Infusion|Survival at 60 Days Post First Infusion|Time to Recovery|Ventilator-Free Days Throughout 28 Days Post Second Infusion|Ventilator-Free Days Throughout 90 Days|Respiratory Rate and Oxygenation Index (ROX Index)|Oxygenation Index (OI)|Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)|Sequential Organ Failure Assessment (SOFA) Scores|Smell Identification Test (SIT) Scores|White Blood Cell Count (WBC)|Platelets Count|Hemogoblin|Hematocrit|Neutrophils|Lymphocytes|Glomerular Filtration Rate|Total Protein|Sodium|Potassium|Creatinine|Glucose|Albumin|Alkaline Phosphatase|Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)|Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)|Total Bilirubin|Blood Urea Nitrogen (BUN)|Calcium|Chloride|Carbon Dioxide (CO2)|C-Reactive Protein Levels|Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio|D-dimer Levels|25-Hydroxy Vitamin D Levels|Tumor Necrosis Factor-alpha (TNFα)|Tumor Necrosis Factor-beta (TNFβ)|Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)|Viral Load by SARS-CoV-2 RT-PCR|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion|Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG"
1052,1,survival after intervention|sequential organ failure assessment score|interleukin-6|The number of allergic reactions|The number of people who get cancer|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system
1053,1,Number of all-cause mortality|Number of days alive off mechanical ventilatory support|Number of adverse events|Number of participants alive at day 7|Number of participants alive at day 14|Number of participants alive at day 60|Number of participants alive at day 90|Number of participants alive at 12 Months|Number of participants with resolution and/or improvement of ARDS|Severity of ARDS|Length of stay|Readmissions|Length of Stay in Intensive Care Unit|Clinical Improvement Scale|Change in plasma hs-CRP concentration|Change in serum hs-CRP concentration|Change in IL-6 inflammatory marker level|Change in IL-8 inflammatory marker level|Change in TNF-alpha inflammatory marker level|Pulmonary symptoms
1054,1,Child Pugh Score|Examination of liver function|MELD Score
1055,1,Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in a prior negative repeat biopsy patient cohort.
1056,1,Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses
1057,1,Interleukin-6|C Reactive protein|Oxygenation|TNF alpha|IL-10|Return to room air (RTRA)|EKG qt interval|Leukocyte differential|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|NK cell surface antigen (CD3-CD54+)|CD4+/CD8+ ratio|Myoglobin|Troponin|Creatinine kinase MB|Serum ferritin|Adverse events|7-point ordinal scale|D-dimer|Chest X-ray|CT scan|PCR test for SARS-CoV-2
1058,1,Number of participants with Dose Limiting Toxicity Events|The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples|The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen|The time in days from the 1st FT516 infusion to hospital discharge
1059,1,Objective response rate (ORR)|Safety and tolerability of the combination of AB-16B5 and docetaxel: number of subjects with an adverse event|Clinical benefit rate (CBR)|Duration of response (complete response and partial response)|Duration of stable disease|Progression free survival (PFS)|Overall survival (OS)|Determination of plasma concentrations of AB-16B5
1060,1,Adverse events assessment|Blood oxygen saturation|Intensive care unit-free days|Clinical symptoms|Respiratory efficacy|Biomarkers concentrations in plasma
1061,1,Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment|Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment|Mortality from any cause at 28 days|Days without mechanical respirator and without vasopressor treatment for 28 days|Patients alive without mechanical ventilation and without vasopressors on day 28|Patients alive and without mechanical ventilation on day 14|Patients alive and without mechanical ventilation on day 28|Patients alive and without vasopressors on day 28|Days without vasopressors for 28 days|Patients cured at 15 days|Incidence of Treatment-Emergent Adverse Events
1062,1,Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate
1063,1,Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score|Visual Analog Scale (VAS) score|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)|Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|International Knee Documentation Committee (IKDC) score|36-Item Short Form health survey questionnaires (SF-36) score|Structural changes in knee joint|Kellgren-Lawrence grade|Number and amount of rescue medication use
1064,1,Signal to Noise Quotient|Side to side difference in anterior tibial translation|Patient reported outcomes- Tegner Score|Patient reported outcomes- Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)|Patient reported outcomes- International Knee Documentation Committee (IKDC) Score
1065,1,Changes in the ulcer area from baseline to eight weeks|Pain change
1066,1,"Number of subjects with adverse events (AE), including serious adverse events (SAEs).|Determining dose limiting toxicities (DLT) and optimally tolerated dose range|Evaluation of persistence of genetically modified T cells.|Measurement of RCL in genetically modified T cells.|Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).|Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.|Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.|Interval between the date of first documented evidence of stable disease (SD) until first documented disease progression or death due to any cause.|Interval between the date of first T cell infusion and the earliest date of disease, progression or death due to any cause|Interval between the date of first T cell infusion and date of death due to any cause.|Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)"
1067,1,Safety and tolerability
1068,1,"Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation|Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation|Change baseline Magnetic Resonance Imaging at 6 month after transplantation|The National Institute of Health Stroke Scale (NIHSS) Scoring|modified Rankin Scale (mRS)"
1069,1,1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection|Confirmation of the degree of pain improvement in VAS|Confirmation of the degree of improvement in disability (ODI)|Confirmation of increase in water content in the nucleus using MRI
1070,1,Recording of Adverse Events and Serious Adverse Events|International Knee Documentation Committee (IKDC) score|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Visual Analog Score (VAS)|Magnetic resonance imaging (MRI)|Immunohistochemistry (IHC)
1071,1,Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC)
1072,1,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test
1073,1,Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive
1074,1,improvement in Visual Analogue Scale|improvement in Oswestry Disability Index|Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry|Presence of new vertebral fracture|Change in the bone mineral density (computed tomography) of fractured vertebrae
1075,1,Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR
1076,1,Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10
1077,1,Efficacy-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessment|Efficacy-Visual Analogue Scale (VAS) assessment|Efficacy-SF-36 Quality of Life (QoL) health survey questionnaire|Efficacy-Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Efficacy-knee joint space width (JSW)|Efficacy-synovial fluid|Efficacy-rescue medication|Safety-AE/SAE based on NCI-CTCAE v5.0|Safety-vital signs|Safety-laboratory examination|Safety-physical examination
1078,1,The type and content of circulating exosomes|Modified Rankin scale (mRS) scores|mortality|hospital stay
1079,1,Change in number of adverse events and severe adverse events post-intervention|Number of grade ≥3 adverse reaction attributable to the γMSC product|Change in lung function test|In- vivo trafficking of MSCs after intravenous infusion|Upper airway inflammation of MSC treatment|Circulating inflammatory cells of MSC treatment|Biophysical characteristics of the cell products and correlation with clinical outcome
1080,1,Incidence of any treatment-emergent adverse events (TE-AEs)|Clinical healing
1081,1,"Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan|Memory change tested on Ray Auditory Verbal Learning Task|Memory change tested on Benson Complex Figure Draw and Memory|Efficacy on PET scan reflected by change in fluorodeoxyglucose (FDG) PET scan|Change in Biomarkers including CSF amyloid, tau and neurofilament|Memory change tested on mini-mental status examination (MMSE)|Memory tested on Alzheimer's Disease Assessment Scale, Cognitive component (ADAS-Cog)"
1082,1,"Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)|Changes in eGFR|Changes in BUN|Changes in Creatinine"
1083,1,Changes of Total Cholesterol|Changes of Low-Density Lipoprotein Cholesterol|Changes of High-Density Lipoprotein Cholesterol|Changes of Triglyceride|Changes of Degree of Coronary Stenosis|Changes of Volume of Carotid Artery Plaques|Changes of Stability of Carotid Artery Plaques
1084,1,Incidence of Heart Failure|Change in Left Ventricular Function from base line|Cardiovascular Death|Composite outcome of cardiovascular death and heart failure incidence
1085,1,Overall response rate|Progression Free Survival (PFS)|Overall Survival (OS)|Evaluate Safety
1086,1,Percent of participants able to complete treatment|Incidence of adverse events|Overall Survival|Myelosuppression|Detection of P140K transduced BG and TMZ resistant cells|Enrichment of P140K-MGMT|Tumor Response using imaging|PFS using imaging
1087,1,Incidence of adverse events|American Spinal Injury Association (ASIA) impairment scale|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walking index for spinal cord injury (WISCI II)|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|Spinal Cord Independence Measure III (SCIM III)|World Health Organization Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF
1088,1,Compare the omics differences of blood samples between the experimental and control groups|Compare the omics differences of urine samples between the experimental and control groups|Compare the omics differences of alveolar lavage fluid samples between the experimental and control groups
1089,1,Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders
1090,1,Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide
1091,1,Infant DNA methylation status|Infant behavioral regulation|Infant proteomic patterns
1092,1,Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC)
1093,1,Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
1094,1,Incidence of major serious adverse events (SAEs)|Incidence of severe arrhythmia|Incidence of newly formed tumors|Changes in penal reactive antibodies (PRA)|Changes in donor specific antibodies (DSA)|Overall Left Ventricular systolic performance as assessed by MRI|Overall Left Ventricular systolic performance as assessed by PET/ECT Scan|Functional status by 6 minute walk test|Functional status by New York Heart Association (NYHA) Classification|Minnesota Living With Heart Failure Questionnaire (MLHFQ)
1095,1,The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose
1096,1,Change in maximal oxygen uptake|Change in time trial performance|Change in total hemoglobin mass
1097,1,"To evaluate the safety of EXO-CD24 in the treatment of patients with moderate or severe COVID-19 disease|To assess the efficacy of EXO-CD24 in the clinical improvement of COVID-19 disease|To evaluate respiratory failure (defined as the need for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow oxygen devices) rate.|To evaluate the death rate.|To evaluate time to improvement and recovery (COVID-19 clinical severity score of 3 or lower).|To evaluate time from hospitalization to hospital discharge.|To assess the COVID-19-related symptoms using patient-reported outcome measure (PRO) score.|To evaluate the effect of EXO-CD24 on the respiratory rate.|To evaluate the effect of EXO-CD24 on the change in blood oxygen saturation (SpO2).|To evaluate the effect of EXO-CD24 on the proportion of patients requiring ventilation.|To evaluate the effect of EXO-CD24 on the level of inflammatory markers (eg, CRP, ferritin, fibrinogen, di-dimers, IL-6, LDH, lymphocytes count."
1098,1,"Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14"
1099,1,pulse wave velocity
1100,1,Number and frequency of adverse events (AEs)|Changes of vital signs from 1 hour after infusion to day 28±3|Changes of complete blood count (CBC) from day 1 to day 28±3|Changes of blood biochemical from day 1 to day 28±3|Changes of coagulation function from day 1 to day 28±3|Routine urine analysis|Urine pregnancy test (female only)|Cardiac rate measured by twelve-lead electrocardiogram|Percentage of participants achieving ACR20|Percentage of participants achieving ACR50|Percentage of participants achieving ACR70|Change from baseline of the disease activity score based on DAS28-CRP|Change from baseline of the disease activity score based on DAS28-ESR|EULAR response|Change from baseline of the health assessment questionnaire(HAQ) score|Change from baseline of the simplified disease activity index (SDAI) score|Change from baseline of the clinical disease activity index (CDAI) score|Change from baseline of TNF-α level|Change from baseline of IL-6 level
1101,1,Changes in IIEF-5 Score after stem cells injection|Changes in Peak Systolic Velocity (PSV) after stem cells injection|Changes in End Diastolic Velocity after stem cells injection|Changes in Resistive Index after stem cells injection|Changes in Pulsatility Index after stem cells injection|Changes in E-selectin expression after stem cells injection|Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection|Changes in Bcl-2 expression after stem cells injection|Changes in microRNA 16 expression after stem cells injection|Changes in microRNA 126 expression after stem cells injection|Changes in Hba1c after stem cells injection|Changes in Fasting Blood Glucose after stem cells injection|Changes in total cholesterol after stem cells injection|Changes in low-density lipoprotein (LDL) after stem cells injection|Changes in high-density lipoprotein (HDL) after stem cells injection|Changes in Triglycerides (TG) level after stem cells injection|Number of participants with side effects after intracavernosal injection
1102,1,Dose Limiting Toxicity(DLT)|International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)|Response rate of IMACS-TIS|Changes of Core Set Activity Measures(CSAM)|Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Changes of Peak Pruritus Numeral Rating Scale(PPNRS)
1103,1,28-day mortality|Hospital mortality|90-day mortality|Length of stay|Duration of infection
1104,1,X-ray evaluation immediately following surgery.|X-ray evaluation at 4 weeks following surgery|X-ray evaluation at 8 weeks following surgery.|X-ray evaluation at 12 weeks following surgery.|X-ray evaluation at 16 weeks following surgery.|Ultrasonography evaluation at 2 weeks|Ultrasonography evaluation at 4 weeks|Ultrasonography evaluation at 8 weeks|Ultrasonography evaluation at 12 weeks|Ultrasonography evaluation at 16 weeks|Functional evaluation at 8 weeks following surgery.|Functional evaluation at 12 weeks following surgery.|Functional evaluation at 16 weeks following surgery.
1105,1,Dose limiting toxicities (DLTs)|Treatment-emergent adverse events (TEAEs)|Serious adverse events (SAEs)|Deaths|Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])|Concentrations of REGN5093-M114 in serum|Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serum|Concentrations of M24 in plasma|Objective response rate (ORR)|ORR|TEAEs|SAEs|Laboratory abnormalities (grade 3 or higher per CTCAE)|Duration of response (DOR)|Disease control rate (DCR)|Time to tumor response (TTR)|Progression free survival (PFS)|Overall survival (OS)|Immunogenicity as measured by anti-drug antibody (ADA) to REGN5093-M114
1106,1,Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS)
1107,1,Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels
1108,1,Left ventricular ejection fraction|Mortality|NT-proBNP|Left ventricular end diastolic diameter|6 minutes walking distance|Minnesota Living with Heart Failure Questionnaire（MLHFQ）|PET/CMR
1109,1,EV-Score|Survival significance of EV-Score
1110,1,"1. Changes in the total score MDS-UPDRS Part II.|2. Incidence of treatment-emergent Adverse Event (TEAEs).|3. Incidence of treatment-emergent Serious Adverse Events (SAEs).|4. AEs of special interest (serious or non-serious) - thromboembolic events.|5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities|6. AEs of special interest (serious or non-serious) - infections|7. AEs of special interest (serious or non-serious) - hypersensitivities.|8. Laboratory value Complete Blood Count (CBC)|9. Laboratory values Chemistry Metabolic Panel (CMP)|10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern|11. Vital signs. - Respiratory Rate (breaths per minute)|12. Vital signs. - Heart Rate (beats per minute)|13. Vital signs. - Body Temperature (Fahrenheit )|14. Vital signs. - Blood Pressure (mmHg)|15. Weight in lb.|16. Physical examination results. General|17. Physical examination results. Body Systems.|18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.|19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.|20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.|21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.|22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).|23. Changes in Parkinson's disease fatigue scale (PFS-16)|24. Changes in Parkinson's disease Questionnaire (PDQ-39).|25. Changes in Visual Analog Scale for Pain.|26. Changes in Visual Analog Scale for Muscle spasms.|27. Changes in Dosage of medications taken to treat Parkinson's disease."
1111,1,oxygenation index|The value of arterial blood cLAC|The content of IL-1β|The content of IL-6|The content of TGF-α|The content of HMGB1|The content of IL-10|The content of B-type natriuretic peptide (BNP)|electrocardiogram|The average length of stay in hospital|The visual analog scale（VAS）score|The hospital for special surgery (HSS) Knee Score|The New York Heart Association (NYHA) Functional Classification|The 36-Item Short Form Survey (SF-36)|The Hamilton Anxiety Scale|The incidence of allergic reaction|The body temperature|The pulse rate|The respiration rate|The blood pressure|The content of C-reactive protein (CRP)
1112,1,Assessment of changes in bone density and quantity|Assessment of bone quantity|Presence of bone formation markers
1113,1,"Respiratory situation at 24 hours, 3 and 7 days based on the PaO2 / FiO2 ratio that graduates respiratory distress into mild (200-300), moderate (100-200) and severe (<100).|Immune hyperactivation situation: LDH, D-dimer and ferritin value at 24 hours, 3 and 7 days. Each one is a quantitative variable.|Mechanical ventilation: qualitative variable (yes or no)|Combined variable of variables i, iii and in-hospital mortality (this is understood to be: respiratory deterioration or need for mechanical ventilation or in-hospital death)|Number of patients admitted to the ICU|Time to admission to the ICU (from the beginning of the trial and from the beginning of the picture)|Time to the start of mechanical ventilation (from the start of the trial and from the start of the picture)|Time of admission to ICU|Total admission time|In-hospital mortality|Mortality at 30 and 60 days|Respiratory situation at 30 and 60 days according to pulse oximetric O2 saturation, respiratory rate and presence of dyspnea and NYHA grade.|Documented nosocomial infections"
1114,1,Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)
1115,1,Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction
1116,1,Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R)
1117,1,28-day mortality|Ventilator days|ICU stay
1118,1,"Number of participants with dose limiting toxicities (DLTs) in Dose escalation (Part 1A and 1B)|Number of participants with adverse events|Number of participants with clinically significant laboratory abnormalities|Objective response rate in the dose expansion (Part 2) arms|Objective response rate in dose escalation (Part 1A and 1B)|Maximum concentration (Cmax) of viral load titer of PF-07263689|Time to maximal plasma concentration (Tmax) of viral load titer after PF-07263689 dosing|Area under the Curve from time 0 to the last measurable timepoint (AUClast) of viral load titer after PF-07263689 dosing|Viral titers for vector shedding of PF-07263689 in saliva, urine, injection site swab, and swab from any spontaneous skin pox lesion|Sasanlimab trough concentration (Part 1B and 2)|Incidence and titers of anti-IL2 antibodies and anti-drug antibody (ADA) against PF-07263689 and sasanlimab as applicable|Anti-tumor activity (Part 2)|Overall survival (Part 2)"
1119,1,Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation
1120,1,Safety: Incidence of adverse events improvement) in one or more areas of ailments related to PTHS|Safety: Incidence of serious adverse events|Change in motor function in individuals with PTHS|Change in communication abilities in individuals with PTHS.|Change in sleep habits|Change in gastrointestinal health|Change in breath holding spells|Change in cognition|Change in adaptive function|Change in autistic features|Change in parent assessment of quality of life|Change in global clinical status
1121,1,Duration of hospital stay|Post-administration clinical and radiological improvement|Adverse Event and Serious Adverse Event Evaluation
1122,1,Safety (adverse events)|Efficacy: Single Assessment Numeric Evaluation Score (SANE)
1123,1,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Pulmonary function test
1124,1,Severity and incidence of adverse events (SIAE) on the day of treatment|3rd day SIAE|1 week SIAE|1 month SIAE|3 months SIAE|6 months SIAE|12 months SIAE|24 months SIAE|RQLQ score|VAS score|Detection of serum inflammatory factors|Detection of inflammatory factors in nasal secretions|Nasal function test|Nasal endoscopy
1125,1,Disease-related clinical reactions|PFS
1126,1,Severity and incidence of adverse events (SIAE) on the 3rd day after the first administration|1 week SIAE after the first administration|3 weeks SIAE after the first administration|3 week SIAE after the the second administration|1 month SIAE after the last administration|3 months SIAE after the last administration|6 months SIAE after the last administration|12 months SIAE after the last administration|24 months SIAE after the last administration|Child-Pugh score (effectiveness evaluation index)|Survival rate (effectiveness evaluation index)|Liver function (effectiveness evaluation index)|The Model for End-Stage Liver Disease (MELD) score (effectiveness evaluation index)|KPS score (effectiveness evaluation index)
1127,1,Safety of ALLO-ASC-SHEET versus matching control|Proportion of complete wound closure
1128,1,VAS score|Kellgren-Lawrence score
1129,1,Safety and tolerability of BC-101 injection|Changes in wrinkle severity assessment from baseline
1130,1,"Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA)|Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE)|Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR)|Change in cognitive function over time as assessed by Verbal Fluency Test|Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward|Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B)|Change in cognitive function over time as assessed by Boston Naming Test (BNT)|Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF)|Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT)|Changes in concentrations of blood neuro-exosomal GAP43, neurogranin, SNAP25, and synaptotagmin1over time|The area under curve of the blood neuro-exosomal synaptic proteins (GAP43, neurogranin, SNAP25, and synaptotagmin1) for the accurate diagnosis of AD"
1131,1,"Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.|Percentage of area change of study ulcer from baseline to weeks 12 and 24|Number of days to complete ulcer healing|Number of days to 50% ulcer healing|Percentage change in ulcer volume from baseline to weeks 12 and 24|Changes from baseline in ulcer pain assessed using a Numeric Rating Scale|Number clinic/home care visits across groups|Differences across groups on ulcer dressing products used|Changes from baseline in Quality of Life assessed using the Cardiff Wound Impact Schedule|Duration of clinic/home care visits across groups"
1132,1,"• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|monoclonal antibodies. • To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers."
1133,1,Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT
1134,1,The relapse-free period|The need for surgical intervention|The need for the use of basic drug therapy|Adverse effects associated with the therapy
1135,1,Change in UMSARS total (= UMSARS I + UMSARS II) score|Change in UMSARS I score|Change in UMSARS II score|Change in modified UMSARS score|Change in COMPASS select score|Rate of atrophy of selected brain regions
1136,1,Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin
1137,1,Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0|Best Overall Response (BOR) as assessed by RECIST v1.1|Objective Response Rate (ORR) as assessed by RECIST v1.1|Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1|Disease Control Rate (DCR) as assess by RECIST v1.1|Progression-Free Survival (PFS) as assess by RECIST v1.1|Maximum serum concentration (Cmax) of EMB-01|Trough serum concentration (Ctrough) of EMB-01|Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t)|Area under the concentration-time curve from time 0 to infinity (AUC0-inf)|Elimination half-life (T1/2)|Systemic clearance (CL)|Apparent volume of distribution at steady-state (Vss)|Accumulation Ratio (AR) after multiple dosing|Incidence of positive ADA
1138,1,The absence of oral/GI severe regimen related toxicities (oral/GI SRRT).|Duration of oral/GI SRRT|Symptom burden per MD Anderson Symptom Inventory (MDASI)|Duration of febrile neutropenia|Time to neutrophil engraftment
1139,1,"Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline|Change amount of WOMAC total score at post-dose 24 weeks from the baseline|Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline|Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline|Change in T2 mapping at post-dose 52 weeks from the baseline|Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline|Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.|Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks"
1140,1,"Evaluation of surviva|Evaluation of proliferation|Evaluation of apoptosis, phenotype, function of cells|Evaluation of phenotype"
1141,1,Cytokine profile in supernatants|Immune phenotyping|Genetic predisposition for hyperinflammation
1142,1,Establish a model to predict curative effect
1143,1,overall cure rate|time to cure
1144,1,The total score of Montgomery Asperger Depression Scale (MADRS) decreased from baseline after 8 weeks of treatment|Effective rate of treatment (effective: the total score of MADRS decreased by ≥ 50% compared with baseline)|Remission rate of treatment (remission: MADRS total score ≤ 11 points)
1145,1,Primary Objective|Secondary Objective
1146,1,Number of Participants with abnormal Total bilirubin|Number of Participants with abnormal albumin|Ishak Inflammation Rating System|Ishak Fibrosis Score|Overall survival (OS)|HBV-DNA|incidence of liver cancer|Number of Participants with abnormal immunoglobulin|portal vein flow rate|portal vein width|abdominal volume|Number of Participants with abnormal coagulation function
1147,1,MR Elastography|The level of serum alanine aminotransferase (ALT)|Clinical Examination|The level of glomerular filtration rate (GFR)|The level of serum albumin (ALB)|The level of serum total bilirubin (TB)
1148,1,"Nature, incidence and severity of adverse events (AEs)|Change in Numerical Rating Scale (NRS)|Change in joint swelling|Change in the 36-Item Short Form Survey (SF-36)|Change in Knee injury and Osteoarthritis Outcome Score (KOOS)|Change in the International Knee Documentation Committee (IKDC 2000)|Change in cartilage morphology|Change in cartilage T2 relaxation time mapping in MRI|Changes in bone marrow edema-like lesions (BMLs)|Change in weight distribution on stable platform|Change in Range of motion (ROM)|Change in ultrasonographic findings in knee joint"
1149,1,Overall Survival at 12 and 24 months|Progression Free Survival at 6 months (PFS-6)|Overall Survival (OS)|Progression Free Survival (PFS)
1150,1,Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).
1151,1,evaluation the best passage of MSC culture by CD49 surface marker
1152,1,Grading of Adverse Events|Routine physical examinations|Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]|Changes in vital signs: blood pressure [Safety of Mitocell]|Changes in vital signs: pulse rate [Safety of Mitocell]|Changes in vital signs: body temperature [Safety of Mitocell]|Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]|Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]|Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]|Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]|Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]|Electrocardiogram (ECG)|Magnetic Resonance Imaging (MRI)|MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)|Modified Hoehn & Yahr staging|18F-DOPA PET|levodopa equivalent daily dose (LEDD)|PDQ-39 (Parkinson's Disease Questionnaire)|Beck Depression Inventory (BDI-II) scores|Hamilton Depression Rating Scale (HAM-D-17) scores|Mini Mental State Examination (MMSE) Scores
1153,1,Evaluate the safety and tolerability of C5252|Characterize Dose Limiting Toxicities|Identify the maximum tolerated dose (MTD) and/or the RD of C5252|Evaluate the PK of C5252|Evaluate the viral shedding of C5252|Overall response rate (ORR)|Progression-free survival (PFS)|Overall Survival (OS)
1154,1,Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score
1155,1,"Feasibility of administering genetically engineered glucocorticoid receptor knock out virus specific cytotoxic T-lymphocyte (CTL) lines, as indicated by Overall Survival"
1156,1,The association of disease recurrence with plasma levels of exosome and its subgroups.|The change of plasma exosome level during the postoperative surveillance from baseline|The correlation of the therapeutic response with plasma levels of exosome and its subgroups.|The correlation of microfluidic chip based exosome quantification with conventional approach
1157,1,Percentage of participants with Adverse Events (AEs)|Percentage of participants with dose modifications|Dose intensity|Overall Response Rate (ORR)|Overall Intracranial Response Rate (OIRR)|Duration of Response (DOR|Time To response (TTR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)
1158,1,The incidence of serious adverse events.|Number to patients with All-Cause Mortality at 28 days|Ventilator-free days at 28days|Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.
1159,1,Maximum tolerated dose of Descartes-25|Overall Response Rate according to the IMWG response criteria|Median Duration of Response
1160,1,To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index|To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test|To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)|To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events
1161,1,Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale
1162,1,Cartilage Repair|Visual Analog Score for pain|International Knee Documentation Committee Questionnaire|Western Ontario and McMaster Universities Osteoarthritis Index|Perioperative and post-operative complications|Measurement of health resources expenses
1163,1,Gene Measurements|Wound Size|Infection|Pain Level
1164,1,Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 48 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
1165,1,Assessment of inflamation marker levels|Assessment of clinical outcome|Assessment of laboratory routine|Assessment of photo thorax|Assessment of RT-PCR conversion|Mortality rate
1166,1,"Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29"
1167,1,Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue|Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog|Changes in Visual Analog Scale of Neurological Symptoms. - Headache|Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities.|AEs of special interest (serious or non-serious) - infections.|AEs of special interest (serious or non-serious) - hypersensitivities.|Changes in Laboratory values. - CBC.|Changes in Laboratory values. - CMP.|Changes in Laboratory values. - Coagulation Panel.|Changes in Vital Signs. - Respiratory Rate (breaths per minute)|Changes in Vital Signs. - Heart Rate (beats per minute)|Changes in Vital Signs. - Body Temperature (Fahrenheit )|Changes in Vital Signs. - Blood Pressure (mmHg)|Changes in Weight in lb.|Changes in Physical examination results. - General|Changes in Physical examination results. - Body Systems|Changes in Subject's energy - Fatigue Assessment form.|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity|Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough|Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches|Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain|Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire|Changes in Subject's level of depression - PHQ 9 scale.
1168,1,To evaluate full upper limb function at Month 12 following 4 IV administrations of CAP-1002|To evaluate cardiac muscle function and structure at Month 12 following 4 IV administrations of CAP-1002
1169,1,Current Primary Outcome Measure
1170,1,Change from the baseline in ADAS-Cog|Change in CDR-SOB|Change from the baseline in K-MMSE(korean version)|Change from the baseline in CGA-NPI|Change from the baseline in SIB|ADAS-Cog Response Rate|Change in CIBIC-plus|Change from the baseline in CSF biomarkers
1171,1,Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product|Efficacy of the PMSC-ECM Product
1172,1,Adverse events and serious adverse events rate|Rate of clinical significant changes in laboratory|Rate of abnormal neurological physical examination results|Rate of imaging changes|Change of NIHSS scores|Change of BI scores|Change of mRS scores|Change of MMSE scores|Change of GDS scores
1173,1,Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.
1174,1,"Change on Extracellular Vesicles|Change on Distress|Change on Cancer antigen 15-3 (CA 15-3)|Change on Prostate-specific antigen (PSA)|Change on Carcinoembryonic Antigen (CEA).|Change on Adrenocorticotropic Hormone (ACTH).|Transcript inflammatory response genes (Interleukins, ILs, IL-1, IL-6, IL-8, IL-10, IFNγ and TNF).|Change on Analytic biomarkers (Erythrocyte number).|Change on Analytic biomarkers (PCR number).|Change on Analytic biomarkers (telomerase activity).|Change on Analytic biomarkers (hemoglobin glycosylated).|Change on Global distress|Change on quality of life|Change on fear of cancer recurrence|Change on satisfaction perceived social support|Change on emotional suppression|Change on mindfulness abilities|Change Interview|Change on smoking dependency|Change on physical activity|Change on sleep quality|Change on posttraumatic growth"
1175,1,Mortality at Day 28|Mortality at Days 60 and 90|Number of ventilator-free days|Improvement in oxygenation|SOFA score at Day 28
1176,1,Mean change in average low back pain score on 0-10 numerical rating scale|Hospital Anxiety and Depression Scale score|Athens Insomnia Scale score|Patient global impression of change (PGIC) score|Oswestry disability index score|Disc Degeneration based on MRI|Average low back pain score on 0-10 numerical rating scale|Mean change in worst low back pain score on 0-10 numerical rating scale|Worst low back pain score on 0-10 numerical rating scale|Positive categorical outcome
1177,1,Rate of complete remission|Overall survival|Rate of partial remission|Infusion toxicity
1178,1,Synovial Fluid Cytokine Measurement
1179,1,"Sensitivity of molecular profile of thyroid-derived extracellular vesicles|Specificity of molecular profile of thyroid-derived extracellular vesicles|Negative predictive value of molecular profile of thyroid-derived extracellular vesicles|Positive predictive value of molecular profile of thyroid-derived extracellular vesicles|Quantity of thyroid-derived extracellular vesicles captured in patients with localized, regional, and distant disease versus benign thyroid adenomas|Quantity of thyroid-derived extracellular vesicles captured in patients with excellent, indeterminate, biochemically incomplete, and structural incomplete responses to initial therapy|Combination of ribonucleic acid/deoxyribonucleic acid-based tests that can be perf thyroid-derived extracellular vesicles"
1180,1,Health Status using the 36 item Short Form Health Survey (SF-36)|Assessment of Visual Attention and Task Switching|Assessment of Contextual Verbal Learning|Assessment of Verbal Fluency|Assessment of Attention and Executive functions|Assessment of Unstructured Verbal Learning and Memory|Assessment of Visuospatial Learning and Memory|Assessment of Symptoms of Anxiety over Time|Assessment of Pain|Assessment of Sleep Quality|Assessment of Treatment by Participant|Assessment of Depression by Participant
1181,1,Death from any cause|Response|Incidence of adverse events|Graft versus host disease status|Proportion of response|Time to complete response|Time to very good partial response|Time to partial response|Incidence of complete response for each organ|Incidence of very good partial response for each organ|Incidence of partial response for each organ|Durability of organ response|Cumulative incidence of non-relapse mortality (NRM)|Cumulative incidence of relapse/progression of the primary disease|Overall survival|Disease-free survival|Graft versus host disease-free survival|Incidence of chronic graft versus host disease|Incidence of systemic infections|Incidence of toxicities|Incidence of any grade cytokine release|Incidence of any infusional toxicity
1182,1,Dose-limiting toxicity (DLT)|Adverse events|Incidence of abnormal laboratory test results|Incidence of abnormal vital signs|Incidence of abnormal ECG recordings|Incidence of abnormal X-ray findings
1183,1,"Joint rank scores (CAFS, Combined Assessment of Functional and Survival)|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score|Time to event"
1184,1,Humoral Response Rate -PCV13 vaccine|Increase in PCV13 specific serotype IgG levels|Increase in On-Specific Serotype IgG levels|Response Rate of CD19-targeted CAR T therapy when combined with PCV13 vaccination|Progression Free Survival|Overall Survival
1185,1,"Primary safety endpoint: Adverse events|Exploratory Endpoint: Alive at Day 5 without bronchospasms, unexpected infections, or clinical deterioration|Exploratory Endpoint: Proportion of patients with respiratory rate ≤ 23/min for 24 hours|Exploratory endpoint: Change in respiratory rate from baseline to Day 5|Exploratory endpoint: Proportion of patients with SpO2 saturation ≥94% for at least 24 hours|Exploratory endpoint: Change in SpO2 saturation from baseline to Day 5|Exploratory endpoint: Proportion of patients with no artificial ventilation after 5 days of treatment|Exploratory endpoint: Proportion of patients with a change in absolute lymphocyte count, sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in the absolute lymphocyte count from baseline to Day 5|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR), sustained for ≥48 hours after 5 days of treatment|Exploratory endpoint: Change in neutrophil-to-lymphocyte ratio (NLR) from baseline to Day 5"
1186,1,Neurophysiological parameters - Combined evoked potentials|Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events
1187,1,Change from baseline knee pain measured with a Visual Analogue Scale (VAS) at 1 year|Change from baseline functionality measured with Knee Injury and Osteoarthritis Outcome Score (KOOS) at 1 year|Change from baseline quality of life measured with SF-36 questionnaire at 1 year.|Change from baseline disability measured with WHODAS 2.0 questionnaire at 1 year.|Change from baseline joint cartilage characteristics measured with Magnetic Resonance Imaging at 1 year.
1188,1,Healing rate|Incontinence rate|Treatment related adverse events
1189,1,Change in patients clinical manifestation|Need for a ventilator|Duration of using a ventilator|Length of stay|Routine blood profile|CRP|D-dimer|Blood Gas Analisis (BGA)|Photo thorax|Survival
1190,1,Dose-Limiting Toxicities rate (DLTs)|Objective response rate|Feasibility of the combination/monotherapy|Incidence of treatment-Emergent Adverse Event|Progression-free survival (PFS)|Overall Survival (OS)|Antiadenoviral humoral immune response in patients|Antiadenoviral tumoral immune response in patients|Replication kinetics of Icovir-5
1191,1,Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration
1192,1,Change of tympanic membrane perforation size|Change in Chronic Otitis Media Questionnaire 12 score|Change in hearing threshold level
1193,1,Evaluation of safety related adverse ocular events including immune response|Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart|Measurement of electrical activity/function of retina using Electroretinography (ERG) test|Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test|Examination of retinal damage by Fundus Photography|Evaluation of visual field sensitivity using perimeter
1194,1,Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR|Post-PCI coronary artery endothelial function as assessed via FFR|Target lesion lumen loss|Flow Mediated Diameter Percentage (FMD%)|EPC-CFUs levels|Circulating angiogenic factors marker levels|Circulating inflammatory markers|Seattle Angina Questionnaire (SAQ) Angina Frequency|EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire|EQ-5D Quality of life Questionnaire Overall Health Status Question|Short Form (SF) 36 Questionnaire Quality of Life Questionnaire|International Index of Erectile Function (IIEF) Questionnaire|Sexual Quality of Life - Females (SQOL-F) Questionnaire|Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)|Incidence of Major Adverse Cardiac Events (MACE)|Rates of Adverse Events|Number of participants with abnormal lab values|Number of participants with Target Vessel Failure
1195,1,Salivary gland function|Incidence of treatment-emergent adverse events|Patient-Reported Outcome of xerostomia|Salivary composition
1196,1,Correlation of the ExoDx Prostate test results with the outcome of prostate biopsies in an initial biopsy patient cohort.
1197,1,Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers
1198,1,Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms
1199,1,Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage
1200,1,Changes in Motor Performance.
1201,1,Extracellular Vesicles analysis-NTA|Extracellular Vesicles analysis-microscopy|Extracellular Vesicles analysis-western blot|Extracellular Vesicles analysis-PCR|Extracellular Vesicles analysis-proteomics|Extracellular Vesicles analysis-RNAsequencing|Extracellular Vesicles analysis-reporter assays|Quantification of HIV DNA and RNA|Immunological analysis-FACS|Immunological analysis-ELISA|Gene expression analysis/transcriptomics|Microbiome monitoring|Virological analysis-FLIPS|Virological analysis-integration site
1202,1,"Intrapatient variation in molecular profiles at progression compared to baseline|longitudinal changes in VOCs profile and exosomes according to response to treatment|Proportion of alterations / molecular signatures unique or shared between patients at progression|Correlation between tumor signatures, VOCs and exosomes"
1203,1,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Functional motor power outcome pre-surgery|Functional motor power outcome at 12 months follow-up|Initial elbow flexion MRC grade 1 (in months)|Initial elbow flexion MRC grade 3 (in months)|Pain outcome pre-surgery|Pain outcome at 12 months follow-up|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at 12 months follow-up|Short Form-36 (SF-36) score pre-surgery|Short Form-36 (SF-36) score at 12 months follow-up"
1204,1,Maximum tolerated dose (MTD)|Number Of Adverse Events related to the treatment|Overall Survival improvement (OS)|Progression Free Survival (PFS)|Tumor assessment in regard to the investigational drug based on the RANO criteria|Clinical efficacy assessment
1205,1,Changes in ischemic pain|Changes in pain-free walking distance|Changes in TBI (Toe Brachial Index)|Changes in ABI (Ankle Brachial Index)|Change in size of the Ulcer|Determination of maximum tolerable dose according to DLT occurrence|Incidence of abnormal laboratory tests results|Incidence of abnormal blood pressure|Incidence of abnormal temperature|Incidence of abnormal physical condition
1206,1,Acute dose limiting toxicities (DLTs)|Maximum Tolerated Dose (MTD) of PEP|Adverse events
1207,1,Tumour transcriptome by RNA sequencing|Tumour protein profile by multiplex immunohistochemistry|Incidences of treatment related adverse events
1208,1,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Pain pre-surgery|Pain at follow-up 12 months|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months|Constant-Murley Score (CS) pre-surgery|Constant-Murley Score (CS) at follow-up 12 months|Tear recurrence (re-tear)"
1209,1,Cardiotoxicity rate|Overall survival|Cancer-specific survival|Progression-free survival|Other toxicity rates
1210,1,Antral follicular count (AFC) serum levels|anti-Müllerian hormone (AMH) serum levels|Regular menstruation and/or pregnancy
1211,1,Measurment of Cell Viability and Apoptosis|Measurment of cell differantiation
1212,1,"Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months."
1213,1,Assessment of efficacy by measuring scar/wound area at day 1.|Assessment of efficacy by measuring scar/wound area at day 21.|Assessment of efficacy by measuring scar/wound area at day 27.|Assessment of efficacy by measuring scar/wound area at day 48.|Assessment of efficacy by measuring scar/wound area at day 76.|Assessment of efficacy by measuring scar/wound area at day 104.|Assessment of efficacy by measuring scar/wound depth at day 1.|Assessment of efficacy by measuring scar/wound depth at day 21.|Assessment of efficacy by measuring scar/wound depth at day 27.|Assessment of efficacy by measuring scar/wound depth at day 48.|Assessment of efficacy by measuring scar/wound depth at day 76.|Assessment of efficacy by measuring scar/wound depth at day 104.|Assessment of efficacy by measuring scar erythema and pigmentation at day 1.|Assessment of efficacy by measuring scar erythema and pigmentation at day 21.|Assessment of efficacy by measuring scar erythema and pigmentation at day 27.|Assessment of efficacy by measuring scar erythema and pigmentation at day 48.|Assessment of efficacy by measuring scar erythema and pigmentation at day 76.|Assessment of efficacy by measuring scar erythema and pigmentation at day 104.|Assessment of efficacy by assessing scar/wound healing at day 6 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 13 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 20 (during Nefopam cream treatment).|Assessment of efficacy by assessing scar/wound healing at day 27 (after completion of Nefopam cream application).|Assessment of efficacy by assessing scar/wound healing at day 48 (after completion of Nefopam cream application).|Assessment of efficacy by assessing scar/wound healing at day 104 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 27 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 48 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 76 (after completion of Nefopam cream application).|Assessment of the scar using the Patient and Observer Scar Assessment Scales (POSAS) at day 104 (after completion of Nefopam cream application).|Assessment of efficacy by performing qPCR of the fibrotic molecules at day 27 (after completion of Nefopam cream application).|Assessment of efficacy by performing qPCR of the fibrotic molecules at day 104(after completion of Nefopam cream application).|Assessment of efficacy by performing Immunohistochemistry at day 27(after completion of Nefopam cream application).|Assessment of efficacy by performing Immunohistochemistry at day 104 (after completion of Nefopam cream application).|Assessment of Safety by assessing drug tolerability.|Assessment of heart rate.|Assessment of temperature.|Assessment of blood pressure.|Assessment of respiration.|Measurement of routine hematology parameters.|Measurement of routine clinical chemistry parameters.|Serum Nefopam absorption assessment.
1214,1,Transplant free survival (TFS)|Survival rate|Change amount of Child-Pugh score|Change amount of MELD score|Change amount of Liver function test|Change amount of Fibrosis-4|Change amount of FibroScanⓇ|Change amount of EQ-5D|Change amount of EQ-VAS
1215,1,ORR|OS|DFS|Response rate|EBV DNA-emia|CMV DNA-emia|PGF
1216,1,Number of participants with Adverse event|Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery|Number of complication associated with drug administration method
1217,1,The number of patients with improved LVEF|Incidence of adverse events and defects [Safety and Tolerability]|Incidence of serious adverse events [Safety and Tolerability]|Incidence of abnormal vital signs [Safety and Tolerability]|Incidence of abnormal general blood tests [Safety and Tolerability]|Incidence of abnormal blood biochemical tests [Safety and Tolerability]|Incidence of abnormal tumor marker tests [Safety and Tolerability]|Incidence of cardiac function clinical events such as death and hospitalization [Safety and Tolerability]|Number of Responder patients 26 and 52 weeks after transplantation of this product|Contraction function of the entire left ventricle|Left ventricular remodeling (LVESVI)|Left ventricular remodeling (LVEDVI)|New York Heart Association functional classification|Specific Activity Scale (SAS)|The Minnesota Living with Heart Failure Questionnaire|36-Item Short Form Survey (SF-36)|6-minute walking distance|Brain natriuretic peptide (BNP)|N-terminal pro-brain natriuretic peptide (NT-proBNP)|Exercise tolerance (VO2max)|Exercise tolerance (AT)|Exercise tolerance (VE/VCO2)|Cumulative number of rejections that occurred during the observation period
1218,1,Change from Baseline in Plasma Lipids in Healthy Subjects|Change from Baseline in Plasma Lipids in Subjects with Metabolic Syndrome|Change from Baseline in Waist Circumference in Healthy Subjects|Change from Baseline in Waist Circumference in Subjects with Metabolic Syndrome|Change from Baseline in Body Mass Index (BMI) in Healthy Subjects|Change from Baseline in Body Mass Index (BMI) in Subjects with Metabolic Syndrome|Change from Baseline in Glycemia in Healthy Subjects|Change from Baseline in Glycemia in Subjects with Metabolic Syndrome|Change from Baseline in Glycated Haemoglobin in Healthy Subjects|Change from Baseline in Glycated Haemoglobin in Subjects with Metabolic Syndrome|Change from Baseline in Subclinical Atherosclerosis in Subjects with Metabolic Syndrome|Change from Baseline in Plasma Cytokines in Subjects with Metabolic Syndrome
1219,1,variation of urinary extracellular vesicle concentration between both groups
1220,1,Safety and tolerability after hAMSCs injection.|The ratio of transplantable embryo in DOR patients after hAMSCs injection.|Ovarian function in DOR patients after hAMSCs injection.|Outcomes of IVF in DOR patients after hAMSCs injection.
1221,1,"Safety : Observation of at least one adverse effect|Efficacy : Rate of complete or almost complete reepithelialisation|Rate of observed and predicted death by the SCORTEN|Duration of hospitalisation according to our historical cohort related to BSA involved|Duration of hospitalisation according to our historical cohort related to onset of the disease|Duration of hospitalisation according to our historical cohort related to SCORTEN|Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)|Rate of sepsis|Rate of intensive care transfer|Rate of sequelae|Th1/Th2 immune response in the peripheral blood of the patients|Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood|Epidermal chimerism study on healed skin biopsy|Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed."
1222,1,Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0
1223,1,PASI score improvement rate|PASI (Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI (Dermatology Life Quality Index)
1224,1,Treatment related adverse events|Complete clinical healing|Partial clinical healing|Lack of response|Worsening of disease
1225,1,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes in exercise performance using 6-min walk test (6MWT).|Changes in grip strength.|Changes in quality of life measured by change in SF12 (12-Item Short Form).|Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in Clinical Frailty Scale.
1226,1,specific molecule levels in urine exosomes
1227,1,"Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion"
1228,1,"Expression of PARP1 gene as indicator of base excision repair|Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair|Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair|Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair"
1229,1,Collection of serious adverse events|Proportion of patients related with Respiratory rate and SpO2 saturation|Improvement of COVID19 status from severe to moderate|Time to recovery|Death rate|No need for mechanical ventilation|Patients status regarding haemodynamic instability|Oxygen saturation|Time to death or respiratory failure|Hospital discharge time|No of patients that will need Intensive Care Unit|No of patients with respiratory rate < 23/min|No of patients with change in respiratory change|No of patients with SpO2 >94%|No of patients with change in oxygen saturation|No of patients with change in lymphocyte count|Changes in absolute lymphocyte count|No of patients with changes in the neutrophil-to-lymphocyte ratio|Changes in the neutrophil-to-lymphocyte ratio|No of patients with changes in disease severity|Time of disease improvement|Changes in COVID-19 clinical severity|Changes in common COVID-19 related symptoms|Changes in supplemental oxygen over time|Duration of oxygen administration
1230,1,Number of Subjects with Dose-Limiting Toxicity (DLT) in Phase I Arm|Number of Subjects with Dose-Limiting Toxicity (DLT) in Surgical Arm|Percentage of Subjects whose Treatment Delivery Meets Feasibility Criteria|Expansion and Persistence of HER2 CAR T Cells at First Infusion in patients who received this treatment|Expansion and Persistence of HER2 CAR T Cells at Second Infusion in patients who received this treatment|Expansion and Persistence of HER2 CAR T Cells at Third Infusion in patients who received this treatment|Presence of intra-tumoral HER2 CAR T Cells following First Infusion in Surgical Arm|Presence of HER2 CAR T Cells following Second Infusion in Surgical Arm|Presence of HER2 CAR T Cells following Third Infusion in Surgical Arm|Best antitumor Response of Infused HER2 CAR T Cells in Phase I Arm|Best Antitumor Response of Infused HER2 CAR T Cells in Surgical Arm|Event-free Survival (EFS)|Overall Survival (OS)
1231,1,All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation
1232,1,All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation
1233,1,All-cause mortality rate at Day 28|All-cause mortality rate at Days 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Clinical status at Day 28|Change in oxygenation
1234,1,Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Change in Pulmonary Function Tests (PFTs)|Change in oxygenation|Change in biomarker levels
1235,1,"the sensitivity and specificity of salivary miRNAs (412,512) to detect the malignant transformation of oral potentially malignant lesions"
1236,1,"Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo."
1237,1,tensile strength of posterior cruciate ligament|Thrombosite of Growth Factor - beta 1|basic fibroblast of growth factor
1238,1,Adverse events and serious adverse events|Reduced activities|Slowing of mobility|reduction of handgrip strength|exhaustion|the level of pain in the knee|respiratory function|Quality of Life|patients' inflammation|patients' immune|immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells|Cellular senescence|metabolic profiles of CD3+ cells
1239,1,Sensitivity of combining multimodality MR Imaging with circulating exosomal miRNA expression in evaluating acute rejection in patients with heart transplantation.|Specificity of combining multimodality MR Imaging with circulating exosomal miRNA expression in evaluating acute rejection in patients with heart transplantation.
1240,1,"Changes in MDS-UPDRS Part II.|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities|AEs of special interest (serious or non-serious) - infections|AEs of special interest (serious or non-serious) - hypersensitivities.|Laboratory values. CBC|Laboratory values. CMP|Laboratory values. Coagulation Panel|Vital signs. - Respiratory Rate (breaths per minute)|Vital signs. - Heart Rate (beats per minute)|Vital signs. - Body Temperature (Fahrenheit )|Vital signs. - Blood Pressure (mmHg)|Weight in lb.|Physical examination results. General|Physical examination results. Body Systems.|Changes in MDS-UPDS total score.|Changes in MDS-UPDRS Part I.|Changes in MDS-UPDRS Part III.|Changes in MDS-UPDRS Part IV.|Changes in Neuro-QOL. - Communication|Changes in Neuro-QOL. - Social Roles and Activities|Changes in Neuro-QOL. - Anxiety|Changes in Neuro-QOL. - Depression|Changes in Neuro-QOL. - Dyscontrol|Changes in Neuro-QOL. - Fatigue|Changes in Neuro-QOL. - Mobility|Changes in Neuro-QOL. - Well-Being|Changes in Neuro-QOL. - Sleep|Changes in Neuro-QOL. - Fine Motor|Changes in Neuro-QOL. - Stigma|Changes in Neuro-QOL. - Social Roles|Changes in Neuro-QOL. - Cognition|Changes in Parkinson's disease fatigue scale (PFS-16).|Changes in Parkinson's disease Questionnaire (PDQ-39).|Changes in Visual Analog Scale for Pain.|Changes in Dosage of medications taken to treat Parkinson's disease.|Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).|Incidence and risk of AEs of special interest (serious or non-serious),|Clinically significant changes in laboratory values. - CBC|Changes in Visual Analog Scale for muscle spasms.|Clinically significant changes in vital signs. - Respiratory Rate|Clinically significant changes in vital signs. - Heart Rate|Clinically significant changes in vital signs. - Body Temperature.|Clinically significant changes in vital signs. - Blood Pressure.|Clinically significant changes in vital signs. - Oxygen Saturation.|Clinically significant changes in physical examination results.|Clinically significant changes in weight in lb.|Clinically significant changes in laboratory values. - CMP|Clinically significant changes in laboratory values. - Coagulation Panel"
1241,1,Left ventricular ejection fraction|Left ventricular end diastolic volume|Left ventricular end systolic volume|Stroke volume|Left ventricular apex four-chamber end systolic diameter|6 minutes walking distance|THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF
1242,1,"Evaluate size distribution, concentration and molecular profiling of pulmonary vein exosomes at inclusion|Size distribution, molecular profiling of peripheral vein exosome sat inclusion|Mutations and polymorphism in resected lung cancer|Overall survival|Two-year disease-free survival"
1243,1,Percentage of Participants who Achieve Combined Remission|Percentage of Participants who Achieve Clinical Remission|Percentage of Participants who Achieve Clinical Response|Percentage of Participants who decrease in PDAI|Percentage of Participants who decrease in IBDQ|Percentage of Participants who decrease in VAS scale|Percentage of Participants who decrease in Wexner incontinence score
1244,1,Safety and Tolerability|Left Ventricular Ejection Fraction in Cardiac MRI scan & Echocardiography|Myocardial wall motion evaluation in Echocardiography|Myocardial blood flow in SPECT|Myocardial viability in SPECT|6-minute walk distance|Kansas City Cardiomyopathy Questionnaire (KCCQ)|5-level EQ-5D version (EQ-5D-5L)|N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
1245,1,Change of serum thyroglobulin level|Change of serum free T4 level|Change of serum TSH level|Change of anti-thyroglobulin level|Urinary exosomal thyroglobulin detection|Urinary exosomal galectin-3 detection|Urinary exosomal calprotectin A9 detection|Urinary exosomal transketolase detection|Urinary exosomal keratin 19 detection|Urinary exosomal angiopoietin-1 detection|Urinary exosomal tissue inhibitor of metalloproteinase detection|Urinary exosomal keratin 8 detection|Urinary exosomal calprotectin A8 detection|Urinary exosomal annexin II detection|Urinary exosomal afamin detection
1246,1,PaO2/FiO2|the days of ventialtion and hospital stay
1247,1,Magnetic Resonance Imaging in the 6th month after surgery|Magnetic Resonance Imaging in the 12th month after surgery|Magnetic Resonance Imaging in the 24th month after surgery|The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index|International knee documentation committee (IKDC) Knee Joint Score Sheet
1248,1,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.|Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).|Whole Organ Magnetic Resonance Imaging Score (WORMS).|Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.|Amount of rescue medications required.
1249,1,Ventilator Free Days
1250,1,Overall Response Rate|Complete Response Rate|Duration of Response|Best Overall Response|Progression Free Survival|Overall Survival|Pharmacokinetics of MB-CART2019.1 [Maximum concentration (Cmax)]|Pharmacokinetics of MB-CART2019.1 [Time to maximum concentration (Tmax)]|Pharmacokinetics of MB-CART2019.1 [Area under the curve (AUC)]
1251,1,Investigation of cell proliferation of AT-MSCs|Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte|Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast|Measurement of gene expression profile of AT-MSCs|Healing of anal fistula after treatment|Evaluation of fistula healing after treatment|Functional gastroenterological outcome after treatment|Defecation disorder evaluation after treatment|Functional urological outcome after treatment
1252,1,"Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime."
1253,1,"The cumulative incidence of reactogenicity for all the subjects received at least 1 dose of investigational medicinal product (IMP), regardless of whether the subject withdrew early, delayed/missed the second dose or received any antipyretic.|The seroconversion rate for serum RBD-specific binding antibodies for all the subjects received 2 doses of IMP, excluding subjects who missed the second dose, received any COVID-19 vaccine other than the IMPs or had a post-dose COVID-19 infection."
1254,1,Proportion of modified Rankin Scale (mRS) 0-2|changes in Fugl-Meyer scale|changes in Purdue hand function test|changes in box and block test|Proportion of modified Rankin Scale (mRS) 0-1|changes in the national institutes of health stroke scale (NIHSS)|changes in Mini-mental State Examination (MMSE) score|changes in Montreal Cognitive Assessment (MoCA) score|The changes of head images|changes in some serum biomarkers
1255,1,"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness"
1256,1,CTC phenotype
1257,1,Arthroscopy|WOMAC total score|WOMAC subscale score|VAS score|RAND-36|IKDC|Biopsy|Use of rescue medication|Kellgren-Lawrence grade
1258,1,Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC
1259,1,Safety of treatment|Short-time efficacy of treatment
1260,1,"Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)|Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment"
1261,1,Adverse Events|Adverse Events (Special Attention Target)
1262,1,Reduction of corticosteroid dose to ≤ 7.5 mg/day of prednisone or equivalent|Hematologic improvement without ongoing SLE treatment|Renal response improvement|Proportion of subjects who achieve a prednisone dose of ≤ 7.5mg/day or equivalent|Proportion of subjects achieving Low Level Disease Activity State|Proportion of subjects with ≥ 4 point reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 4 having SLE responder index 4 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 5 having SLE responder index 5 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 6 having SLE responder index 6 (SRI6)|Time to first severe modified SLE Flare Index (SFI) flare|Change from baseline of hematologic parameters|Time to first hematologic flare|Change in baseline of renal function parameters|Time to event for each of the individual components of treatment failure|Time to complete remission|Time to first renal flare
1263,1,To define the Max tolerated dose (MTD) of RGV004|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Objective remission rate (ORR)|RGV004 viral DNA in blood|RGV004 viral shedding in saliva|RGV004 viral shedding in urine
1264,1,"Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups.|Change in the means of durability of clinical remission between the AVB-114 and standard of care groups.|Change in means of time to clinical remission between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups.|Change in means of time to fistula relapse between the AVB-114 and standard of care groups.|Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups.|Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups.|Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups.|Change in number of adverse events between the AVB-114 and standard of care groups.|Change in number of serious adverse events between the AVB-114 and standard of care groups."
1265,1,Visual analog scale (VAS)|Roland Morris Disability Questionnaire (RDQ)|SF 36 health questionnaire|Functional rating index|MRI
1266,1,"The death rate of children|Marshall Multiple Organ Dysfunction Score|the age, PaO2/FlO2, and plateau pressure score (APPS)|length of stay in PICU"
1267,1,Positivity of the liquid biopsy|Prediction of the response of rectal cancer to neoadjuvant treatment|Genetic profile of the primary tumor predictive of the response to nCRT
1268,1,Decrease in joint pain|Increased joint functionality|Improvement in the quality of life|Imaging improvement of articular cartilage
1269,1,Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay
1270,1,Adverse events and/or serious adverse events
1271,1,"Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation"
1272,1,"ETDRS visual acuity:|Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)|Ganglion cell complex thickness (GCC thickness, µm):|Pattern visual evoked potential (pVEP)"
1273,1,Change in inflammation on Colonoscopy|Change in Subjective symptoms
1274,1,Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse
1275,1,To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.|Change in MELD (Model for End stage Liver disease) score.|Change in Child Pugh score.|Change in the percentage of CD 34 cells in liver.
1276,1,"adverse event according to CTCAE 5.0, clinically meaningful abnormalites in laboratory tests (blood)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|Knee injury and Osteoarthritis Outcome Score (KOOS)|International knee documentation committee (IKDC)|Cartilage damage evaluation through knee MRI|SF-36 questionnaire|Serum inflammatory cytokine, acute phase reactant, bone turnover marker|Cartilage damage evaluation through knee x-ray"
1277,1,Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale
1278,1,Changes in the protein expression of EMT markers
1279,1,BUN|Cr|eGFR|Cystatin C|Urine protein|Hb|Hct|Ca|P|ALT|PTH|VitD|ALB|TC|TG
1280,1,Albumin (ALB)|Alanine aminotransferase (ALT)|Prealbumin (PA)|Total bilirubin (TB)|Direct bilirubin (DB)|Blood urea nitrogen (BUN)|Uric acid (UA)|Serum creatinine (Scr)|Child-Pugh|Model for end-stage liver disease (MELD)|Quality of life (QOL)
1281,1,Number of patients who experience adverse events (AEs)|Change in low back pain and function following injection of AD-MSCs|Changes from Baseline in disc height index as measured by X-ray at 12 months and 24 months|Changes from Baseline in T2 weighted signal intensity of the Nucleus Pulposus (NP) as measured by MRI without contrast
1282,1,"Localization of EMT indicators TGF- β1, Vimenten, E-Cadherin"
1283,1,Number of patients with adverse events (AEs) and serious AEs (SAEs)|Change of liver function evaluated by Child-Pugh Score|Improvement rate of Child-Pugh score|Improvement rate of Child-Pugh grade|Number of patients with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) findings|Number of patients with abnormal pulse rate findings|Number of patients with abnormal body temperature findings|Number of patients with abnormal electrocardiogram (ECG) findings|Number of patients with abnormal clinical chemistry parameters|Number of patients with abnormal clinical hematology parameters|Number of patients with abnormal urinalysis parameters
1284,1,Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events
1285,1,"Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI."
1286,1,"Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant."
1287,1,Exosomes quantity excreted from the epicardial fat (nm)|Inflammatory cytokines secretion from epicardial fat
1288,1,Fasting blood glucose|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose|C-peptide|Blood insulin level
1289,1,Incidence of any treatment-emergent serious adverse events|Difference in subject quality of life assessment - SF-12|Difference in subject quality of life assessment - Oswestry Low Back Pain|Death from any cause.|Change in pain using the Numeric rating scale
1290,1,change of level of urinary transglutaminase 2
1291,1,Prognostic biological markers via this prospective study
1292,1,Change in glucose tolerance as measured by a glucose tolerance test|Change in serum insulin levels during a glucose tolerance test|Serum Testosterone|Sex hormone binding globulin|Stool sample|Inflammatory marker cluster of differentiation 4 (CD4)|Inflammatory marker cluster of differentiation 8 (CD8)|Inflammatory marker Foxp3|Inflammatory marker cluster of differentiation 11b (CD11b)|Inflammatory marker cluster of differentiation 33 (CD33)|Inflammatory marker F4/80|Inflammatory marker interleukin 10 (IL-10)|Inflammatory marker interleukin 1b (IL-1b)|Inflammatory marker tumor necrosis factor alpha (TNF-a)|Inflammatory marker interleukin 6 (IL-6)
1293,1,NCC cotransporter expression|Phosphorylated NCC cotransporter expression|pendrine expression in kidney transplant group
1294,1,Proportion of Participants who Achieve Operational Tolerance|Proportion of Participants who Remain Off Immunosuppression|Proportion of Participants who Return to Immunosuppression|Proportion of Participants who Achieve Belatacept Monotherapy|Proportion of Participants who Die|Time from Transplant to the First Episode of Rejection|Incidence of Participants who Develop Donor Specific Antibody (DSA)|Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration|Frequency of Select Adverse Events (AEs)|Incidence of Post-Transplant Diabetes|Frequency of Antibody-Mediated Acute Cellular Rejection|Frequency of Antibody-Mediated Chronic Rejection
1295,1,Change in forced expiratory volume in one second (FEV1)|Response of iPS cells to treatment|Change in sweat chloride|Change in nasal potential difference (NPD) measurements|Change in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Score
1296,1,Incidence of dose limiting toxicity|Feasibility of NY-ESO-1 TCR transgenic cells|Persistence of transduced T cells|Engraftment and persistence of transduced progeny T cells|Engraftment and persistence of transduced T cells and progeny T cells|Persistence of TCR gene transduced cells|Long term monitoring for replication competence of retrovirus (RCR) and lentivirus (RCL)|Immunological monitoring|Objective response|Duration of overall complete response|Duration of overall response|Time to disease progression
1297,1,Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray
1298,1,serious adverse events attributable to intervention|healing
1299,1,adverse effects regarding UCMSC infusion|Pathological score of liver inflammation|Changes of biliary lesions in magnetic resonance image|alanine aminotransferase
1300,1,"Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment"
1301,1,SLEDAI-2000 score|BILAG-2004 score|Health Assessment Questionnaire (HAQ) score
1302,1,Evaluate the uptake and distribution of the imaging agent 18F-TFB|Imaging Sensitivities
1303,1,"The number of Serious Adverse Events that are attributable to the treatment|The severity of Serious Adverse Events that are attributable to the treatment|Amputation free survival|median time to amputation,|Change in Transcutaneous Pressure of Oxygen TcPO2|Change in Ankle Brachial Index|Collateral vessel formation|Change in Ischemic rest pain|Change in Ulcer size|Change in Quality of Life"
1304,1,Production of cancer antigen-specific T-cells|Availability of stored specimens and/or data
1305,1,Engraftment
1306,1,"Number of subjects with specific Long Term Follow-Up adverse events (AEs), including serious adverse events (SAEs) associated with administration of autologous T cell receptors that have been genetically modified by lentiviral vectors.|Measurement of Replication Competent Lentivirus (RCL) in genetically modified T cells|Persistence of genetically modified cells in the body|Assess the pattern of vector integration sites if at least 1% of cells in the surrogate sample are positive for vector sequences by PCR|Overall Survival (OS) post-infusion"
1307,1,Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）
1308,1,Percentage of subjects who have severe BPD or are dead|Percentage of subjects who have moderate/severe BPD or are dead|Percentage of subjects by severity of BPD|Percentage of subjects in death due to lung disease|intubation duration|ventilation duration|continuous positive airway pressure (CPAP) treatment duration|treatment duration with supplemental oxygen|% of subjects treated with steroid for weaning ventilator|Retinopathy of prematurity (ROP) with stage III or higher|number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy|z-score|days in hospitalization|changes in tracheal suction fluid examination
1309,1,Dose determination GCSF
1310,1,Change from baseline to 6 months follow-up in LVEF.|Change from baseline to 6 months follow-up in infarct size.|Change from baseline to 6 months follow-up in exercise distance increment|Change from baseline to 6 months follow-up in quality of life measured by MLHFQ|Change from baseline to 6 months follow-up in NYHA Classification.|Percent of patients with adverse events.|Change from baseline to 6 months follow-up in exercise time increment.|Change from baseline to 6 months follow-up in quality of life measured by KCCQ
1311,1,Generating iPSCs from peripheral blood|Differentiate iPSCs into CD34+ cells and mesoderm
1312,1,Reduction of infarct size|Infarct size reduction|Myocardial perfusion improvement|Increase of left ventricle ejection fraction (LVEF)|Left ventricle ejection fraction (LVEF) change against baseline.|Left ventricle end-systolic volume (ESV) change against baseline.|Left ventricle end-diastolic volume (EDV) change against baseline.|The occurrence of major adverse cardiovascular events|Quality of life improvement
1313,1,"Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372"
1314,1,Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)|Change in the mid-level (elbow) dimension of the PUL|Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI
1315,1,Functional Benefit and Pain Level Changes using iHOT33 Questionnaire|Functional Benefit and Pain level Changes using the modified Harris Hip Score (HHS)|Functional Benefit and Pain level Changes using the The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Burden of Disease and Quality of Life Changes using the Veterans RAND 12 Item Health Survey (VR-12)|Pain Changes using the Visual Analogue Scale (VAS)
1316,1,Improvement in the tendon ecotexture|Presence of patellar tendon regeneration by the peritendinous and intratendinous infusion of MSV patellar tendinopathy compared to the P-PRP group|the strength of the extensor muscle group|subjective clinical evolution of the patient|strength of the extensor muscle group
1317,1,Response rate|Safety and tolerance
1318,1,The Gross Motor Function Measure (GMFM)-88 item score|Fine Motor Function Measure scale (FMFM) score|The Modified Ashworth scale (MAS) score|Gesell Development Schedule score|Incidence of adverse reactions
1319,1,Left ventricle ejection fraction (LVEF) increase|An increase the result of 6 minute walk test|Myocardial perfusion improvement|An improvement the result of spiroergometric test|Left ventricle ejection fraction (LVEF) change against baseline|Left ventricle end-systolic volume (ESV) change against baseline|Left ventricle end-diastolic volume (EDV) change against baseline|NT pro-BNP level|The occurrence of major adverse cardiovascular events|Quality of life improvement
1320,1,Relation between the expression level of circulating microRNAs and the occurrence of SpO2 <90% during at least 5 seconds within the course of the seizure and/or within the five minutes following the end of the seizure|Relation between the expression level of circulating microRNAs and the desaturation nadir|Relation between the expression level of circulating microRNAs and the patient's age|Relation between the expression level of circulating microRNAs and the epilepsy duration|Relation between the expression level of circulating microRNAs and the total number of seizures (ie focal seizures and GTCS) over the past three months|Relation between the expression level of circulating microRNAs and the Number of GTCS over the past three months
1321,1,"Change in pain-free walking distance|Amputation-free survival period|Ulcer-free survival|Ulcer-extension free survival|Change in tissue oxygen/CO2 tension|An improvement of tissue perfusion|Change in transcutaneous pressure of O2|Change in ABI score|Quality of life improvement, assessed by SF-36 questionnaire"
1322,1,"Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 20|Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 20|Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90) at week 20|Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 12,16,36,52|Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 12,16,36,52|Frequency of Adverse Events and Serious Adverse Events|Proportion of subjects who experience psoriasis relapse"
1323,1,Twelve whole blood samples donated for the manufacture and banking of iPS cells
1324,1,Macular holes closure|Best corrected visual acuity(BCVA)
1325,1,Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.
1326,1,Change of pain visual analogue scale (VAS) during activity|Change of pain visual analogue scale (VAS) at rest|Change of Mayo elbow performance index (MEPI)|Ultrasonographic assessment|Shear wave elastography|Magnetic resonance image (MRI) assessment
1327,1,"Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial."
1328,1,overall survival
1329,1,"Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24"
1330,1,live birth rate|clinical pregnancy rate|number of oocytes retrieved|fertility rate|normal fertility rate|good quality embryo rate
1331,1,Clinical Examination|MR Elastography|The level of serum alanine aminotransferase (ALT)|The level of glomerular filtration rate (GFR)|The level of serum prothrombin time (PT)|The level of serum total bilirubin (TB)|The level of serum albumin (ALB)|MELD Score
1332,1,The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)
1333,1,"The incidence and frequency of adverse events related to administration of UMC119-01.|The percentage of subjects who died from any cause during the study.|Changes of the oxygen saturation.|Changes of chest x-ray findings in participants before and after administration.|Changes of inflammatory markers (pg/ml) before and after administration.|Comparison of the incidence and severity of preterm children's complications in participants before and after administration.|The number of days of intubation, or where ventilator or oxygen therapy.|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)."
1334,1,complete and partial response rate|Adverse events that are related to treatment
1335,1,6 Minute Walk Distance (6MWD)
1336,1,"To study in type 2 diabetic participants with liver biopsy, the performance of a composite biomarker (3rd generation test) for the diagnosis of NASH|To study in type 2 diabetic participants with or without liver biopsy, performance of a composite biomarker for the diagnosis of clinically significant metabolic liver diseases|To study in type 2 diabetic participants with liver biopsy, the performance of a single or composite biomarker for the diagnosis of NASH elemental lesions|To study inter-center and intra-participants reproducibility of imaging measurements. a graphical evaluation will be conducted using a representation of Bland-Altman.|To study inter-center and intra-participants reproducibility of imaging measurements.a graphical evaluation will be conducted using a representation of Bland-Altman.|To study in type 2 diabetic participants the performance of second-generation tests for the diagnosis of metabolic liver diseases|Constitution of a bio-collection"
1337,1,Progression Free Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Overall Response Rate|Disease Control Rate|Duration of Response|Overall Survival
1338,1,To evaluate the relevance and effectiveness of a multi-omics approach to the diagnosis of ID of unknown genetic origin.|The assessment of metabolomics consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines|The assessment of morphological consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines
1339,1,Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments
1340,1,bone gain in periodontal defects(by mm)|the regenerative power of the defect was evaluated by growth factor concentration in GCF.
1341,1,Serious adverse events|Serious adverse reactions|Changes of fistula size|Changes in rectovaginal soft tissue density and flexibility|Quality of life monitoring - 1|Quality of life monitoring - 2
1342,1,Number of disease relevant iPSC differentiation protocols generated within the study
1343,1,Overall survival up to a year|1. Success of immune reconstitution|2. Change of infection status
1344,1,Oxygen requirement 3 days after transplantation|Oxygen requirement 7 days after transplantation|Duration of ventilator dependence|Incidence of severe BPD|Survival rate|Temperature|Heart rate|Respiratory rate|Duration of CPAP treatment|Percentage of participants treated with steroids for weaning from ventilator|Growth velocity (Z-score)|bronohoalveolar lavage (BAL) cytokine level|The severity of BPD in X-ray patterns
1345,1,Integration of the mesenchymal stem cells.|Knee Injury and Osteoarthritis Outcome Score (pain subscale)
1346,1,MSC identification using MRI in-vivo on day 0|MSC identification using MRI in-vivo on day 1|MSC identification using MRI in-vivo on day 7|MSC identification using MRI in-vivo after 2 weeks|MSC identification using MRI in-vivo after 4 weeks|MSC identification using MRI in-vivo after 8 weeks|MSC identification using MRI in-vivo after 12 weeks|MSC identification using MRI in-vivo after 26 weeks|Cardiac pump function changes|CCS class|Seattle Angina Questionnaire|Weekly number of angina attacks|Weekly nitroglycerin consumption|Adverse events
1347,1,Change of alkaline phosphatase (ALP)|Change of other liver function indices|Change of liver histology
1348,1,Efficacy: 12 week mortality rate|Clinical remission rate at week 12
1349,1,"Nature, incidence and severity of adverse events (AEs)"
1350,1,Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity
1351,1,Assessment of Prognostically Significant CAD|Examination of Medical Records|Quantification of Extracellular Vesicles (obtained from blood samples) by Flow Cytometry|Assessment of Time to Diagnosis|Analysis of Potential Cost Savings Through the Use of Novel Biomarkers By the Reduction in Unnecessary Procedures|Investigation into the use of stress echocardiography as a clinical procedure in the UK.
1352,1,Change in mean total hair density (hair/cm2)|Compare visual assessment before and after cosmetic treatment|Change in mean Telogen hair density|Change in mean Anagen hair density|Change in hair growth speed|Change in hair diameter
1353,1,"Safety of FURESTEM-RA Inj. - number of adverse events|Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate|Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate|Efficacy as measured by DAS(Disease activity scores)28-ESR|Efficacy as measured by KHAQ(Korean Health assessment questionnaire)|Efficacy as measured by CDAI (clinical disease activity index)|Efficacy as measured by 100mm Pain VAS(Visual analogue scale)|Total number of use and consumed amount of rescue medicine|Change in Cytokine(TNF-a, Interleukin (IL)-1b, IL-4,IL-6,IL-8,IL-10,IL-13,IL-17A,IL-21,IL-22)"
1354,1,"Change From Baseline in Endoscopic Score (as Measured by Ulcerative Colitis Endoscopic Index of Severity)|Change from Baseline in clinical response (CDAI points)|To evaluate the quality of life index, Short Inflammatory Bowel Disease Questionnaire (SIBDQ)|Histologic Evaluation of Ulcerative Colitis|Immune response in ulcerative colitis.|Incidence of Treatment Adverse."
1355,1,exosome in cancer tissue and para cancerous tissue
1356,1,Time trail cross-country roller skiing performance|Maximal oxygen consumption|Lactate threshold in double poling|Double poling economy|Maximal strength|Jump height|Genotypes|Tick-bourne disease|Exosomes|Training volume|Training intensity|Age|Maximal power
1357,1,Peripheral Arterial Tonometry - Reactive Hyperemic Index|miRNA 92a and miRNA 210 levels|miR 92a and miR 210 levels
1358,1,Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)|Changes of in the Hoehn and Yahr staging|Changes of the Mini-Mental State Examination (MMSE)|Changes of the Hamilton depression scales 24 (HAMD 24)|Changes of the Hamilton Anxiety Scale 14 (HAMA-14)|Adverse reaction
1359,1,survival after intervention|adverse events|sequential organ failure assessment score(SOFA)|interleukin-6|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system
1360,1,Global Aesthetics Improvement Scale (GAIS)
1361,1,Healing|Health-related quality of life assessed by a disease specific questionnaire|Health-related quality of life assessed by a generic questionnaire
1362,1,Number of participants with adverse reactions related to infusion after treatment|Changes of high-resolution chest CT in participants|Changes of temperature in participants|Changes of blood pressure in participants|Changes of heart rate in participants|Changes of respiratory rate in participants|Changes of oxygen saturation in participants|Growth velocity (Z-score) in participants
1363,1,Toxicity of allogeneic MSC injection according to CTCAE|Toxicity of allogeneic MSC injection according to CTCAE Month 1|Toxicity of allogeneic MSC injection according to CTCAE Month 3|Toxicity of allogeneic MSC injection according to CTCAE Month 6|Toxicity of allogeneic MSC injection according to CTCAE Month 12|Proportion of subjects with Clinical Response Month 3|Proportion of subjects with Clinical Response Month 6|Proportion of subjects with Clinical Response Month 9|Proportion of subjects with Clinical Response Month 12|Disease activity measured by the BILAG index Month 3|Disease activity measured by SELENA-SLEDAI Month 3|Disease activity measured by SELENA-SLEDAI Month 6|Disease activity measured by the BILAG index Month 6|Disease activity measured by the BILAG index Month 9|Disease activity measured by SELENA-SLEDAI Month 9|Disease activity measured by the BILAG index Month 12|Disease activity measured by SELENA-SLEDAI Month 12|SRI Month 3|SRI Month 6|SRI Month 9|SRI Month 12|comorbidities Month 3|comorbidities Month 6|comorbidities Month 9|comorbidities Month 12|Quality of life Month SF-36 Month 3|Quality of life EQ-5D Month 3|Quality of life Month SF-36 Month 6|Quality of life EQ-5D Month 6|Quality of life Month SF-36 Month 9|Quality of life EQ-5D Month 9|Quality of life Month SF-36 Month 12|Quality of life EQ-5D Month 12|Steroids Month 3|Steroids Month 6|Steroids Month 9|Steroids Month 12
1364,1,"The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media"
1365,1,Assessment of changes in the bone volume at the grafted alveolar cleft site from the immediate postoperative to 6 months|Assessment of changes in the bone density at the grafted alveolar cleft site from the immediate postoperative to 6 months
1366,1,Pigmentary change
1367,1,Osteogenic potential|Adipogenic potential|Genotype assay
1368,1,Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS)
1369,1,Total remission rate|The time for subjects of the two groups to achieve PR and CR|Levels of 24-hour urinary protein|Ratio of Urinary Protein / Creatinine|Levels of serum albumin|Levels of serum creatinine|The estimated glomerular filtration rate ( eGFR )|Levels of Complement component 3 (C3)|Levels of Complement component 4 (C4)|The antinuclear antibody (ANA) levels|The anti-double stranded DNA antibody (dsDNA) levels|Patient Health Assessment Questionnaire (HAQ) score|Physician Global Assessment (PhGA) score|The (Systemic lupus Erythematosis Disease Activity index) SLEDAI score|The (British Isles lupus assessment group ) BILAG score|The SLE reaction index|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
1370,1,Characterization of the protein profile in tumor derived exosomes from the gallbladder carcinoma patients|The expression of protein A in the circulating exosomes from patients
1371,1,Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR)|Graft survival rate
1372,1,Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment
1373,1,endometrial thickness|ongoing pregnancy rate|live birth rate|endometrial blood flow
1374,1,the accumulative duration of oxygen therapy|Changes of blood pressure in participants|Changes of heart rate in participants
1375,1,Safety evaluation of all AE/SAEs|Procedure tolerance (procedure pain/discomfort incidence)|WOMAC questionnaire|OAKHQOL questionnaire
1376,1,Quantification of target mRNA expression in human bronchial epithelial cells (BEAS-2 B) exposed to EVs isolated from LBA of patients
1377,1,"Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip"
1378,1,Infusion associated events|Mortality|Ventilation free days(VFDs)|Oxygenation index(OI) changes|Lung injury score(LIS)|Positive end expiratory pressure(PEEP)|Plateau pressure(Pplat)|Driving pressure|Static compliance
1379,1,Intrauterine adhesion patients efficacy evaluation|Incision lacuna and incision diverticulum patients efficacy evaluation|Ultrasound of uterus evaluation|Hysteroscopy evaluation|Pain score
1380,1,Kellgren-Lawrence Grading Scale|Assessment of Preoperative Cartilage Defect Severity (AMADEUS)|Lysholm scoring|The international knee documentation committee (IKDC) knee evaluation form|Visual Analogue Scale/Score（VAS）
1381,1,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery."
1382,1,Presence of Tau in extracellular vesicles in CSF|The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.|The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.
1383,1,Occurrence of study related adverse events|Anti-tumor responses to tanCART19/22 cell infusions
1384,1,Bicuspid aortic valve and thoracic aortic aneurysm|Health-related quality of life
1385,1,Safety assessed by dose limiting toxicity (DLT)|Safety assessed by dose limiting toxicity|Safety assessed by change in spirometry|Safety assessed by all adverse events|Change in patient reported outcomes|DAS28-CRP
1386,1,Treatment related-adverse events counting|Modified Rankin Scale|Barthel activities of daily living (ADL) Index|NIH stroke scale (NIHSS)
1387,1,"number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation|Post therapy diffusing capacity of CO% (DLCO)predicted|post therapy forced vital capacity (FVC)% predicted."
1388,1,"production of protective HBsAb|impact on Insulin resistance, fibrosis regression"
1389,1,Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine
1390,1,Comparison between iPSC-derived cells|Correlate the findings from the iPSC-derived cells with the clinical phenotype of cardiovascular toxicity
1391,1,Concentrations of total circulating EVs in platelet-free plasma (PFP) detected by flow cytometry|Concentrations of total circulating EVs in platelet-free plasma (PFP) detected by nanoparticle tracking analysis (NTA)|Pro-thrombotic activities of circulating EVs in PFP|Characterisation of circulating EVs in PFP and serum detected by fluorescence flow cytometry|Characterisation of circulating EVs in PFP and serum detected by fluorescence NTA|Ex vivo agonist-stimulated platelet activation detected by plate-based platelet activation and aggregation assays|Pro-thrombotic activities of platelet-derived extracellular vesicles (PEVs) prepared from the supernatants of stimulated platelets|Fatty acid composition analysis|Blood pressure|Concentrations of total triglyceride and cholesterol in plasma
1392,1,"Efficacy: Change of liver functions as assessed by MELD score|Safety: Adverse events as assessed according to CTCAE 4.03|Survival Benefit: Survival Rate at different time points|Histological change of the liver: Histological scores assessed by liver biopsy|Clinical benefit: Incidences of cirrhosis-related complications such as GI bleeding, ascites, hepatorenal syndrome, hepatoencephalopathy"
1393,1,Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations
1394,1,Number of participants experiencing drug-related adverse events|Changes from baseline in circulating FVIII activity (IU/dL or % normal)
1395,1,"Restoration of corneal surface|Cosmetic improvement|Corneal Thickness|Best corrected visual acuity|Corneal power, astigmatism and aberration|Density of stromal nerve and stromal keratocytes|Corneal haze"
1396,1,The change of Complement levels(C3 and C4) in peripheral blood|Erythrocyte sedimentation rate|C-reactive protein|adverse reaction
1397,1,The check of granulocyte transplantation-granulocyte plant living standards|The check of granulocyte transplantation-platelet plant living standards|Effect of cell transplantation
1398,1,change in number of acute surgeries|change in days of acute inpatient treatment|change in number of curative surgical procedures after oral mucosa transplantation|change in conjunctival inflammation
1399,1,Objective response rate (ORR)|Disease control rate (DCR)|Progression-free survival (PFS)
1400,1,Changes in cellular properties of mesenchymal stromal cells|Number of differential biomarkers in mesenchymal stromal cells
1401,1,the percent of cornea perforation
1402,1,Adverse events|Amputation-free survival|Limb salvage from major amputation|Relief of the rest pain|Improvement in healing trophic disorders|Improvement in perfusion by the ankle-brachial index|Improvement in perfusion by radioisotope scintigraphy|Improvement in total walking distance (TWD) using a standard treadmill test
1403,1,Incidence of dose limiting toxicity|Detection of replication competent retrovirus and replication competent lentivirus|Duration of overall complete response|Duration of overall response|Persistence of transduced T cells|Engraftment and persistence of transduced progeny T cells|Engraftment and persistence of transduced T cells and progeny T cells|Feasibility of generation NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cells that meet the lot release criteria|Immunological monitoring will consist primarily of quantifying T cells bearing surface NY-ESO-1 TCR|Objective response|Persistence of TCR gene transduced cells|Time to disease progression
1404,1,Amputation rate|hospital stay|Wound healing time|Transcutaneous oxygen partial pressure
1405,1,Tumor formation|Adverse events
1406,1,Treatment related-adverse events counting|Improvement in clinical function
1407,1,Safety assessed by clinically measured abnormality of laboratory tests and adverse events|Area of re-epithelization
1408,1,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement
1409,1,"Change From Baseline in visual analogue scale (VAS)|Change From Baseline in western Ontario and McMaster Universities Osteoarthritis Index score|Change From Baseline in knee society score (KSS)|Change From Baseline in MOS item short from health survey(SF-36)|The number of cartilage defects, thickness of cartilage evaluated by X-ray and MRI|The IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 of articular cavity fluid"
1410,1,Number of Participant with treatment emergent serious adverse events|Difference in lung function|Decrease in peripheral eosinophilia|Difference in subject reported dyspnea and quality of life assessments|Death from any cause
1411,1,The evaluation of alveolar bone regeneration|Probing pocket depth (PPD)|Attachment level (AL)|Gingival index (GI)|Tooth mobility degree (TMD)
1412,1,"Incidence of treatment-emergent adverse events including dose-limiting toxicities|Incidence of clinically significant abnormal measurements in physical examination, ophthalmological examination, vital signs, electrocardiogram (ECG), pregnancy test, lab tests and ECOG performance status|Objective Response Rate|Percentage change in tumour size|Maximal OMO-1 plasma concentration Cmax|Area under the OMO-1 plasma concentration curve (AUC)|'Proof of mechanism' and 'proof of principle' pharmacodynamic biomarkers, including markers of tumour cell proliferation and apoptosis."
1413,1,Objective Response Rate (ORR)|Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)|Progression-free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Disease Control Rate (DCR)
1414,1,Maximum Tolerated Dose|MRI Changes in Permeability|MRI Changes in Volume|MRI Changes in Flow|Viral Shedding in Saliva|HSV1 Viremia|HSV1 Antibody Response
1415,1,"Positive predictive value on a lesion level|Positive predictive value on a patient level|To assess the biodistribution of FAPI PET signal in comparison to PSMA-PET signal|To assess the biodistribution of FAPI and PSMA PET signal in comparison to histology|To assess the biodistribution of FAPI and PSMA PET signal in comparison to immunohistochemistry|To assess the biodistribution of FAPI and PSMA PET signal in comparison to biomarkers in ""wet"" samples"
1416,1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells three years after infusion.|Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector
1417,1,proportion of participants who have a TRSAE after infusion of MSCTC 0010|Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42|Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42|Occurrence of addition of escalated immunosuppressive therapy by day 90|Occurrence of Formation of ectopic tissue foci at day 90
1418,1,physical function improvement|Change in pain density|Joint swelling|Joint erythema|Deterioration of joint function|Allergic reactions
1419,1,Assessment of endometrial receptivity|Clinical pregnancy rate|Treatment-Emergent Adverse Events
1420,1,Numerical Rating Scale|Wheelchair User's Shoulder Pain Index (WUSPI)|Patient Global Impression of Change|Brief Pain Inventory interference items (BPI-I7)|Physical Examination of the Shoulder Score (PESS)
1421,1,functional bronchial epithelium from iPS?|functional bronchial epithelium from HBEC-ALI?
1422,1,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only|Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline|Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline|Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline|Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings|Overall Response Rate|Time to Response|Duration of Response|Progression-free Survival|Maximum Persistence (Cmax) of GSK3377794|Time to Maximum Persistence|Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])
1423,1,Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo
1424,1,Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum
1425,1,Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in CIBIC-plus|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers
1426,1,Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale|Adverse events procedure-related (intravitreal injection)
1427,1,Safety assessment(evaluation)
1428,1,Motor function analysis|Neurological deficits analysis|Limb motor function analysis|Barthel Index analysis
1429,1,Heart color ultrasound evaluation|Single therapy effectiveness evaluation
1430,1,MRI imageological examination|Harris Hip Score
1431,1,"Safety evaluation through vital signs, the results of clinical lab tests and adverse events|Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence"
1432,1,Effective Dose|Clinical neurological worsening over the treatment|BMI assessment|Risk of suicidal ideation|CNS assessment|Clinical Interview Based impression of Severity (CIBIS)
1433,1,Correlation of cytokine profile with left ventricular global longitudinal strain|Adrenergic susceptibility of pluripotent stem cell-derived cardiomyocytes
1434,1,Exploratory assay development
1435,1,Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function
1436,1,Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization
1437,1,Bone consolidation|Radiological Bone consolidation|Level of Pain|Complications|Health status
1438,1,Isolation and Expansion of Mesenchymal Stem Cells|Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments
1439,1,Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells
1440,1,BOLD-fMRI drived DTI scanning|FIM|NIHSS|Motor evoked potential
1441,1,Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months
1442,1,Percent change from baseline to week 12 in total wound size of the target leg|Assessment of adverse event (AE) occurrence|Time to total healing of all relevant ulcers at target leg|Percent change in total wound size of the target leg|Absolute change in total wound size of the target leg|Ankle-brachial index (ABI) of target leg;|Number of amputated toes at target leg|Time to major amputation at target leg until week 12;|Assessment of epithelialization in % of wound area of all relevant ulcers of the target leg|Assessment of further wound healing parameters: formation of granulation tissue in % of wound area and wound exudation of all relevant ulcers of the target leg|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Pain assessment as per numerical rating scale (NRS).|Physical examination at week 12;|Vital signs: Body temperature at week 12;|Vital signs: Blood pressure at week 12;|Vital signs: Heart rate at week 12;|Assessment of Laboratory values (Hematology) at Week 12:|Assessment of Laboratory values (Clinical chemistry) at Week 12|Time to major amputation
1443,1,Insulin dose|Adverse events|Hemoglobin A1c (HbA1c) level
1444,1,"Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male"
1445,1,Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events|Treatment responses|Quality of life
1446,1,Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting
1447,1,Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide
1448,1,Unexplained local and systemic symptoms or death|VAS score|WOMAC score
1449,1,To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the clinical score IIEF-5 (International Index of Erectile Function-5)|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the EHS score|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of arterial insufficiency|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of venous insufficiency (venous leakage)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the number of bone marrow extraction|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the bone marrow samples|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the cell culture of the marrow of diabetic patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the cell transport delay (between preparation and injection)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the patient recruitment rate calculated by the ratio between the number of participants and the number of eligible patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved
1450,1,MRI integrity|American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES)|University at California at Los Angeles Shouder Rating Scale (UCLA)|Visual Analog Scale for Pain (VAS)
1451,1,"The reduction in days on mechanical ventilation, or renal replacement therapy, or vasopressors.|Incidence of treatment-emergent adverse events (Safety and tolerability)|Biological endpoints as markers of vascular permeability|Mortality|Organ Failure Scores|Organ Support Measures|Length of ICU Stay (in days)|Length of Hospital Stay (in days)|Hospital Re-Admissions|Patient Reported Outcomes-FIM|Patient Reported Outcomes-SF 36"
1452,1,Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure between the two groups|Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups|Change rates in wound size and depth compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations
1453,1,Occurrence of adverse events|Changes in neurological function test
1454,1,death|Bayley Scales of Infant Development
1455,1,Scale for the assessment anf rating of ataxia (SARA)|Image examinations|Inventory of Non-Ataxia Symptoms (INAS) score|Cerebrospinal fluid (csf) routine
1456,1,Change in Visual Analog Pain Scale (VAS) Over Time|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Over Time|Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Over Time
1457,1,Progression free survival (PFS)|Overall survival (OS)
1458,1,serum creatinine|glomerular filtration rate|apparent relaxation rate
1459,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Evaluation of the efficacy of the injected cells (Change from Baseline in partial mayo score)
1460,1,Safety profile of ADR-001 including the incidence of adverse events (Phase 1)|Improvement rate of Child-Pugh score (Phase 2)|Change of liver function evaluated by Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh grade (Phase 1)|Change of liver function evaluated by Child-Pugh score (Phase 2)|Improvement rate of Child-Pugh grade (Phase 2)|Safety profile of ADR-001 including the incidence of adverse events (Phase 2)
1461,1,Change of hemodynamic parameters (heart contractility: CFI)|Change of hemodynamic parameters (preload: GEDI)|Change of hemodynamic parameters (afterload: SVRI)|Change of hemodynamic parameters (fluid responsiveness: SVV)|Change of hemodynamic parameters (lung water: ELWI)|Change of hemodynamic parameters (lung permeability: PVPI)|Autophagy biomarkers in exosomes: LC3II (Western blots)|Autophagy biomarkers in exosomes: LC3II (NTA)|Autophagy modifiers in exosomes: mTOR (Western blots)|Autophagy modifiers in exosomes: mTOR (NTA)|Autophagy modifiers in exosomes: HSP70 (Western blots)|Autophagy modifiers in exosomes: HSP70 (NTA)|Autophagy modifiers in exosomes: sequestosome 1 (Western blots)|Autophagy modifiers in exosomes: sequestosome 1 (NTA)|Exosomes marker: CD9 (Western blots)|Exosomes marker: CD9 (NTA)|ICU mortality|28-day mortality|Hospital mortality|Length of stay in ICU|Length of stay in hospital
1462,1,Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Epithelialization|Assessment of further wound healing parameters: formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs at Week 6.1 and Week 12
1463,1,Change in volume over time after breast augmentation|Change in cosmetic facial appearance over time after facial filling
1464,1,"Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT|Effect of AZD6094 at therapeutic dose (600 mg) on additional time-matched ECG variables|Effect of moxifloxacin 400 mg on Fridericia-corrected QT interval (QTcF) compared to placebo.|Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC(0-∞)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Area under the plasma concentration-time curve from time zero to t hours after dosing (AUC(0-t)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Observed maximum concentration (Cmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Time to reach maximum concentration (tmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Lag-time (tlag - from the individual concentration-time curve) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal rate constant (λz) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal half-life (t½) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent clearance for parent drug estimated as dose divided by AUC (CL/F) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent volume of distribution for parent drug at terminal phase (Vz/F, extravascular administration) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Assessment of relationship between the plasma concentration of AZD6094 and moxifloxacin and ECG variables, including baseline-adjusted and placebo-subtracted QTc interval.|Number of participants with adverse events (AEs) of AZD6094|Systolic blood pressure [SBP]|Diastolic blood pressure [DBP]|Pulse rate|Twelve-lead (12-Lead) electrocardiograms (ECGs)|Physical examination|Laboratory assessments of Hematology|Laboratory assessments of Clinical chemistry|Laboratory assessments of urinalysis|Effect of AZD6094 at therapeutic dose (600 mg) on time-matched ECG variable - heart rate (HR)"
1465,1,complete healing|Rate of healing|rate of ulcer recurrence
1466,1,Detectable pimonidazole staining
1467,1,Patient satisfaction (Patient Assessment Scar Scale)|Doctor satisfaction (Vancouver Scar Scale)
1468,1,exosomal miRNAs in serum samples
1469,1,"Dose-Limiting Toxicity and Maximum Tolerated Dose of CS10BR05 Inj.|Adverse events, frequency and rate of vitals sign, laboratory test, physical examination, ECG, etc.|Unified Multiple System Atrophy Rating Scale(UMSARS)"
1470,1,Incidence of adverse events (AEs) related to intervention|Incidence of serious adverse events (SAEs) related to intervention|Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）
1471,1,Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI
1472,1,"Percentage of wound surface area reduction|Assessment of adverse event (AE) occurrence|Percentage of invisible and visible wound surface area reduction|Absolute wound surface area reduction|Absolute invisible and visible wound surface area reduction|Assessment of wound infection|Time to first complete wound closure|Proportion of patients achieving complete wound closure|Time to first 30% reduction of wound surface area|Proportion of patients achieving 30% reduction of wound surface area|Assessment of wound exudation, epithelialization and formation of granulation tissue|Time to amputation at target leg until Week 12|Pain assessment as per numerical rating scale (NRS)|Assessment of Quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of Dermatology-specific QoL based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs|Time to amputation of target leg until month 12"
1473,1,Determination of recommended Phase II dose (RP2D) of MSCTRAIL in combination of cisplatin and pemetrexed treatment (Phase 1)|Tumour response rate (Phase 2)|Frequency of adverse events (Phase 1 & 2)|Best Overall response (Phase 1&2)|Progression free survival (Phase 1 & 2)|Overall survival (Phase 2)
1474,1,Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R)
1475,1,Cognitive decline|Functional decline|Neuropsychiatric decline|Quality of life decline|Change in cognitive impairment status
1476,1,Healing time|Safety: All types of adverse events will be collected|Incidence of relapse|Pain assessed using the Visual Analogue Scale (VAS) for pain|Total time of hospitalization|Total time of immobility|Quality of Life using the Short Form 36 (SF-36) questionnaire
1477,1,"Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks|Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|The Disabilities of the Arm, Shoulder and Hand(DASH) Score|Adverse events"
1478,1,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers
1479,1,"Comparison between treatment groups of reovirus tumour infiltration by immunohistochemistry (IHC)|Comparison between treatment groups of reovirus tumour replication, as assessed by qRT-PCR|Comparison between treatment groups of neutralising antibody development development and cell-mediated immune response|Comparison between treatment groups of cell-mediated immune response"
1480,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Evaluation of the preliminary efficacy of the injection on kidney's Estimated Glomerular filtration rate|Evaluation of the preliminary efficacy of the injection on kidney's protein to creatinine ratio
1481,1,life quality score|adverse events
1482,1,Functional progression rate|Electrophisiological progression rate
1483,1,Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs)|Primary graft rejection|Late graft rejection|Time to neutrophil engraftment|Time to platelet engraftment|Lineage specific donor chimerism|Immune reconstitution|Acute GVHD|Chronic GVHD|Transplant-related mortality (TRM)|Event-free survival (EFS)|Overall survival (OS)
1484,1,Number of participants with treatment-related adverse events|Bone regeneration as assessed by high-resolution CT scans|Quality of life as measured by the Glasgow Benefit Inventory
1485,1,Best Overall Response (BOR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)
1486,1,Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls.
1487,1,number of patients with BPD after instillation mesenchymal stem cells
1488,1,Number of study participants with treatment related adverse events (TEAES) and serious adverse events (SAEs) from baseline through Week 104.|Visual Analogue Scale for Pain Assessment - Changes from Baseline in pain as assessed with the VAS score through Week 52|Oswestry Disability Index for Functional Assessment -- Changes from Baseline in function as assessed with the Oswestry Disability Index through Week 52.
1489,1,Incidence of Adverse Events|Changes in KOOS Measurement
1490,1,Number of patients (with clear cell kidney cancer) with CD9+ and CA9+ exosomes by electron microscopy technique|Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients|Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for control patients|Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer|Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients
1491,1,"Change in Pulmonary Vascular Resistance from Baseline|Change from Baseline in Participant Quality of Life Using the SF-36|Change in Plasma NT-pro-BNP levels|Change in the IL-1β, IL-6, PGE-2, TGF-β, TNF-α and IGF-1 (ng/ul)|Incidence of Treatment Adverse|Change in Six Minute Walk distance"
1492,1,Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system|Incidence of Serious adverse event (SAE) as presented by MedDRA coding system|Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system|New York Heart Association (NYHA) Classification|Incidence of major adverse cardiovascular events (MACE)|Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)|Pulmonary function test|12-lead ECG Test|Cardiac MRI (cMRI) for baseline and efficacy evaluation
1493,1,12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements
1494,1,Adverse events and serious adverse events|The proportion of patients win from oxygen|The lung fibrosis
1495,1,Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10
1496,1,Adverse Event Reporting|Headache Diary|Headache Impact Test (HIT-6)
1497,1,Incident HIV infection|A clinical decision to discontinue the vaccine regimen for an adverse event that is considered related to product|A clinical decision to discontinue PrEP regimen for an adverse event that is considered related to product|Grade 3 and worse solicited clinical and laboratory adverse events|Discontinuation or interruption of vaccine regimen|Discontinuation or interruption of PrEP|Serious adverse events|Other clinical and laboratory adverse events|Binding antibodies|Resistance mutations to tenofovir and emtricitabine|Number of PrEP pills missed|Tenofovir level in urine|Tenofovir level in red blood cells|Number of PrEP Pills dispensed
1498,1,Safety and Feasibility: Number Of Adverse Events|Radiographic Healing|Clinical Healing
1499,1,"Frequency of dose limiting adverse events|Modified Rankin Scale (mRS) to measure the prognosis|National institute of Health Stroke Scale (NIHSS) to measure stroke recovery|Barthel Index (BI) to evaluate the self-care ability|Rate of muscle strength level of the hemiplegic limb|Mortality rate|Change in Glasgow coma scale (GCS) score|Change in Glasgow outcome scale (GOS) score|MRI (T1, T2, Flair, DWI) scanning"
1500,1,Incidence of adverse events|Overall survival|Event-free survival|Overall response rate (ORR)|Complete response (CR) rate|Partial response (PR) rate|Duration of response|Persistence of infused donor AFM13-NK cells|Immune reconstitution studies
1501,1,Number of patients with Dose Limiting Toxicities|Incidence and severity of treatment-emergent adverse events|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|REGN5093 concentrations in serum over time|Objective response rate (ORR) per RECIST 1.1|ORR per RECIST 1.1|Incidence and severity of TEAEs|Incidence and severity of AESIs|Incidence and severity of SAEs|REGN5093 Pharmacokinetics (PK)|Duration of response (DOR) per RECIST 1.1.|Disease control rate (DCR) per RECIST 1.1.|Progression free survival (PFS) per RECIST 1.1.|Overall survival (OS)|Immunogenicity as measured by Anti-drug antibodies (ADA) to REGN5093
1502,1,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Fasting Blood Sugar (FBS) at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline C-peptide at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline HbA1C at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline 2-hour postprandial blood glucose at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline daily dose of exogenous insulin injected by patients (IU/kg/day) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from baseline Lability Index (LI) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline SF-36 Quality of life (QOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Diabetes Specific Quality of life (DQOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline Autoantibodies levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells
1503,1,Isolation of Exosomes as a stable source of nucleic acid as an early Detection Method to diagnose Melanoma.
1504,1,Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale
1505,1,adverse events|the National Institutes of Health Stroke Scale (NIHSS) of 3 months|the Barthel index (BI) of 3 months
1506,1,"Overall Survival (OS) post-infusion|Incidence of LTFU adverse events (AEs), including serious adverse events (SAEs) associated with administration of Fate Therapeutics genetically modified NK cell product that have been genetically modified by lentiviral vectors."
1507,1,Generation of patient-specific induced pluripotent stem cells and then differentiate them into neural cells.
1508,1,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Modified Rankin Score (mRS)|Changes in National Institute of Health Stroke Scale (NIHSS)|Changes in Barthel Index (BI)|Changes in Brain MRI
1509,1,Validity evaluation by detection the change of the VAS pain score relief rate for Lumbar disc pain of participants in different time point and compare with the VAS pain score before treatment|Observe treatment|Safety evaluation by detecting adverse events and serious adverse events|Safety evaluation by detecting Activated partial thromboplastin time (APTT)|Safety evaluation by detecting Prothrombin time (PT)|Safety evaluation by detecting Fibrinogen|Safety evaluation by detecting Thrombin time (TT)
1510,1,SAE|Antibodies to HLA Class I - number and percent|Antibodies to HLA Class I - Time To Development|Increase Ulcer Size|Adverse Reaction|Suspected Adverse Reaction|Suspected Serious Adverse Reaction|Change in A1c
1511,1,Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume
1512,1,"Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment|Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment|Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline|Change of score in IKDC(International Knee Documentation Committee)compared to baseline|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment|Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment|Change in joint space width compared to the baseline at 3 months and 6 months after treatment|Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment"
1513,1,Vancouver Scar Scale score|Erythema|Pigmentation|Scar Thickness and Uniformity|Subject's satisfaction
1514,1,Change of serum thyroglobulin level|Change of serum free T4 level|Change of serum TSH level|Change of anti-thyroglobulin level|Urinary exosomal NT-proBNP detection|2-D Cardiac Doppler ultrasonography evaluation
1515,1,Number of participants experiencing drug-related adverse events|Changes from baseline in circulating FIX activity (IU/dL or % normal)
1516,1,"Substudy 1: Overall response rate (ORR)|Substudy 2: Overall response rate (ORR) as assessed by central independent review|Substudy 1 and 2: Time to response|Substudy 1 and 2: Duration of response (DOR)|Substudy 1 and 2: Disease control rate (DCR)|Substudy 1 and 2: Progression free survival (PFS)|Substudy 1 and 2: Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity|Substudy 1 and 2: Number of participants with replication competent lentivirus (RCL)|Substudy 1 and 2: Number of participants with insertional oncogenesis (IO)|Substudy 2: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis parameters|Substudy 1 and 2: Maximum transgene expansion (Cmax) of letetresgene autoleucel|Substudy 1 and 2: Time to Cmax (Tmax) of letetresgene autoleucel|Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t]) of letetresgene autoleucel|Substudy 2: Overall response rate (ORR) as determined by the local investigators|Substudy 2: Overall Survival (OS)|Substudy 2: Number of participants with positive anti-drug antibodies (ADA) and titers of ADA against letetresgene autoleucel"
1517,1,The number of donors needed to obtain 3 BM harvest.
1518,1,Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro
1519,1,Adverse birth outcomes in pregnant women vaccinated with RIV4 versus IIV4|Preterm birth after RIV4 versus IIV4 vaccination|Combined fetal and neonatal death after RIV4 versus IIV4 vaccination|Spontaneous abortion after RIV4 versus IIV4 vaccination|Pregnant women with moderate/severe solicited reactogenicity events (local and systemic) within 8 days after vaccination with RIV4 versus IIV4
1520,1,Characterize the level of proliferation of organoids
1521,1,"The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372."
1522,1,Proteomic profiles issued from cerebrospinal fluid at diagnosis|Cytology of cerebrospinal fluid at diagnosis|Proteomic profiles issued from cerebrospinal fluid|Histological subtype|Hormonal receptors status|Likehood of leptomeningeal metastasis according to the EANO-ESMO classification.|Overall survival|Proteomic profiles issued from blood
1523,1,Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan
1524,1,"To assess the change of the number (per biopsy or per mL of blood) and/or frequency (among live hematopoietic cells CD45+) of immune cells that are present in the skin and the blood of AD patients after Dupilumab or TCS treatment.|To investigate correlations between each immunological parameter and each clinical score as a continuous quantitative variable, as well as each immunological parameter and quality of life index as a continuous quantitative variable.|To investigate correlations between each immunological parameter and change in clinical score as a qualitative variable with 2 modalities as well as each immunological parameter and quality of life index, as a qualitative variable with 2 modalities.|To investigate correlations between each immunological parameter and the development of new AD lesions in the 3 following months, as well as each immunological parameter and the interval of time between the end of treatment and AD relapse."
1525,1,Quantification of CD20 and PDL-1 in exosomes purified from cell cultures of DLBCL human cell lines and from Healthy volunteers|Evaluation if peripheral exosomes can be used as novel diagnostic biomarkers in DLBCL
1526,1,The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life
1527,1,Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|Change of Visual Analog Scale (VAS) scores from baseline|WOMAC 3 subscale score|VAS score|KOOS|SF-36|IKDC|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan|Use of rescue medication
1528,1,Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on lumbar spine BMD in men with low bone mass|Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on serum P1NP in men with low bone mass|Effects of treatment with TPTD+cinacalcet compared to TPTD+PBO on femoral neck BMD in men with low bone mass
1529,1,Incidence of treatment - emergent adverse events|Transcutaneous oxygen pressure
1530,1,Respiratory outcome: Number of hospitalizations|Mortality|Growth measured by Z-score|Neurological developmental status: Korean Developmental Screening Test for infants and children(K-DST)|Deafness or Blindness|Bayley Scales of Infant and Toddler Development (Third Edition)|Gross Motor Function Classification System for Cerebral Palsy|Number of adverse events|Number of admissions to Emergency Room (ER)|Medical treatment records
1531,1,Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size
1532,1,Left ventricular ejection fraction (LVEF)|Final diastolic and systolic volumes|Left ventricule viability|Ventricular arrhythmias|Estimated functional status|Change in the median score of Quality of life|Delayed enhancement of the left ventricle|Improvement in the 6-minute walk test|Mortality at 3 and 12 months due to cardiovascular causes|Mortality at 3 and 12 months due to all causes
1533,1,Changes of the platelet counts after hUC-MSCs infusion|Incidence of adverse events after hUC-MSCs infusion|Changes in virus safety indicators after hUC-MSCs infusion|Changes of concentration of hUC-MSCs in peripheral blood|Changes of antibody production of hUC-MSCs in peripheral blood|Changes of immune function in refractory ITP patients after hUC-MSCs infusion
1534,1,All-cause death|Number of participants with worsening of dyspnea|Number of participants with respiratory functional worsening|Impairment of exercise capacity|Increased oxygen use
1535,1,CTC enumeration capacity|CTC recovery capacity|Comparison of AR and EMT characteristics|Relationship of CTC count to disease features|CTC counts and prognosis of OS and PFS
1536,1,Volume of oxygen consumed at peak effort|Volume of oxygen consumed at ventilatory/anaerobic threshold (VAT)|Rate of work performed at peak effort|Rate of work performed at VAT|Heart rate at peak effort|Heart rate at VAT|Systolic blood pressure at seated rest|Systolic blood pressure at peak effort|Respiratory Exchange Ratio (RER) at peak effort
1537,1,Overall Survival (OS) post-Infusion
1538,1,"Frequency of TEAEs, SAEs, and DLTs|To determine maximum tolerated dose and optimal immunological dose|Best Overall Response|Overall Survival|Progression-Free Survival|Immunological effect"
1539,1,Identification of a specific acetylation profile of RSTS|Identification of different target genes between SRT patients and controls|Evidence of a significantly different level of expression for common target genes for RSTS patients and controls
1540,1,UACR|HbA1c|insulin/C peptide|insulin dosage|eGFR
1541,1,"The change from baseline in modified Marshall score on Day 7 for organ failure subject|The change from baseline in CTSI Score on Day 28|Percentage of subjects whose organ failure was resolved at 3 days, 7 days, 14 days and 28 days|The change from baseline in modified Marshall score at each assessment point up to Day 28|The change from baseline in sequential organ failure assessment (SOFA) at each assessment point up to Day 28|Duration of Systemic inflammatory response syndrome (SIRS)|Time to resolution of organ failure|The change from baseline value of C-Reactive Protein(CRP) which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of Tumor Necrosis Factor(TNF)-α which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-6 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-8 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of lymphocyte count ratio which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|Duration of intensive care unit (ICU) stay|The change from baseline in Computed Tomography Severity Index(CTSI) on Day 28|Incidence of pancreatic complication|Requirement of drainage or surgery|Rate of infection|Mortality on Day 28 and 90"
1542,1,Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])|Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR]).|Organ-specific Assessments|Patient-Reported Outcomes|Clinician-Assessed Global Rating/Scale|Failure-free Survival
1543,1,The difference in the renal function between the two groups (MSC treatment group vs placebo control group) within 28 days after receiving MSC/ placebo treatment|Overall survival within 28 days after receiving MSC/ placebo treatment|Overall survival within 3 months after receiving MSC/ placebo treatment|Renal replacement therapy (RRT) dependent within 3 months after receiving MSC/ placebo treatment|Complete renal recovery within 3 months after receiving MSC/ placebo treatment|Partial renal recovery within 3 months after receiving MSC/ placebo treatment|ICU and hospitalization duration of stay among all AKI patients within 3 months after receiving MSC/ placebo treatment|Adverse events within 3 months after receiving MSC/ placebo treatment
1544,1,Radiological healing.|Radiological Healing|Time from randomisation to assessed as 'Clinically Healed'.|Time to 'Healing' as a composite assessment.|Time from randomisation to discharge from rehabilitation.|Pain symptoms on a visual analogue pain scale.|Difference in Quality of life|Adverse events
1545,1,[trMDD] Beck Depression Inventory (BDI-II)|[Anxiety] Beck Anxiety Inventory (BAI)|[Dementia] Quick Dementia Rating Scale (QDRS)|[ALL] Global Rating of Change (GRC)|[trMDD] Patient Depression Questionnaire (PDQ-9)|[trMDD] Hamilton Depression Rating Scale (HAM-D)|[Anxiety] Hamilton Anxiety Rating Scale (HAM-A)|[Dementia] Repeatable Battery Assessment of Neuropsychological Status (RBANS) versions A-D|[Dementia] Montreal Cognitive Assessment (MoCA) versions 7.1-7.3
1546,1,Brief Pain Inventory (BPI)|Patient Health Questionnaire (PHQ-9)|Adverse Event Reporting|Global Rating of Change (GRC)
1547,1,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Forced Vital Capacity (FVC).|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).|Changes in exercise performance using 6-min walk test (6MWT).|Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).|Changes in modified medical research council (mMRC) -dyspnea scale.
1548,1,WOMAC Score|MRI quantitative analysis of articular cartilage|VAS Score|SF-36|Adverse Events and Serious Adverse Events|Changes of laboratory test indexes and vital signs
1549,1,Avoiding arthroplasty|Harris Hip Score
1550,1,Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height
1551,1,Maintenance of effectiveness on clinical progression of the disease|Clinical neurological worsening over the treatment by UHDRS|BMI assessment|Risk of suicidal ideation and/or behavior by C-SSRS|Risk of suicidal ideation and/or behavior by HDS|CNS assessment by MRI (Magnetic Ressonance Imaging)
1552,1,"Safety of grafting SIN RV-mediated COL7A1 gene-modified autologous skin equivalent: Adverse Events (AE), Serious Adverse Events (SAEs), Adverse Reactions (ARs) and Serious Adverse Reactions (SARs)|Change in C7 protein expression|Change in anchoring fibrils number|Change in scar quality: Vancouver Scar Scale (VSS)|Changes in blister number over the grafted skin|Changes in clinical appearance of grafted skin|Changes in pruritus of grafted skin|Change in Quality of life: QOLEB questionnaire (Quality of Life for Epidermolysis Bullosa)|Change in Birmingham Epidermolysis Score (BEBS)|Change in Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) - Activity|Change in Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) - Damage|Change in instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).|Evaluation of the humoral immune response against recombinant C7|Evaluation of the cytotoxic immune response against recombinant C7"
1553,1,Ranges of Movement of ankle joint|duration of hospital stay|Weight bearing capacity of patients
1554,1,Number of Participants with Clinical Global Impression-Improvement Scale ≤ 2
1555,1,Radiographic Changes|Subjective Knee Symptom Changes
1556,1,"Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers"
1557,1,ETDRS visual acuity|Outer retinal thickness
1558,1,TRG|Toxicities|Overall Survival|Progression-free Survival|Local Control rate|pCR
1559,1,"Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|Tumor necrosis factor-alpha|Interleukin-1|Interleukin-6|C-reactive protein|Amyloid beta 40|Amyloid beta 42|Volumetric changes in hippocampus, ventriculus, and whole brain|Mini Mental Status Exam|Alzheimer's disease Cooperative Study Activities of Daily Living|Quality of Life Enjoyment and Satisfaction Questionnaire|Altoida Neuro Motor Index|Clinical Dementia Rating Questionnaire"
1560,1,Comparing the total pain score pre- and post-injection differences between the two arms|Comparing MOAKS pre-and post-injection differences between the two arms|Clinical outcomes-extension|Clinical outcomes-flexion|Clinical outcomes-stability|Cartilage thickness|Patient-based outcomes|Pain score-other follow-ups
1561,1,Incidence of different Adverse Events of transplantation of mesenchymal cells from human embryonic stem cells|Normal recovery rate of endometrial thickness|recurrence rate of intrauterine adhesions|Intrauterine adhesions score|The endometrial biopsies for CD31|Menstrual volume change|Clinical pregnancy rate|The endometrial biopsies for estrogen|The endometrial biopsies for Ki67
1562,1,wound healing rate|Vancouver score
1563,1,Number of subjects with Immediate reaction|percentage of subjects with Immediate reaction|Number of subjects with Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with Adverse Events from 1 day to 28 days after vaccination|Number of subjects with Serious Adverse Events from 1 day to 28 days after vaccination|Percentage of subjects with serious Adverse Events from 1 day to 28 days after vaccination|Number of Lab Deviation for adults subjects in 7 days of immunization|Safety Comparison between each intervention group|Protectivity of Hepatitis B vaccine (number of subject with protective anti HbsAg)|Protectivity of Hepatitis B vaccine (4 times increasing antibody)|Protectivity of Hepatitis B vaccine (Geometic Mean Titers)|Anti-HBs description between groups
1564,1,Efficacy evaluation|Safety eveluation
1565,1,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient|Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment
1566,1,urine exosome protein abundance pattern|urine electrolyte ratio in a spot urine as a surrogate to 24-h urine collection to assess nutritional consumption.|24-h urine collection as a measure of adherence to the DASH diet
1567,1,CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio
1568,1,Determination of differential expression of miRNA by second-generation sequencing technology|Diagnostic value of the differential microRNAs evaluate by qPCR in patients of myocardial infarction
1569,1,Kellgren and Lawrence's rating|WOMAC score|Volume of femoral surface of knee joint on MRI|relaxation time of femoral surface of knee joint on MRI
1570,1,Percent change in myofiber Cross Sectional Area (CSA).|Percent change in myofibrillar protein synthesis (MyoKsyn).|Percent change in serum extracellular vesicle number (EV #).|Percent change in the expression of muscle Rab27b mRNA.
1571,1,FAOS questionnaire|EQ-5D questionnaire|Tegner activity score|Kellgren and Lawrence score
1572,1,Change in Numerical Rating Scale|Wheelchair User's Shoulder Pain Index|Patient Global Impression of Change|Physical Examination of the Shoulder Scale|Ultrasound Shoulder Pathology Rating Scale|Quantitative Ultrasound of the Supraspinatus Tendon
1573,1,Protein expression difference|survival
1574,1,To strengthen preliminary data|Potential marker of PD|Analysis both MM cells and MM-BMSC compartment.|To investigate eNAMPT role|To determine the effects
1575,1,EASI-50|EASI-75|EASI score|SCORAD-50|SCORAD-75|SCORAD score|SCORAD subgroup|Severity|IGA grade|IGA -1 or more grade|IGA -2 or more grade|Total IgE|PGE2 and ECP|Immune cytokine|Remedy used days and frequency|Remedy used subjects
1576,1,Fusion|Failure of hardware or obvious non-union|Foot and Ankle Ability Measure (FAAM)|Vitamin D levels|Visual Analog Pain Scale|American Orthopaedic Foot and Ankle Society(AOFAS) hindfoot score|VR-12 (Veterans RAND 12)|Patient-Reported Outcomes Measurement Information System Physical Function-Short Form 8b (PROMIS Item Bank v2.0-Physical Function -Short Form 8b)
1577,1,Initial and absolute claudication distance|Assess the effects on ABI of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Assess the effects on endothelial function of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Muscle microvascular perfusion by CEU|Assess the effects on the endothelial circulating progenitor cells concentration of a six month treatment with Liraglutide compared to control group (standard-of-care treatment).|Changes from baseline in HbA1c
1578,1,"The events of stroke in-evolution, stroke recurrence and hypoglycemia in acute ischemic stroke patients with time restricted fasting (TRF) or normal eating (NE)|3 months functional outcome, defined as modified Rankin Scale (mRS) <=1 as good outcome|Diffusion tensor imaging on MRI at baseline and 3 months post stroke"
1579,1,motor symptoms change|non-motor symptoms change|sleep quality change|daytime sleepiness change|signs of depression change
1580,1,"Safety evaluation: Incidence of Treatment-Emergent Adverse Events as assessed by protocol.|Cutaneous mechanical resistance|Skin surface affected|Number of blisters|Non-specific general markers of systemic inflammation: white blood cell count|Non-specific general markers of systemic inflammation: Negative acute phase reactant (albumin)|Non-specific general markers of systemic inflammation: Negative acute phase reactants (pre-albumin, transferrin and retinol-binding protein)|Non-specific general markers of systemic inflammation: Positive acute phase reactants (c-reactive protein and fibrinogen)|Non-specific general markers of systemic inflammation: Positive acute phase reactants (ferritin)|Severity index according to ""The Birmingham Epidermolysis Bullosa Severity Score"" before and after treatment|Severity index according to ""The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) before and after treatment|Expression of Collagen VII (C7) in skin biopsy|Analysis of anchoring fibrils|Variation of pain respect to baseline status: Visual Analog Scale|Modification in itching perceived|Change in quality of life of patient: European Quality of Life-5 Dimensions-5 level (EUROQL-5D)|Evaluation of circulating anti-C7 antibodies|Change in general condition of the patient"
1581,1,Exosome cargo levels
1582,1,"RNA expression on platelets and allelic DNA balance of EVs in the blood of adult RB1 mutation carriers (Rb-survivors) and retinoblastoma patients (children).|RNA expression on platelets, allelic DNA balance of EVs in blood and genomic analysis on tumor tissue of RB1-mutation carriers diagnosed with a second primary malignancy."
1583,1,Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines|Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines|Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation|Attempt to replicate functional changes observed
1584,1,Adverse Events and Sever Adverse Events|Efficacy of Celltex AdMSCs
1585,1,Dose Limiting Toxicity|Wound size evaluation
1586,1,"To evaluate number of Participants with Treatment-Related Adverse Events|Improvement in General Well-Being, as assessed by our 'Quality of Life' Questionnaire, adapted from SF36.|Change in inflammatory marker levels|Change in medication dosage (if any)"
1587,1,over 50% reduction ratio of Eczema Area and Severity Index (EASI) as contrasted with baseline value (EASI-50)|Score change from Baseline in Eczema Area and Severity Index(EASI) score|Percentage of subjects who have EASI-75 (improvement of ≥75% in EASI score from Baseline)|Percentage of subjects who have EASI-90 (improvement of ≥90% in EASI score from Baseline)|Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1|Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more|Score change from Baseline on Pruritus Numerical Rating Scale (NRS)|Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more|Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)|Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index|Score change from Baseline in the Dermatology Life Quality Index (DLQI)|Score change from Baseline the Patient-Oriented Eczema Measure (POEM)|Change from Baseline in biomarker (Immunoglobulin E [IgE])|Change from Baseline in biomarker (eosinophil count)|Change from Baseline in biomarker (interleukin [IL]-13)|Change from Baseline in biomarker (interleukin [IL]-17)|Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])|Change from Baseline in biomarker (interleukin [IL]-22)
1588,1,Diagnostic efficiency of ctDNA and exosome combined detection in the identification of benign and malignant pulmonary nodules.
1589,1,Numbers of CTC pre- and post- neoadjuvant chemotherapy and after operation.|Types of CTC pre- and post- neoadjuvant chemotherapy and after operation.|Mutation rate of ctDNA pre- and post- neoadjuvant chemotherapy and after operation.|Concentration of cfDNA pre- and post- neoadjuvant chemotherapy and after operation.|The relationship between tumor response and changes in numbers of CTC pre- and post-neoadjuvant chemotherapy and after operation.|The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.|Disease Free Survival(DFS)|Overall survival(OS)|Types of tumor-associated DNA in tumor tissues after operation.
1590,1,Diagnostic Clinical Performance: prediction of clinically significant prostate cancer at biopsy
1591,1,Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Evaluation of cartilage repair under MRI postoperative 3 month|Evaluation of cartilage repair under MRI postoperative 6 month|Degree of meniscus injury under MRI postoperative 3 month|Degree of meniscus injury under MRI postoperative 6 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Satisfaction of patients postoperative 1 month|Satisfaction of patients postoperative 3 month|Satisfaction of patients postoperative 6 month
1592,1,Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Hospital for special surgery knee score postoperative 12 month|Hospital for special surgery knee score postoperative 24 month|Hospital for special surgery knee score postoperative 36 month|Visual Analogue Scale Postoperative Day 1|Visual Analogue Scale Postoperative Day 2|Visual Analogue Scale Postoperative Day 3|Visual Analogue Scale Postoperative Day 7|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Visual Analogue Scale Postoperative 12 month|Visual Analogue Scale Postoperative Day One|Visual Analogue Scale Postoperative 24 month|Visual Analogue Scale Postoperative 36 month|Evaluation of cartilage repair under MRI postoperative 12 month|Evaluation of cartilage repair under MRI postoperative 24 month|Evaluation of cartilage repair under MRI postoperative 36 month|Degree of meniscus injury under MRI postoperative 12 month|Degree of meniscus injury under MRI postoperative 24 month|Degree of meniscus injury under MRI postoperative 36 month|Evaluation of cartilage repair under arthroscope postoperative 12 month|Degree of meniscus injury under arthroscope postoperative 12 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Squatting to Standing Time postoperative 12 month|Squatting to Standing Time postoperative 24 month|Squatting to Standing Time postoperative 36 month
1593,1,Early wound healing index (Supercell in early wound healing index)|Change in probing pocket depth and clinical attachment gain (Supercell as a regenerative novel material)|Change in the bone level (Supercell as a biological material)|Change in the clinical parameters of gingival index and plaque index (Supercell as a regenerative material using clinical indices)
1594,1,"Alveolar bone filling rate|Serious adverse events|Non serious adverse events|Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair|Position of the canine tooth and formation of dental root|Patient-reported outcome (PRO, including appearance, fuction and quality of life)"
1595,1,Number of participants with adverse reactions related to infusion after treatment|The incidence and severity of BPD defined by the National Institutes of Child Health and Human Development (NICHD) workshop.|Changes of high-resolution chest CT in participants|Changes of temperature in participants|Changes of blood pressure in participants|Changes of respiratory rate in participants|Changes of oxygen saturation in participants
1596,1,degree of LRRK2 enrichment achieved. The measure will vary depending on the method of LRRK2 enrichment used|Power analysis to guide future research|Time from IRB submission to approval by central IRB|Time from central IRB approval to site approval|Time from site selection to contract full execution|Completion of Recruitment|Proportion of samples conforming to collection|Retention
1597,1,To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.|To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.
1598,1,3-month postoperative hip function evaluated by Harris Hip Score|6-month postoperative hip function evaluated by Harris Hip Score|12-month postoperative hip function evaluated by Harris Hip Score|3-month postoperative degree of collapse evaluated by plain radiograph|6-month postoperative degree of collapse evaluated by plain radiograph|12-month postoperative degree of collapse evaluated by plain radiograph|6-month postoperative degree of collapse evaluated by MRI
1599,1,Change in IKDC (International Knee Documentation Committee) subjective score|Variation in KOOS (Knee Injury and Osteoarthritis Outcome) Score|VAS (Visual Analogue Scale) for pain|MRI (Magnetic Resonance Imaging) Changes in subchondral bone edema and cartilage status from basal to 12 months' follow-up
1600,1,Incidence of Treatment-Associated Adverse Events|Determination of Immune Cell Phenotype|Determination of Immune Cell Number|Determination of Immune Cell Function
1601,1,3-month postoperative shoulder function evaluated by Constant Shoulder Score|6-month postoperative shoulder function evaluated by Constant Shoulder Score|12-month postoperative shoulder function evaluated by Constant Shoulder Score|3-month postoperative degree of healing evaluated by plain radiograph|6-month postoperative degree of healing evaluated by plain radiograph|12-month postoperative degree of healing evaluated by plain radiograph|6-month postoperative degree of healing evaluated by MRI|12-month postoperative degree of healing evaluated by MRI
1602,1,3-month postoperative spinal function evaluated by Oswestry Disability Index|6-month postoperative spinal function evaluated by Oswestry Disability Index|12-month postoperative spinal function evaluated by Oswestry Disability Index|3-month postoperative degree of pain evaluated by visual analogue scale|6-month postoperative degree of pain evaluated by visual analogue scale|12-month postoperative degree of pain evaluated by visual analogue scale|3-month postoperative degree of bone healing evaluated by plain radiograph|6-month postoperative degree of bone healing evaluated by plain radiograph|12-month postoperative degree of bone healing evaluated by plain radiograph|12-month postoperative degree of bone healing evaluated by computed tomograph
1603,1,1-month postoperative degree of union evaluated by plain radiograph|2-month postoperative degree of union evaluated by plain radiograph|3-month postoperative degree of union evaluated by plain radiograph|6-month postoperative degree of union evaluated by plain radiograph|12-month postoperative degree of union evaluated by plain radiograph
1604,1,Change from baseline Gross Motor Function Classification System (GMFCS)|Change from baseline GROSS MOTOR FUNCTION MEASURE (GMFM66)|Change from baseline Manual Ability Classification System for Children with Cerebral Palsy (MACS)|Change from baseline Pediatric Evaluation of Disability Inventory (PEDI)|Change from baseline Modified Ashworth scale|Change from baseline acquired Brain Magnetic Resonance Imaging (MRI) findings|Change from baseline Brain Magnetic Resonance Spectroscopy (MRS)|Change from baseline Diffuse Tensor Imaging (DTI) fiber count of periventricular white matter
1605,1,"Maximum tolerated dose (MTD) (phase 1 only)|Adverse Events (AEs), and Serious Adverse Events (SAEs)|Overall Response Rate (ORR) (phase 2 only)|Maximum Serum Concentration (Cmax)|Area Under the Plasma Concentration-Time Curve (AUC)|Trough Serum Concentration (Ctrough)|Elimination half-life (t1/2)|Clearance (CL)|Volume of distribution at steady state (Vss)|Accumulation Ratio (AR)|Dose Proportionality|Anti-Drug Antibodies (ADA)|Duration Of Response (DOR)|Progression-Free Survival (PFS)"
1606,1,"Improvement rate of blood routine hemoglobin (HGB) compared to baseline.|Improvement rate of forced vital capacity (FVC) and/or carbon monoxide diffusing capacity (DLCO) compared to baseline.|The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70.|White blood cell count and platelet count improved compared to the baseline.|Improvement rate of forced vital capacity (FVC) and/or carbon monoxide|Image improvement of lung on high resolution CT.|Improvement of 6-minute walking distance compared to baseline."
1607,1,Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.|Death rate or rehospitalization due to cardiovascular causes|Rate of relevant arrhythmias in Holter of 24 hours|Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels|Changes in the necrotic myocardial mass ratio|Changes of regional contractility|Changes in ejection fraction of the left ventricle|changes in left and right ventricular geometric remodeling|Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).|Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used.
1608,1,Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation
1609,1,concentration of exosomes in blood
1610,1,Cartilage T2 map score|IKDC score|WOMAC score|VAS score
1611,1,Incidence of adverse events|Change in WOMAC score|Change in VAS score|Changes in structural joint assessment by MRI
1612,1,exosomal PD1 expression|exosomal PD-L1 expression
1613,1,Menstrual changes|Kupperman score|hormone level|Follicular development
1614,1,Change in Visual Analog Pain Scale (VAS-pain) Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Symptoms Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activities of Daily Living (ADL) Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sports and Recreation Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of Life (QoL) Subscale Score|Change in EuroQuality of Life (EQ-5D-3L) Index Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) Score
1615,1,Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events
1616,1,"Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement|Number of Participants Achieving a Physician Global Assessment (PGA) of (0, 1)|Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score|Adverse event"
1617,1,"Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure"
1618,1,Obtention of induced pluripotent stem cell line (iPS): yes/no|Functional bronchial epithelium present for the iPS? yes/no|Cystic fibrosis transmembrane conductance regulator (CFTR) channel function: yes/no
1619,1,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events.|Number of fractures.|Time (days) to first fracture after each stem cell administration.|Numbers of fractures at birth.|Change in bone-marrow density (g/cm2).|Growth (cm).|Growth (kg).|Change in clinical status of OI.|Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples."
1620,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Drug Reduction Rate test|Tractography|Blood-based biomarkers|Cerebrospinal Fluid (CSF) based biomarkers
1621,1,Incidence of adverse events|Maximum tolerated dose (MTD)|Change in Immunological parameters associated with T cell persistence|Tumor response rates to treatment|Progression-free survival|Overall survival|Duration of response|Appearance of target antigen/major histocompatibility complex loss variants upon disease recurrence|Assessment of bioactivity|Assessment of Immunological parameters associated with functionality
1622,1,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|The effect of single inject of HB-adMSCs on TNF-a in patients with acute RA|The effect of single inject of HB-adMSCs on IL-6 in patients with acute RA|The effect of single inject of HB-adMSCs on CRP in patients with acute RA|The effect of single inject of HB-adMSCs on ESR in patients with acute RA|The effect of single inject of HB-adMSCs on joint count in patients with acute RA.
1623,1,Rate of treatment related adverse events|Changes in Pain -Visual Analogue Scale (VAS) for back pain|Changes in Pain - Oswestry Disability Index (ODI) scores over time|changes in Quality of life - Short form Health Survey 36 (SF-36)|changes in MRI monitoring of transplant site
1624,1,sensitivity of the prostasome purification methodology|specificity of the prostasome purification methodology|Quantification of the miRNA expression profiles of the purified protostomes both before and after treatment (in patients cohort only)|Time to disease progression(in patient cohort only)|Time to disease relapse (in patient cohort only)|Overall survival (in patient cohort only)
1625,1,Temporary Wound Closure|Long-term Safety and Tolerability|Definitive Wound Closure|Improved Wound Healing
1626,1,Adverse Events (AEs) reported during the trial|Change in MRI scans from baseline|Change from baseline in EDSS score|Time to Confirmed Disease Progression (CDP)
1627,1,hiPSC-cardiomyocytes culture
1628,1,"Number of subjects with treatment limiting toxicities (TLT)|Number of subjects with AEs|Severity of AEs|Number of subjects with serious adverse events (SAEs)|Number of subjects with AE /SAEs leading to pembrolizumab administration delay, interruptions, and withdrawals|Number of subjects with abnormal hematology parameters|Number of subjects with abnormal clinical chemistry parameters|Number of subjects with abnormal urine parameters|Number of subjects with abnormal vital signs|Eastern Cooperative Oncology Group (ECOG) performance scores|Lansky performance scores|Number of subjects with abnormal electrocardiogram (ECG) parameters|Overall Response Rate|Progression free survival|Disease Control Rate|Duration of Response|Time to Response|Maximum transgene persistence (Cmax)|Time to Cmax (Tmax)|Area under the time curve from zero to time t (AUC[0-t])|Number of subjects with NY-ESO-1/LAGE-1a expression in tumor tissues"
1629,1,Blood proteome enrichment pathway analysis in GO annotation|Blood markers of iron
1630,1,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.
1631,1,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires
1632,1,the change of endometrial thickness|pregnancy rate|live birth rate|abortion rate
1633,1,Number of patients with fistula healed|Number of adversus events
1634,1,Change in Expression of E-cadherin levels in all the groups in IHC|Change in Expression of vimentin levels in all the groups in IHC|Change in Expression of collagen IV levels in all the groups in IHC|Change in Expression of miRNA 21 in all three groups using Real Time-PCR|CHange in E cadherin levels in PCR|Change in vimentin levels in PCR|Change in e-cadherin expression with respect to disease category clinically in OSMF patients with habits|Change in e-cadherin expression with respect to disease category histologically in OSMF patients with habits|Change in vimentin expression with respect to disease category clinically in OSMF patients with habits|Change in vimentin expression with respect to disease category histologically in OSMF patients with habits|Change in collagen IV expression with respect to disease category clinically in OSMF patients with habits|Change in collagen IV expression with respect to disease category hstologically in OSMF patients with habits|Change in mi RNA 21 expression with respect to disease category clinically in OSMF patients with habits|Change in mi RNA 21 expression with respect to disease category histologically in OSMF patients with habits
1635,1,68Ga-DOTATATE PET Positive Maximum Intensity Projection
1636,1,Differential expression of miRNA/lncRNA|Progression-free survival
1637,1,Changes in the characteristics and degree of discomfort of xerostomia trough OHIP questionnaire|Changes in the characteristics and degree of discomfort of xerostomia.|Sialometry results|Restoration of the glandular structure.|Measurement of submaxillary gland functionalism changes based on Gammagraphy|AEs and SAEs
1638,1,"Time to all-cause composite allograft loss|Incidence and time to death-censored allograft loss|Change in mean estimated glomerular filtration rate (eGFR) from Baseline to End of Treatment (EOT)|Change in spot urine albumin creatinine ratio (UACR) from Baseline to EOT|Change in (Donor-specific antibodies) DSA titers and Mean fluorescence intensity (MFI) scores from Baseline to EOT|Incidence of acute rejection episodes of T cell-mediated rejection(TCMR) and Antibody-mediated rejection (ABMR) from Baseline to EOT|Change in Banff lesion grading score (2015 criteria) of pre-treatment to post-treatment (Week 52) kidney biopsies|Overall patient survival|Maximum serum concentration (Cmax, Cmax ss) of CSL300|Trough serum concentrations (Ctrough, Ctrough ss) of CSL300|Area under the concentration-time curve (AUC0-tau) at steady state of CSL300|Time of maximum serum concentration (Tmax, Tmax ss) of CSL300"
1639,1,PASI score improvement rate|Psoriasis Area and Severity Index(PASI)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|the Body Surface Area (BSA%)|the Dermatology Life Quality Index（DLQI）
1640,1,Changes in exercise-dependently mobilized stem and progenitor cell numbers in the peripheral blood with antioxidative supplementation|Changes in numbers of exercise-induced apoptotic cells and oxidative stress markers in the peripheral blood with antioxidative supplementation
1641,1,"Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues.|Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells|Functional characterisation of airway epithelium"
1642,1,The difference of the amount of circulating tumor cells acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases|The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases|The difference of the amount of circulating tumor cells between portal venous and peripheral blood|The difference of the exosomes between portal venous and peripheral blood
1643,1,"To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis|To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis, with regions being the prostate or prostate bed, pelvis, extra pelvis, and bones|To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis"
1644,1,Validity evaluation by detection of the Model for end-stage Liver Disease score of participants|Safety evaluation by detecting Blood routine|Validity evaluation by detection of the child-pugh of participants
1645,1,Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Change mHHS Surveys from preoperative to various postoperative timepoints|Change RAND-36 Surveys from preoperative to various postoperative timepoints|Degree of Improvement on Hip VAS Pain Score|Patient Satisfaction Questionnaires
1646,1,Temperature|Pulse|Breaths per minute|Blood pressure|Number of antral follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Ovarian volume
1647,1,Pain at injection site: grade|Infection at injection site|Bleeding at injection site|Eyelid function disorder|Periorbital edema|Ocular discomfort|Flu-like symptoms|Fever|OSDI questionnaire|Schirmer's I test|Tear osmolarity|Ocular SICCA Grading Score|HLA anti-bodies
1648,1,To generate patient-specific induced pluripotent stem cells and then differentiate them into neural cells
1649,1,Change in patient's skin condition|Evaluation of skin problems. Assessment of skin related complaints since the last visit.|The assessment of the scar by the patient.|Changes in volume of the skin (USG)|Changes in skin surface morphology (digital imagining)|Record of adverse events
1650,1,Changes in miRNAs content of circulating tumor exosomes|Change in protein content of circulating tumor exosomes|Relationship between plasma levels of circulating tumor exosomes and their content in miRNAs with overall survival and progression of the disease.|Cross-talk between isolated circulating tumor exosomes and commercial lines of bone tissue cells in the metastatic process.
1651,1,Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies
1652,1,Genomic instability : analysis|Genomic instability : size of telomers|Genomic instability : Duplication of centrosomes|cellular ageing : molecular analysis of hiPS cell derived from pathological tissue|cellular ageing : IPS line with the criteria defined for morphological characterization|cellular ageing : molecular characterization
1653,1,"Proportion of patients with deep ulcer healing|Proportion of patients with stricture healing|Proportion of patients with complex perianal fistula healing|Safety assessed by the incidence of treatment-emergent adverse events during the study period|Evolution of clinical disease activity index|Evolution of Short health scale (quality of life)|Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)|Evolution of the "" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube"" obstructive score for Crohn Disease strictures"
1654,1,Safety measured as the number of Major Adverse Cardiac Events (MACE)|Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up
1655,1,Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis
1656,1,Total daily insulin dose|glucose-c peptide release test|Islet function|Composite index of glycosylated hemoglobin (HbAlc) and frequency of hypoglycemia|Continuous dynamic blood glucose
1657,1,Safety: To demonstrate absence of complications at the site of spinal fusion|Efficacy: To assess the quality of life determined by Oswestry Questionnaire.|Efficacy: To assess the quality of spinal fusion by X-ray imaging|Efficacy: To assess the quality of spinal fusion measured by computed tomography (CT).
1658,1,Healing|Safety collecting all types of adverse events|Pain assessed using the Visual Analogue Scale (VAS) for pain|Continence|Patient's satisfaction|Non inferiority compared with the Advancement flap technique
1659,1,Achievement of Global Renal Response (GR) at Study Endpoint|Achievement of Complete Renal Response (CR) at Study Endpoint|Achievement of Partial Renal Response (PR) at Study Endpoint|Treatment Failure|Response of SLE Responder Index (SRI).|Selena Sledai|BILAG score|Disease Flares|Biomarker Response
1660,1,Percentage of subjects with increasing antibody titer >= 4 times|Geometric Mean Titer (GMT)|Percentage of subjects with transition of seronegative to seropositive|Percentage of subjects with at least one immediate reaction|Percentage of subjects with at least one of these adverse events|Serious adverse event after vaccination|Comparison adverse events between Investigational Products (Hepatitis B) and Control|Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine
1661,1,Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation
1662,1,Temperature|Uncontrolled systemic infection|All-cause mortality|NK cell depletion|Change in the following cardiac biomarker|Change in RV systolic function|Hospitalizations due to right heart failure|6 minute walk distance changes|Gout flares
1663,1,"Safety Evaluation assessed by Tumor Marker Test.|Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer.|Safety Evaluation assessed by Vital Signs."
1664,1,"Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I|Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II|Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II|Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II|Change from baseline to all post-treatment visits in body weight|Change from baseline to all post-treatment visits in Blood-pressure|Change from baseline to all post-treatment visits in S.creatinine|Change from baseline to all post-treatment visits in blood urea.|Change from baseline to all post-treatment visits in Hemoglobin level|Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)|Change from baseline to all post-treatment visits in hemoglobin A1c|Change from baseline to all post-treatment visits in random blood sugar (RBS)|Change from baseline to all post-treatment visits in Anti-Hypertensive medication if there is any.|Change from baseline to all post-treatment visits in Hypoglycemic agent if there is any.|Change from baseline to post-treatment visits in urine total protein-creatinine ratio (UPCR)|Change from baseline to all post-treatment visits in urinary Protein-to-creatinine ratio PCR)|Change from baseline to post-treatment level of serum Alpha Feto Protein|Change from baseline to post-treatment level of serum CEA level|Change from baseline to post-treatment level of serum CA 19.9 level|Change from baseline to post-treatment level LDH level|Change from baseline to post-treatment level of Beta 2 Microglobulin level|Change from baseline to post-treatment level of serum CA 125 level (in case of female patients)|Change from baseline to post-treatment level of PSA level (in case of male patients)"
1665,1,WOMAC pain score|MRI|Visual Analogue Scale (VAS)|12-item Short Form (SF-12)
1666,1,"The level of C-peptid and HOMA-β|The level of HOMA-IR and cytokines TNF-α, IL-1β|Blood glucose level|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose and drug dosage"
1667,1,Liver function|The incidence of serious complications|The incidence of adverse events|Disease-free survival time|Incidence of hepatocellular carcinoma (HCC) events
1668,1,Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL
1669,1,Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse
1670,1,Exosomal Biomarkers Assessment|Exosomal Expression|Exosomal Functionality Assessment
1671,1,Readmission rate|Duration of the hospital stay due to respiratory infection|Rate of Survival|Incidence of Tumorigenicity|Growth measured by Z-score|Number of neurological developmental delay|Number of blindness and deafness
1672,1,Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)
1673,1,Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)|Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24|Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24|Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24|Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24|Change from Baseline of rheumatoid factor at Week 12 and Week 24|Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24
1674,1,"The expression levels of serum exosome long non-coding RNA|the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1|the CT scans of the lung for the patients"
1675,1,Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire
1676,1,Safety: To assess the occurrence of adverse events of treatment by hAMSC - systemic reactions.|Safety: To assess the occurrence of adverse events of treatment by autologous mesenchymal stem cells - local reactions.|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Visual Analogue Score (VAS)|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Constant Shoulder Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - UCLA Shoulder Rating Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Continuation / discontinuation of the rotator cuff|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Fatty degeneration
1677,1,The change in number of adverse events based on the National Cancer Institute-Common Terminology Criteria for Adverse Events|Ultrasound of knee joint|Visual Analog Score for pain（VAS）|Range of knee motion|Lysholm Knee Scale|MRI of knee|Global posture analysis system|Dynamic balance test
1678,1,Adverse Events|Kidney Function
1679,1,The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.|Objective-response rate (ORR)|Duration of FT500 persistence
1680,1,Primary Efficacy Outcome: Change in the ACR CRISS at 12 months|Primary Safety Outcome: The proportion of participants who experience at least one Grade 3 or higher adverse event at or before 12 months|Proportion of patients who experience at least one grade 2 or higher adverse event|Number Infectious Adverse Events Across all Participants|Number Adverse Infusion Reactions Across all Participants|Number Injection Site Reactions Across all Participants|Number Adverse Events Across all Participants|Change in the CRISS at 6 months|Change in the MRSS at 6 and 12 months|Change in FVC and DLCO|Forced Vital Capacity (FVC)|Changes in the Short Form-36 (SF-36) Health Survey|Change in the scleroderma health assessment questionnaire-disability index (sHAQ-DI)|Change in PROMIS-29|Change in gastrointestinal tract (GIT) in scleroderma score|Change in Scleroderma Skin Patient Reported Outcome (SSPRO)|Change in Disease Activity Score 28 (DAS-28)|Change in joint count|Change in Clinical Disease Activity Index (CDAI): Measures joint tenderness and swelling|Change in Global Combined Response Index
1681,1,Rate of Complete Response (CR) at Day 28|Rate of Partial Response (PR) at Day 28|Rate of PR and CR at Day 14|Percentage of patient requiring MMF rescue during treatment|Rate of long term complication incidence|Rate of chronic clinical response incidence|Overall survival (OS) rate at 3 months|Correlation between response to Cyto-MSC at Day 14 and Day 28 to survival at 90 days|Relapse-free survival at 3 months|Disease relapse at 3 months|Incidence of infection|Incidence of CMV reactivation|Measurement quality of life of cancer patients by using EORTC QLQ-C30 questionnaire|Measurement quality of life in bone marrow transplantation by using FACT-BMT questionnaire|Measurement of health-related quality of life in children and young people by using PEDsQL questionnaire (patients age less than 18 years old)|Measurement of generic health status among patients by using EQ-5D questionnaire
1682,1,Maximum effective dose for prophylactic CD45RA-depleted DLI|One-year Event Free Survival (EFS) after completion of the protocol|The number of patients experiencing Blinatumomab permanent discontinuation due to toxicity|The estimate of cumulative incidence of relapse|The cumulative incidence of acute and chronic Graft-Versus-Host Disease (GVHD)|The cumulative incidence of transplant related mortality
1683,1,number of human cell models obtained
1684,1,Vaccine efficacy|High-titer response|Long-term efficacy|Long-term high-titer response|Hepatitis B incident infection rate|Hepatitis C infection and syphilis infection rate|HIV seroconversion among HIV-negative MSM
1685,1,success rate of fibroblasts culture|success rate of turning fibroblasts into mesenchymal stem cells|success rate of CRISPR/Case9 gene therapy treatment on patients' cells
1686,1,Number of Subjects With Treatment-emergent Adverse Events During the Post-treatment Phase (Safety and Tolerability)
1687,1,"Change of Model for End-Stage Liver Disease (MELD) score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.|Assessment of adverse event (AE) occurrence|Change of MELD score at Weeks 3, 4, 8, 12, 16 and 20|Change of Child-Pugh-Score at Weeks 3, 4, 8, 12, 16, 20 and 24|Change of CLIF-C ACLF score at Weeks 3, 4, 8, 12, 16, 20 and 24|Overall survival time until Week 24|Complications of ACLF (hepatorenal syndrome [HRS], variceal bleeding, ascites, hepatic encephalopathy [HE], spontaneous bacterial peritonitis [SBP])|Transient elastography assessment at Weeks 4, 12 and 24|Infections (proven infection necessitating systemic use of antibiotics)|Change of levels of C-reactive protein in serum at Weeks 3, 4, 8, 12, 16, 20 and 24|Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24|Changes in the profile of 80 different immunomodulatory cytokines at Weeks 3, 4, 8, 12, 16, 20 and 24|Changes in dialytic treatment until Week 24|Time to respiratory failure after first IMP administration until Week 24|Duration of the initial hospital stay|Duration of initial intensive care stay|Optional: Evaluation of liver biopsy (necrosis quantification)|Physical examination at Week 24|Vital signs at Week 24: Body temperature|Vital signs at Week 24: Blood pressure|Vital signs at Week 24: Heart rate|Vital signs at Week 24: Respiratory rate|Hematological laboratory parameters at Week 24|Clinical chemistry parameters at Week 24|Coagulation parameter ""factor V"" at Week 24|Coagulation parameter ""INR"" at Week 24|Overall survival at Week 24 and at Month 24"
1688,1,survival rate|Adverse reactions|White blood cell|Platelet|Hemoglobin|Creatinine|ALT|ALB|TBil|INRs|AFP|MELD scores|Tumor formation|Liver failure-associated serious complications
1689,1,Changes in wound size|Changes in wound morphology|Changes in pro-angiogenic factors expression|Changes in wound-associated pain|Changes in the quality of life|Record of adverse events
1690,1,"HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)|Harris Hip Score|Knee injury and Osteoarthritis Outcome Score (KOOS)|modified Harris Hip Score for knee|The International Knee Documentation Committee (IKDC Questionnaire)|WOMAC (for hip and knee)|Disability of Arm, Shoulder and Hand [DASH]|The Constant-Murley score (CMS)|Visual Analog Scale (VAS)|1. Nature, incidence and severity of adverse events (AEs)|2. Change in radiographic/magnetic resonance joint morphology|3. Change in cartilage thickness|4. Change in cartilage volume|5. Change in cartilage morphology|6. Change in subchondral bone morphology|8. Inflammation monitoring"
1691,1,Reprogramming patient-derived fibroblasts into induced pluripotent stem cells (iPSCs)|Differentiation of patient-specific iPSCs into disease-affected cell types
1692,1,"HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)|Harris Hip Score|Knee injury and Osteoarthritis Outcome Score (KOOS)|modified Harris Hip Score for knee|The International Knee Documentation Committee (IKDC Questionnaire)|WOMAC (for hip and knee)|Disability of Arm, Shoulder and Hand [DASH]|The Constant-Murley score (CMS)|Visual Analog Scale (VAS)|Nature, incidence and severity of adverse events (AEs)|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Inflammation monitoring"
1693,1,Reprogramming patient-derived fibroblasts into induced pluripotent stem cells
1694,1,"Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation|Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci"
1695,0,
